hsic-20250927

false

0001000228

--12-27

none

480000000

0.01

0.01

1000000

33.33

0.004

3

118567917

124155884

Q3

NASDAQ

http://fasb.org/us-gaap/2024#SecuredOvernightFinancingRateSofrMember

http://fasb.org/us-gaap/2024#SecuredOvernightFinancingRateSofrMember

P5Y

P3Y

http://fasb.org/us-gaap/2024#SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMember

http://fasb.org/us-gaap/2024#SellingGeneralAndAdministrativeExpense

P4Y

P3Y

P4Y

P3Y

P3Y

P4Y

P3Y

P10Y

P1Y

true

0001000228

2023-12-31

2024-09-28

0001000228

2024-12-29

2025-09-27

0001000228

2025-09-27

0001000228

2024-12-28

0001000228

us-gaap:RetainedEarningsMember

2024-12-29

2025-09-27

0001000228

2023-12-30

0001000228

us-gaap:AccumulatedOtherComprehensiveIncomeMember

2024-12-29

2025-09-27

0001000228

us-gaap:NoncontrollingInterestMember

2024-12-29

2025-09-27

0001000228

us-gaap:AdditionalPaidInCapitalMember

2024-12-29

2025-09-27

0001000228

us-gaap:CommonStockMember

2024-12-29

2025-09-27

0001000228

us-gaap:CommonStockMember

2025-06-29

2025-09-27

0001000228

us-gaap:EmployeeStockOptionMember

2023-12-31

2024-09-28

0001000228

us-gaap:EquityMethodInvesteeMember

2023-12-31

2024-09-28

0001000228

2025-06-29

2025-09-27

0001000228

us-gaap:RetainedEarningsMember

2025-06-29

2025-09-27

0001000228

us-gaap:AccumulatedOtherComprehensiveIncomeMember

2025-06-29

2025-09-27

0001000228

us-gaap:NoncontrollingInterestMember

2025-06-29

2025-09-27

0001000228

us-gaap:AdditionalPaidInCapitalMember

2025-06-29

2025-09-27

0001000228

hsic:PerformanceBasedRestrictedStockRestrictedUnitsMember

2024-12-29

2025-09-27

0001000228

hsic:NonEmployeeDirectorStockIncentivePlanMember

hsic:TimeBasedRestrictedStockRestrictedUnitsMember

2024-12-29

2025-09-27

0001000228

us-gaap:EmployeeStockOptionMember

2024-12-29

2025-09-27

0001000228

hsic:TimeBasedRestrictedStockRestrictedUnitsMember

2024-12-29

2025-09-27

0001000228

us-gaap:VariableInterestEntityPrimaryBeneficiaryMember

us-gaap:AssetPledgedAsCollateralMember

2024-12-28

0001000228

us-gaap:VariableInterestEntityPrimaryBeneficiaryMember

us-gaap:RecourseMember

2024-12-28

0001000228

us-gaap:EquityMethodInvesteeMember

2024-12-29

2025-09-27

0001000228

2024-06-30

2024-09-28

0001000228

us-gaap:EquityMethodInvesteeMember

2024-06-30

2024-09-28

0001000228

us-gaap:OtherNoncurrentLiabilitiesMember

2025-09-27

0001000228

us-gaap:OtherNoncurrentLiabilitiesMember

2024-12-28

0001000228

hsic:TimeBasedRestrictedStockRestrictedUnitsMember

2024-12-28

0001000228

hsic:TimeBasedRestrictedStockRestrictedUnitsMember

2025-09-27

0001000228

hsic:PerformanceBasedRestrictedStockRestrictedUnitsMember

2024-12-28

0001000228

hsic:PerformanceBasedRestrictedStockRestrictedUnitsMember

2025-09-27

0001000228

us-gaap:EmployeeStockOptionMember

2024-12-29

2025-09-27

0001000228

us-gaap:EmployeeStockOptionMember

2024-06-30

2024-09-28

0001000228

us-gaap:RestrictedStockUnitsRSUMember

2024-12-29

2025-09-27

0001000228

us-gaap:RestrictedStockUnitsRSUMember

2024-06-30

2024-09-28

0001000228

hsic:ActionsConsolidatedInTheMultiDistrictLitigationMember

2023-12-31

2024-12-28

0001000228

us-gaap:NoncontrollingInterestMember

2024-12-28

0001000228

us-gaap:CommonStockMember

2024-12-28

0001000228

us-gaap:RetainedEarningsMember

2024-12-28

0001000228

us-gaap:AdditionalPaidInCapitalMember

2024-12-28

0001000228

us-gaap:AccumulatedOtherComprehensiveIncomeMember

2024-12-28

0001000228

us-gaap:RestrictedStockUnitsRSUMember

2023-12-31

2024-09-28

0001000228

us-gaap:NoncontrollingInterestMember

2025-06-28

0001000228

us-gaap:CommonStockMember

2025-06-28

0001000228

us-gaap:RetainedEarningsMember

2025-06-28

0001000228

us-gaap:AdditionalPaidInCapitalMember

2025-06-28

0001000228

us-gaap:AccumulatedOtherComprehensiveIncomeMember

2025-06-28

0001000228

2024-09-28

0001000228

us-gaap:FairValueInputsLevel1Member

us-gaap:FairValueMeasurementsRecurringMember

us-gaap:DesignatedAsHedgingInstrumentMember

2025-09-27

0001000228

us-gaap:FairValueInputsLevel2Member

us-gaap:FairValueMeasurementsRecurringMember

us-gaap:DesignatedAsHedgingInstrumentMember

2025-09-27

0001000228

us-gaap:FairValueInputsLevel3Member

us-gaap:FairValueMeasurementsRecurringMember

us-gaap:DesignatedAsHedgingInstrumentMember

2025-09-27

0001000228

us-gaap:FairValueMeasurementsRecurringMember

us-gaap:DesignatedAsHedgingInstrumentMember

2025-09-27

0001000228

us-gaap:FairValueInputsLevel1Member

us-gaap:FairValueMeasurementsRecurringMember

us-gaap:DesignatedAsHedgingInstrumentMember

2024-12-28

0001000228

us-gaap:FairValueInputsLevel2Member

us-gaap:FairValueMeasurementsRecurringMember

us-gaap:DesignatedAsHedgingInstrumentMember

2024-12-28

0001000228

us-gaap:FairValueInputsLevel3Member

us-gaap:FairValueMeasurementsRecurringMember

us-gaap:DesignatedAsHedgingInstrumentMember

2024-12-28

0001000228

us-gaap:FairValueMeasurementsRecurringMember

us-gaap:DesignatedAsHedgingInstrumentMember

2024-12-28

0001000228

us-gaap:FairValueInputsLevel1Member

us-gaap:FairValueMeasurementsRecurringMember

us-gaap:NondesignatedMember

2025-09-27

0001000228

us-gaap:FairValueInputsLevel2Member

us-gaap:FairValueMeasurementsRecurringMember

us-gaap:NondesignatedMember

2025-09-27

0001000228

us-gaap:FairValueInputsLevel3Member

us-gaap:FairValueMeasurementsRecurringMember

us-gaap:NondesignatedMember

2025-09-27

0001000228

us-gaap:FairValueMeasurementsRecurringMember

us-gaap:NondesignatedMember

2025-09-27

0001000228

us-gaap:FairValueInputsLevel1Member

us-gaap:FairValueMeasurementsRecurringMember

us-gaap:NondesignatedMember

2024-12-28

0001000228

us-gaap:FairValueInputsLevel2Member

us-gaap:FairValueMeasurementsRecurringMember

us-gaap:NondesignatedMember

2024-12-28

0001000228

us-gaap:FairValueInputsLevel3Member

us-gaap:FairValueMeasurementsRecurringMember

us-gaap:NondesignatedMember

2024-12-28

0001000228

us-gaap:FairValueMeasurementsRecurringMember

us-gaap:NondesignatedMember

2024-12-28

0001000228

us-gaap:FairValueInputsLevel1Member

us-gaap:FairValueMeasurementsRecurringMember

2025-09-27

0001000228

us-gaap:FairValueInputsLevel2Member

us-gaap:FairValueMeasurementsRecurringMember

2025-09-27

0001000228

us-gaap:FairValueInputsLevel3Member

us-gaap:FairValueMeasurementsRecurringMember

2025-09-27

0001000228

us-gaap:FairValueMeasurementsRecurringMember

2025-09-27

0001000228

us-gaap:FairValueInputsLevel1Member

us-gaap:FairValueMeasurementsRecurringMember

2024-12-28

0001000228

us-gaap:FairValueInputsLevel2Member

us-gaap:FairValueMeasurementsRecurringMember

2024-12-28

0001000228

us-gaap:FairValueInputsLevel3Member

us-gaap:FairValueMeasurementsRecurringMember

2024-12-28

0001000228

us-gaap:FairValueMeasurementsRecurringMember

2024-12-28

0001000228

us-gaap:VariableInterestEntityPrimaryBeneficiaryMember

us-gaap:AssetPledgedAsCollateralMember

2025-09-27

0001000228

us-gaap:VariableInterestEntityPrimaryBeneficiaryMember

us-gaap:RecourseMember

2025-09-27

0001000228

us-gaap:EquityMethodInvesteeMember

2025-06-29

2025-09-27

0001000228

us-gaap:EmployeeStockOptionMember

2025-06-29

2025-09-27

0001000228

us-gaap:RestrictedStockUnitsRSUMember

2025-06-29

2025-09-27

0001000228

2025-10-27

0001000228

us-gaap:EstimateOfFairValueFairValueDisclosureMember

us-gaap:FairValueInputsLevel3Member

us-gaap:FairValueMeasurementsRecurringMember

2025-09-27

0001000228

us-gaap:EstimateOfFairValueFairValueDisclosureMember

us-gaap:FairValueInputsLevel3Member

us-gaap:FairValueMeasurementsRecurringMember

2024-12-28

0001000228

us-gaap:NoncontrollingInterestMember

2025-09-27

0001000228

us-gaap:CommonStockMember

2025-09-27

0001000228

us-gaap:RetainedEarningsMember

2025-09-27

0001000228

us-gaap:AdditionalPaidInCapitalMember

2025-09-27

0001000228

us-gaap:AccumulatedOtherComprehensiveIncomeMember

2025-09-27

0001000228

us-gaap:EquityMethodInvesteeMember

2024-12-28

0001000228

hsic:CyberIncidentMember

2024-12-29

2025-09-27

0001000228

us-gaap:OperatingSegmentsMember

hsic:GlobalDistributionAndValueAddedServicesMember

hsic:GlobalDentalMember

2024-12-29

2025-09-27

0001000228

us-gaap:OperatingSegmentsMember

hsic:GlobalDistributionAndValueAddedServicesMember

hsic:GlobalMedicalMember

2024-12-29

2025-09-27

0001000228

us-gaap:OperatingSegmentsMember

hsic:GlobalDistributionAndValueAddedServicesMember

2024-12-29

2025-09-27

0001000228

us-gaap:OperatingSegmentsMember

hsic:GlobalDistributionAndValueAddedServicesMember

hsic:GlobalDentalMerchandiseMember

2024-12-29

2025-09-27

0001000228

us-gaap:OperatingSegmentsMember

hsic:GlobalDistributionAndValueAddedServicesMember

hsic:GlobalDentalEquipmentMember

2024-12-29

2025-09-27

0001000228

us-gaap:OperatingSegmentsMember

hsic:GlobalDistributionAndValueAddedServicesMember

hsic:GlobalValueAddedServicesMember

2024-12-29

2025-09-27

0001000228

us-gaap:OperatingSegmentsMember

hsic:GlobalSpecialtyProductsMember

2024-12-29

2025-09-27

0001000228

us-gaap:OperatingSegmentsMember

hsic:GlobalTechnologyMember

2024-12-29

2025-09-27

0001000228

hsic:EliminationsAndReconcilingItemsMember

2024-12-29

2025-09-27

0001000228

us-gaap:OperatingSegmentsMember

2024-12-29

2025-09-27

0001000228

hsic:GlobalDistributionAndValueAddedServicesMember

hsic:EliminationsAndReconcilingItemsMember

2024-12-29

2025-09-27

0001000228

hsic:GlobalSpecialtyProductsMember

hsic:EliminationsAndReconcilingItemsMember

2024-12-29

2025-09-27

0001000228

hsic:GlobalDistributionAndValueAddedServicesMember

2024-12-29

2025-09-27

0001000228

hsic:GlobalSpecialtyProductsMember

2024-12-29

2025-09-27

0001000228

hsic:GlobalTechnologyMember

2024-12-29

2025-09-27

0001000228

us-gaap:CorporateNonSegmentMember

2024-12-29

2025-09-27

0001000228

hsic:TriMedIncMember

2024-12-29

2025-09-27

0001000228

hsic:TriMedIncMember

2024-04-01

0001000228

us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember

srt:MinimumMember

2024-12-28

0001000228

us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember

srt:MaximumMember

2024-12-28

0001000228

us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember

2023-12-31

2024-12-28

0001000228

us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember

2024-12-28

0001000228

hsic:TriMedIncMember

2023-12-31

2024-12-28

0001000228

hsic:TriMedIncMember

2024-12-28

0001000228

hsic:OtherShortTermCreditLinesMember

2025-09-27

0001000228

hsic:OtherShortTermCreditLinesMember

2024-12-28

0001000228

us-gaap:LoansPayableMember

srt:MinimumMember

2025-09-27

0001000228

us-gaap:LoansPayableMember

srt:MaximumMember

2025-09-27

0001000228

us-gaap:LoansPayableMember

srt:MinimumMember

2024-12-28

0001000228

us-gaap:LoansPayableMember

srt:MaximumMember

2024-12-28

0001000228

hsic:PrivatePlacementFacilitiesMember

2025-09-27

0001000228

hsic:PrivatePlacementFacilitiesMember

2024-12-28

0001000228

hsic:USTradeAccountsReceivableSecuritizationMember

2025-09-27

0001000228

hsic:USTradeAccountsReceivableSecuritizationMember

2024-12-28

0001000228

us-gaap:LoansPayableMember

2025-09-27

0001000228

us-gaap:LoansPayableMember

2024-12-28

0001000228

hsic:TermCreditAgreementMember

2025-09-27

0001000228

hsic:TermCreditAgreementMember

2024-12-28

0001000228

hsic:PrivatePlacementFacilitiesMember

2024-12-29

2025-09-27

0001000228

srt:MinimumMember

hsic:PrivatePlacementFacilitiesMember

2024-12-29

2025-09-27

0001000228

srt:MaximumMember

hsic:PrivatePlacementFacilitiesMember

2024-12-29

2025-09-27

0001000228

hsic:TermCreditAgreementMember

2024-12-29

2025-09-27

0001000228

hsic:TermCreditAgreementMember

2023-12-31

2024-12-28

0001000228

hsic:USTradeAccountsReceivableSecuritizationMember

2024-12-29

2025-09-27

0001000228

hsic:USTradeAccountsReceivableSecuritizationMember

2023-01-01

2023-12-30

0001000228

hsic:USTradeAccountsReceivableSecuritizationMember

2023-12-31

2024-12-28

0001000228

srt:MinimumMember

hsic:USTradeAccountsReceivableSecuritizationMember

2024-12-29

2025-09-27

0001000228

srt:MaximumMember

hsic:USTradeAccountsReceivableSecuritizationMember

2024-12-29

2025-09-27

0001000228

hsic:PrivatePlacementFacilitiesMember

hsic:PrivatePlacementFacilities1Member

2024-12-29

2025-09-27

0001000228

hsic:PrivatePlacementFacilitiesMember

hsic:PrivatePlacementFacilities2Member

2024-12-29

2025-09-27

0001000228

hsic:PrivatePlacementFacilitiesMember

hsic:PrivatePlacementFacilities3Member

2024-12-29

2025-09-27

0001000228

hsic:PrivatePlacementFacilitiesMember

hsic:PrivatePlacementFacilities4Member

2024-12-29

2025-09-27

0001000228

hsic:PrivatePlacementFacilitiesMember

hsic:PrivatePlacementFacilities5Member

2024-12-29

2025-09-27

0001000228

hsic:PrivatePlacementFacilitiesMember

hsic:PrivatePlacementFacilities6Member

2024-12-29

2025-09-27

0001000228

hsic:PrivatePlacementFacilitiesMember

hsic:PrivatePlacementFacilities7Member

2024-12-29

2025-09-27

0001000228

hsic:PrivatePlacementFacilitiesMember

hsic:PrivatePlacementFacilities8Member

2024-12-29

2025-09-27

0001000228

hsic:PrivatePlacementFacilitiesMember

hsic:PrivatePlacementFacilities9Member

2024-12-29

2025-09-27

0001000228

hsic:PrivatePlacementFacilitiesMember

hsic:PrivatePlacementFacilities10Member

2024-12-29

2025-09-27

0001000228

hsic:PrivatePlacementFacilitiesMember

hsic:PrivatePlacementFacilities1Member

2025-09-27

0001000228

hsic:PrivatePlacementFacilitiesMember

hsic:PrivatePlacementFacilities2Member

2025-09-27

0001000228

hsic:PrivatePlacementFacilitiesMember

hsic:PrivatePlacementFacilities3Member

2025-09-27

0001000228

hsic:PrivatePlacementFacilitiesMember

hsic:PrivatePlacementFacilities4Member

2025-09-27

0001000228

hsic:PrivatePlacementFacilitiesMember

hsic:PrivatePlacementFacilities5Member

2025-09-27

0001000228

hsic:PrivatePlacementFacilitiesMember

hsic:PrivatePlacementFacilities6Member

2025-09-27

0001000228

hsic:PrivatePlacementFacilitiesMember

hsic:PrivatePlacementFacilities7Member

2025-09-27

0001000228

hsic:PrivatePlacementFacilitiesMember

hsic:PrivatePlacementFacilities8Member

2025-09-27

0001000228

hsic:PrivatePlacementFacilitiesMember

hsic:PrivatePlacementFacilities9Member

2025-09-27

0001000228

hsic:PrivatePlacementFacilitiesMember

hsic:PrivatePlacementFacilities10Member

2025-09-27

0001000228

hsic:PrivatePlacementFacilitiesMember

hsic:PrivatePlacementFacilities1Member

2023-12-31

2024-12-28

0001000228

hsic:PrivatePlacementFacilitiesMember

hsic:PrivatePlacementFacilities2Member

2023-12-31

2024-12-28

0001000228

hsic:PrivatePlacementFacilitiesMember

hsic:PrivatePlacementFacilities3Member

2023-12-31

2024-12-28

0001000228

hsic:PrivatePlacementFacilitiesMember

hsic:PrivatePlacementFacilities4Member

2023-12-31

2024-12-28

0001000228

hsic:PrivatePlacementFacilitiesMember

hsic:PrivatePlacementFacilities5Member

2023-12-31

2024-12-28

0001000228

hsic:PrivatePlacementFacilitiesMember

hsic:PrivatePlacementFacilities6Member

2023-12-31

2024-12-28

0001000228

hsic:PrivatePlacementFacilitiesMember

hsic:PrivatePlacementFacilities7Member

2023-12-31

2024-12-28

0001000228

hsic:PrivatePlacementFacilitiesMember

hsic:PrivatePlacementFacilities8Member

2023-12-31

2024-12-28

0001000228

hsic:PrivatePlacementFacilitiesMember

hsic:PrivatePlacementFacilities9Member

2023-12-31

2024-12-28

0001000228

hsic:PrivatePlacementFacilitiesMember

hsic:PrivatePlacementFacilities10Member

2023-12-31

2024-12-28

0001000228

hsic:PrivatePlacementFacilitiesMember

hsic:PrivatePlacementFacilities1Member

2024-12-28

0001000228

hsic:PrivatePlacementFacilitiesMember

hsic:PrivatePlacementFacilities2Member

2024-12-28

0001000228

hsic:PrivatePlacementFacilitiesMember

hsic:PrivatePlacementFacilities3Member

2024-12-28

0001000228

hsic:PrivatePlacementFacilitiesMember

hsic:PrivatePlacementFacilities4Member

2024-12-28

0001000228

hsic:PrivatePlacementFacilitiesMember

hsic:PrivatePlacementFacilities5Member

2024-12-28

0001000228

hsic:PrivatePlacementFacilitiesMember

hsic:PrivatePlacementFacilities6Member

2024-12-28

0001000228

hsic:PrivatePlacementFacilitiesMember

hsic:PrivatePlacementFacilities7Member

2024-12-28

0001000228

hsic:PrivatePlacementFacilitiesMember

hsic:PrivatePlacementFacilities8Member

2024-12-28

0001000228

hsic:PrivatePlacementFacilitiesMember

hsic:PrivatePlacementFacilities9Member

2024-12-28

0001000228

hsic:PrivatePlacementFacilitiesMember

hsic:PrivatePlacementFacilities10Member

2024-12-28

0001000228

us-gaap:RevolvingCreditFacilityMember

2025-09-27

0001000228

us-gaap:RevolvingCreditFacilityMember

2024-12-28

0001000228

us-gaap:RevolvingCreditFacilityMember

2021-08-20

2021-08-20

0001000228

us-gaap:RevolvingCreditFacilityMember

2023-07-11

2023-07-11

0001000228

us-gaap:RevolvingCreditFacilityMember

2024-12-29

2025-09-27

0001000228

us-gaap:RevolvingCreditFacilityMember

2023-12-31

2024-12-28

0001000228

hsic:Plan2024Member

2024-12-29

2025-09-27

0001000228

hsic:Plan2022Member

2024-12-28

0001000228

hsic:Plan2024Member

2024-12-28

0001000228

hsic:Plan2022Member

2024-12-29

2025-09-27

0001000228

srt:MaximumMember

2025-09-27

0001000228

us-gaap:SegmentContinuingOperationsMember

hsic:ActionsConsolidatedInTheMultiDistrictLitigationMember

2023-12-31

2024-12-28

0001000228

us-gaap:ShareBasedCompensationAwardTrancheOneMember

srt:DirectorMember

hsic:TimeBasedRestrictedStockRestrictedUnitsMember

2024-12-29

2025-09-27

0001000228

us-gaap:ShareBasedCompensationAwardTrancheTwoMember

srt:DirectorMember

hsic:TimeBasedRestrictedStockRestrictedUnitsMember

2024-12-29

2025-09-27

0001000228

us-gaap:ShareBasedCompensationAwardTrancheOneMember

srt:VicePresidentMember

hsic:TimeBasedRestrictedStockRestrictedUnitsMember

2024-12-29

2025-09-27

0001000228

us-gaap:ShareBasedCompensationAwardTrancheTwoMember

srt:VicePresidentMember

hsic:TimeBasedRestrictedStockRestrictedUnitsMember

2024-12-29

2025-09-27

0001000228

srt:VicePresidentMember

hsic:TimeBasedRestrictedStockRestrictedUnitsMember

2024-12-29

2025-09-27

0001000228

srt:VicePresidentMember

hsic:PerformanceBasedRestrictedStockRestrictedUnitsMember

2024-12-29

2025-09-27

0001000228

srt:MaximumMember

hsic:EmployeesAndMinorityShareholdersMember

2025-09-27

0001000228

srt:MinimumMember

hsic:EmployeesAndMinorityShareholdersMember

2025-09-27

0001000228

hsic:EmployeesAndMinorityShareholdersMember

2025-09-27

0001000228

hsic:EmployeesAndMinorityShareholdersMember

2024-12-28

0001000228

hsic:EmployeesAndMinorityShareholdersMember

hsic:OperatingLeaseLiabilitiesCurrentMember

hsic:RelatedPartyConcentrationRiskMember

2024-12-29

2025-09-27

0001000228

hsic:EmployeesAndMinorityShareholdersMember

hsic:OperatingLeaseLiabilitiesNoncurrentMember

hsic:RelatedPartyConcentrationRiskMember

2024-12-29

2025-09-27

0001000228

hsic:EmployeesAndMinorityShareholdersMember

hsic:OperatingLeaseLiabilitiesCurrentMember

hsic:RelatedPartyConcentrationRiskMember

2023-12-31

2024-12-28

0001000228

hsic:EmployeesAndMinorityShareholdersMember

hsic:OperatingLeaseLiabilitiesNoncurrentMember

hsic:RelatedPartyConcentrationRiskMember

2023-12-31

2024-12-28

0001000228

hsic:OtherShortTermCreditLinesMember

2024-12-29

2025-09-27

0001000228

hsic:TriMedIncMember

2024-04-01

2024-04-01

0001000228

hsic:Plan2022Member

2025-09-27

0001000228

hsic:Plan2024Member

2025-09-27

0001000228

us-gaap:EquityMethodInvesteeMember

2025-09-27

0001000228

us-gaap:FairValueInputsLevel1Member

us-gaap:FairValueMeasurementsRecurringMember

us-gaap:TotalReturnSwapMember

2024-12-28

0001000228

us-gaap:FairValueInputsLevel2Member

us-gaap:FairValueMeasurementsRecurringMember

us-gaap:TotalReturnSwapMember

2024-12-28

0001000228

us-gaap:FairValueInputsLevel3Member

us-gaap:FairValueMeasurementsRecurringMember

us-gaap:TotalReturnSwapMember

2024-12-28

0001000228

us-gaap:FairValueMeasurementsRecurringMember

us-gaap:TotalReturnSwapMember

2024-12-28

0001000228

us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember

hsic:CustomerRelationshipsAndListsMember

2024-12-28

0001000228

us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember

us-gaap:TrademarksAndTradeNamesMember

2024-12-28

0001000228

us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember

hsic:ProductDevelopmentMember

2024-12-28

0001000228

us-gaap:NoncompeteAgreementsMember

us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember

2024-12-28

0001000228

us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember

hsic:CustomerRelationshipsAndListsMember

2023-12-31

2024-12-28

0001000228

us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember

us-gaap:TrademarksAndTradeNamesMember

2023-12-31

2024-12-28

0001000228

us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember

hsic:ProductDevelopmentMember

2023-12-31

2024-12-28

0001000228

us-gaap:NoncompeteAgreementsMember

us-gaap:SeriesOfIndividuallyImmaterialBusinessAcquisitionsMember

2023-12-31

2024-12-28

0001000228

hsic:ProductDevelopmentMember

hsic:TriMedIncMember

2024-12-29

2025-09-27

0001000228

us-gaap:TrademarksAndTradeNamesMember

hsic:TriMedIncMember

2024-12-29

2025-09-27

0001000228

hsic:ProductDevelopmentMember

hsic:TriMedIncMember

2025-09-27

0001000228

us-gaap:TrademarksAndTradeNamesMember

hsic:TriMedIncMember

2025-09-27

0001000228

us-gaap:InProcessResearchAndDevelopmentMember

hsic:TriMedIncMember

2025-09-27

0001000228

us-gaap:InvestorMember

2025-09-27

0001000228

us-gaap:InvestorMember

2025-05-16

2025-05-16

0001000228

2025-06-28

0001000228

hsic:CyberIncidentMember

2025-06-29

2025-09-27

0001000228

hsic:CyberIncidentMember

2024-06-30

2024-09-28

0001000228

hsic:CyberIncidentMember

2023-12-31

2024-09-28

0001000228

us-gaap:OperatingSegmentsMember

hsic:GlobalDistributionAndValueAddedServicesMember

hsic:GlobalDentalMerchandiseMember

2025-06-29

2025-09-27

0001000228

us-gaap:OperatingSegmentsMember

hsic:GlobalDistributionAndValueAddedServicesMember

hsic:GlobalDentalEquipmentMember

2025-06-29

2025-09-27

0001000228

us-gaap:OperatingSegmentsMember

hsic:GlobalDistributionAndValueAddedServicesMember

hsic:GlobalValueAddedServicesMember

2025-06-29

2025-09-27

0001000228

us-gaap:OperatingSegmentsMember

hsic:GlobalDistributionAndValueAddedServicesMember

hsic:GlobalDentalMember

2025-06-29

2025-09-27

0001000228

us-gaap:OperatingSegmentsMember

hsic:GlobalDistributionAndValueAddedServicesMember

hsic:GlobalMedicalMember

2025-06-29

2025-09-27

0001000228

us-gaap:OperatingSegmentsMember

hsic:GlobalDistributionAndValueAddedServicesMember

2025-06-29

2025-09-27

0001000228

us-gaap:OperatingSegmentsMember

hsic:GlobalDistributionAndValueAddedServicesMember

hsic:GlobalDentalMerchandiseMember

2023-12-31

2024-09-28

0001000228

us-gaap:OperatingSegmentsMember

hsic:GlobalDistributionAndValueAddedServicesMember

hsic:GlobalDentalEquipmentMember

2023-12-31

2024-09-28

0001000228

us-gaap:OperatingSegmentsMember

hsic:GlobalDistributionAndValueAddedServicesMember

hsic:GlobalValueAddedServicesMember

2023-12-31

2024-09-28

0001000228

us-gaap:OperatingSegmentsMember

hsic:GlobalDistributionAndValueAddedServicesMember

hsic:GlobalDentalMember

2023-12-31

2024-09-28

0001000228

us-gaap:OperatingSegmentsMember

hsic:GlobalDistributionAndValueAddedServicesMember

hsic:GlobalMedicalMember

2023-12-31

2024-09-28

0001000228

us-gaap:OperatingSegmentsMember

hsic:GlobalDistributionAndValueAddedServicesMember

2023-12-31

2024-09-28

0001000228

us-gaap:OperatingSegmentsMember

hsic:GlobalSpecialtyProductsMember

2025-06-29

2025-09-27

0001000228

us-gaap:OperatingSegmentsMember

hsic:GlobalTechnologyMember

2025-06-29

2025-09-27

0001000228

hsic:EliminationsAndReconcilingItemsMember

2025-06-29

2025-09-27

0001000228

us-gaap:OperatingSegmentsMember

hsic:GlobalSpecialtyProductsMember

2023-12-31

2024-09-28

0001000228

us-gaap:OperatingSegmentsMember

hsic:GlobalTechnologyMember

2023-12-31

2024-09-28

0001000228

hsic:EliminationsAndReconcilingItemsMember

2023-12-31

2024-09-28

0001000228

us-gaap:OperatingSegmentsMember

2025-06-29

2025-09-27

0001000228

us-gaap:OperatingSegmentsMember

2023-12-31

2024-09-28

0001000228

hsic:GlobalDistributionAndValueAddedServicesMember

hsic:EliminationsAndReconcilingItemsMember

2023-12-31

2024-09-28

0001000228

hsic:GlobalSpecialtyProductsMember

hsic:EliminationsAndReconcilingItemsMember

2023-12-31

2024-09-28

0001000228

hsic:GlobalTechnologyMember

hsic:EliminationsAndReconcilingItemsMember

2024-12-29

2025-09-27

0001000228

hsic:GlobalTechnologyMember

hsic:EliminationsAndReconcilingItemsMember

2023-12-31

2024-09-28

0001000228

hsic:GlobalDistributionAndValueAddedServicesMember

hsic:EliminationsAndReconcilingItemsMember

2024-06-30

2024-09-28

0001000228

hsic:GlobalSpecialtyProductsMember

hsic:EliminationsAndReconcilingItemsMember

2024-06-30

2024-09-28

0001000228

hsic:GlobalTechnologyMember

hsic:EliminationsAndReconcilingItemsMember

2024-06-30

2024-09-28

0001000228

hsic:GlobalDistributionAndValueAddedServicesMember

hsic:EliminationsAndReconcilingItemsMember

2025-06-29

2025-09-27

0001000228

hsic:GlobalSpecialtyProductsMember

hsic:EliminationsAndReconcilingItemsMember

2025-06-29

2025-09-27

0001000228

hsic:GlobalTechnologyMember

hsic:EliminationsAndReconcilingItemsMember

2025-06-29

2025-09-27

0001000228

hsic:GlobalDistributionAndValueAddedServicesMember

2023-12-31

2024-09-28

0001000228

hsic:GlobalSpecialtyProductsMember

2023-12-31

2024-09-28

0001000228

hsic:GlobalTechnologyMember

2023-12-31

2024-09-28

0001000228

hsic:GlobalDistributionAndValueAddedServicesMember

2025-06-29

2025-09-27

0001000228

hsic:GlobalSpecialtyProductsMember

2025-06-29

2025-09-27

0001000228

hsic:GlobalTechnologyMember

2025-06-29

2025-09-27

0001000228

us-gaap:OperatingSegmentsMember

hsic:GlobalDistributionAndValueAddedServicesMember

2024-06-30

2024-09-28

0001000228

us-gaap:OperatingSegmentsMember

hsic:GlobalSpecialtyProductsMember

2024-06-30

2024-09-28

0001000228

us-gaap:OperatingSegmentsMember

hsic:GlobalTechnologyMember

2024-06-30

2024-09-28

0001000228

us-gaap:OperatingSegmentsMember

2024-06-30

2024-09-28

0001000228

us-gaap:CorporateNonSegmentMember

2025-06-29

2025-09-27

0001000228

us-gaap:CorporateNonSegmentMember

2023-12-31

2024-09-28

0001000228

hsic:EliminationsAndReconcilingItemsMember

2024-06-30

2024-09-28

0001000228

hsic:June2026ThroughJune2027Member

2024-12-29

2025-09-27

0001000228

hsic:September2027ThroughJune2030Member

2024-12-29

2025-09-27

0001000228

hsic:Plan2024Member

2025-06-29

2025-09-27

0001000228

hsic:Plan2022Member

2023-12-31

2024-09-28

0001000228

hsic:Plan2022Member

2024-06-30

2024-09-28

0001000228

us-gaap:OperatingSegmentsMember

hsic:SeveranceAndEmployeeRelatedCostsMember

hsic:Plan2024Member

hsic:GlobalDistributionAndValueAddedServicesMember

2025-06-29

2025-09-27

0001000228

us-gaap:OperatingSegmentsMember

hsic:SeveranceAndEmployeeRelatedCostsMember

hsic:Plan2024Member

hsic:GlobalSpecialtyProductsMember

2025-06-29

2025-09-27

0001000228

us-gaap:OperatingSegmentsMember

hsic:Plan2024Member

hsic:GlobalDistributionAndValueAddedServicesMember

hsic:ImpairmentAndAcceleratedDepreciationAndAmortizationMember

2025-06-29

2025-09-27

0001000228

us-gaap:OperatingSegmentsMember

hsic:Plan2024Member

hsic:GlobalSpecialtyProductsMember

hsic:ImpairmentAndAcceleratedDepreciationAndAmortizationMember

2025-06-29

2025-09-27

0001000228

us-gaap:OperatingSegmentsMember

hsic:ExitAndOtherRelatedCostsMember

hsic:Plan2024Member

hsic:GlobalDistributionAndValueAddedServicesMember

2025-06-29

2025-09-27

0001000228

us-gaap:OperatingSegmentsMember

hsic:ExitAndOtherRelatedCostsMember

hsic:Plan2024Member

hsic:GlobalSpecialtyProductsMember

2025-06-29

2025-09-27

0001000228

us-gaap:OperatingSegmentsMember

hsic:Plan2024Member

hsic:GlobalDistributionAndValueAddedServicesMember

2025-06-29

2025-09-27

0001000228

us-gaap:OperatingSegmentsMember

hsic:Plan2024Member

hsic:GlobalSpecialtyProductsMember

2025-06-29

2025-09-27

0001000228

us-gaap:CorporateNonSegmentMember

hsic:SeveranceAndEmployeeRelatedCostsMember

hsic:Plan2024Member

2025-06-29

2025-09-27

0001000228

us-gaap:CorporateNonSegmentMember

hsic:Plan2024Member

hsic:ImpairmentAndAcceleratedDepreciationAndAmortizationMember

2025-06-29

2025-09-27

0001000228

us-gaap:CorporateNonSegmentMember

hsic:ExitAndOtherRelatedCostsMember

hsic:Plan2024Member

2025-06-29

2025-09-27

0001000228

us-gaap:CorporateNonSegmentMember

hsic:Plan2024Member

2025-06-29

2025-09-27

0001000228

hsic:SeveranceAndEmployeeRelatedCostsMember

hsic:Plan2024Member

2025-06-29

2025-09-27

0001000228

hsic:Plan2024Member

hsic:ImpairmentAndAcceleratedDepreciationAndAmortizationMember

2025-06-29

2025-09-27

0001000228

hsic:ExitAndOtherRelatedCostsMember

hsic:Plan2024Member

2025-06-29

2025-09-27

0001000228

us-gaap:OperatingSegmentsMember

hsic:SeveranceAndEmployeeRelatedCostsMember

hsic:Plan2022Member

hsic:GlobalDistributionAndValueAddedServicesMember

2024-06-30

2024-09-28

0001000228

us-gaap:OperatingSegmentsMember

hsic:SeveranceAndEmployeeRelatedCostsMember

hsic:Plan2022Member

hsic:GlobalSpecialtyProductsMember

2024-06-30

2024-09-28

0001000228

us-gaap:OperatingSegmentsMember

hsic:Plan2022Member

hsic:GlobalDistributionAndValueAddedServicesMember

hsic:ImpairmentAndAcceleratedDepreciationAndAmortizationMember

2024-06-30

2024-09-28

0001000228

us-gaap:OperatingSegmentsMember

hsic:Plan2022Member

hsic:GlobalSpecialtyProductsMember

hsic:ImpairmentAndAcceleratedDepreciationAndAmortizationMember

2024-06-30

2024-09-28

0001000228

us-gaap:OperatingSegmentsMember

hsic:ExitAndOtherRelatedCostsMember

hsic:Plan2022Member

hsic:GlobalDistributionAndValueAddedServicesMember

2024-06-30

2024-09-28

0001000228

us-gaap:OperatingSegmentsMember

hsic:ExitAndOtherRelatedCostsMember

hsic:Plan2022Member

hsic:GlobalSpecialtyProductsMember

2024-06-30

2024-09-28

0001000228

us-gaap:OperatingSegmentsMember

hsic:Plan2022Member

hsic:GlobalDistributionAndValueAddedServicesMember

2024-06-30

2024-09-28

0001000228

us-gaap:OperatingSegmentsMember

hsic:Plan2022Member

hsic:GlobalSpecialtyProductsMember

2024-06-30

2024-09-28

0001000228

us-gaap:CorporateNonSegmentMember

hsic:SeveranceAndEmployeeRelatedCostsMember

hsic:Plan2022Member

2024-06-30

2024-09-28

0001000228

us-gaap:CorporateNonSegmentMember

hsic:Plan2022Member

hsic:ImpairmentAndAcceleratedDepreciationAndAmortizationMember

2024-06-30

2024-09-28

0001000228

us-gaap:CorporateNonSegmentMember

hsic:ExitAndOtherRelatedCostsMember

hsic:Plan2022Member

2024-06-30

2024-09-28

0001000228

us-gaap:CorporateNonSegmentMember

hsic:Plan2022Member

2024-06-30

2024-09-28

0001000228

hsic:SeveranceAndEmployeeRelatedCostsMember

hsic:Plan2022Member

2024-06-30

2024-09-28

0001000228

hsic:Plan2022Member

hsic:ImpairmentAndAcceleratedDepreciationAndAmortizationMember

2024-06-30

2024-09-28

0001000228

hsic:ExitAndOtherRelatedCostsMember

hsic:Plan2022Member

2024-06-30

2024-09-28

0001000228

us-gaap:OperatingSegmentsMember

hsic:SeveranceAndEmployeeRelatedCostsMember

hsic:Plan2024Member

hsic:GlobalDistributionAndValueAddedServicesMember

2024-12-29

2025-09-27

0001000228

us-gaap:OperatingSegmentsMember

hsic:SeveranceAndEmployeeRelatedCostsMember

hsic:Plan2024Member

hsic:GlobalSpecialtyProductsMember

2024-12-29

2025-09-27

0001000228

us-gaap:OperatingSegmentsMember

hsic:SeveranceAndEmployeeRelatedCostsMember

hsic:Plan2024Member

hsic:GlobalTechnologyMember

2024-12-29

2025-09-27

0001000228

us-gaap:OperatingSegmentsMember

hsic:Plan2024Member

hsic:GlobalDistributionAndValueAddedServicesMember

hsic:ImpairmentAndAcceleratedDepreciationAndAmortizationMember

2024-12-29

2025-09-27

0001000228

us-gaap:OperatingSegmentsMember

hsic:Plan2024Member

hsic:GlobalSpecialtyProductsMember

hsic:ImpairmentAndAcceleratedDepreciationAndAmortizationMember

2024-12-29

2025-09-27

0001000228

us-gaap:OperatingSegmentsMember

hsic:Plan2024Member

hsic:GlobalTechnologyMember

hsic:ImpairmentAndAcceleratedDepreciationAndAmortizationMember

2024-12-29

2025-09-27

0001000228

us-gaap:OperatingSegmentsMember

hsic:ExitAndOtherRelatedCostsMember

hsic:Plan2024Member

hsic:GlobalDistributionAndValueAddedServicesMember

2024-12-29

2025-09-27

0001000228

us-gaap:OperatingSegmentsMember

hsic:ExitAndOtherRelatedCostsMember

hsic:Plan2024Member

hsic:GlobalSpecialtyProductsMember

2024-12-29

2025-09-27

0001000228

us-gaap:OperatingSegmentsMember

hsic:ExitAndOtherRelatedCostsMember

hsic:Plan2024Member

hsic:GlobalTechnologyMember

2024-12-29

2025-09-27

0001000228

us-gaap:OperatingSegmentsMember

hsic:LossOnDisposalOfBusinessMember

hsic:Plan2024Member

hsic:GlobalDistributionAndValueAddedServicesMember

2024-12-29

2025-09-27

0001000228

us-gaap:OperatingSegmentsMember

hsic:LossOnDisposalOfBusinessMember

hsic:Plan2024Member

hsic:GlobalSpecialtyProductsMember

2024-12-29

2025-09-27

0001000228

us-gaap:OperatingSegmentsMember

hsic:LossOnDisposalOfBusinessMember

hsic:Plan2024Member

hsic:GlobalTechnologyMember

2024-12-29

2025-09-27

0001000228

us-gaap:OperatingSegmentsMember

hsic:Plan2024Member

hsic:GlobalDistributionAndValueAddedServicesMember

2024-12-29

2025-09-27

0001000228

us-gaap:OperatingSegmentsMember

hsic:Plan2024Member

hsic:GlobalSpecialtyProductsMember

2024-12-29

2025-09-27

0001000228

us-gaap:OperatingSegmentsMember

hsic:Plan2024Member

hsic:GlobalTechnologyMember

2024-12-29

2025-09-27

0001000228

us-gaap:OperatingSegmentsMember

hsic:SeveranceAndEmployeeRelatedCostsMember

hsic:Plan2022Member

hsic:GlobalDistributionAndValueAddedServicesMember

2023-12-31

2024-09-28

0001000228

us-gaap:OperatingSegmentsMember

hsic:SeveranceAndEmployeeRelatedCostsMember

hsic:Plan2022Member

hsic:GlobalSpecialtyProductsMember

2023-12-31

2024-09-28

0001000228

us-gaap:OperatingSegmentsMember

hsic:SeveranceAndEmployeeRelatedCostsMember

hsic:Plan2022Member

hsic:GlobalTechnologyMember

2023-12-31

2024-09-28

0001000228

us-gaap:OperatingSegmentsMember

hsic:Plan2022Member

hsic:GlobalDistributionAndValueAddedServicesMember

hsic:ImpairmentAndAcceleratedDepreciationAndAmortizationMember

2023-12-31

2024-09-28

0001000228

us-gaap:OperatingSegmentsMember

hsic:Plan2022Member

hsic:GlobalSpecialtyProductsMember

hsic:ImpairmentAndAcceleratedDepreciationAndAmortizationMember

2023-12-31

2024-09-28

0001000228

us-gaap:OperatingSegmentsMember

hsic:Plan2022Member

hsic:GlobalTechnologyMember

hsic:ImpairmentAndAcceleratedDepreciationAndAmortizationMember

2023-12-31

2024-09-28

0001000228

us-gaap:OperatingSegmentsMember

hsic:ExitAndOtherRelatedCostsMember

hsic:Plan2022Member

hsic:GlobalDistributionAndValueAddedServicesMember

2023-12-31

2024-09-28

0001000228

us-gaap:OperatingSegmentsMember

hsic:ExitAndOtherRelatedCostsMember

hsic:Plan2022Member

hsic:GlobalSpecialtyProductsMember

2023-12-31

2024-09-28

0001000228

us-gaap:OperatingSegmentsMember

hsic:ExitAndOtherRelatedCostsMember

hsic:Plan2022Member

hsic:GlobalTechnologyMember

2023-12-31

2024-09-28

0001000228

us-gaap:OperatingSegmentsMember

hsic:Plan2022Member

hsic:GlobalDistributionAndValueAddedServicesMember

2023-12-31

2024-09-28

0001000228

us-gaap:OperatingSegmentsMember

hsic:Plan2022Member

hsic:GlobalSpecialtyProductsMember

2023-12-31

2024-09-28

0001000228

us-gaap:OperatingSegmentsMember

hsic:Plan2022Member

hsic:GlobalTechnologyMember

2023-12-31

2024-09-28

0001000228

us-gaap:CorporateNonSegmentMember

hsic:SeveranceAndEmployeeRelatedCostsMember

hsic:Plan2024Member

2024-12-29

2025-09-27

0001000228

us-gaap:CorporateNonSegmentMember

hsic:Plan2024Member

hsic:ImpairmentAndAcceleratedDepreciationAndAmortizationMember

2024-12-29

2025-09-27

0001000228

us-gaap:CorporateNonSegmentMember

hsic:ExitAndOtherRelatedCostsMember

hsic:Plan2024Member

2024-12-29

2025-09-27

0001000228

us-gaap:CorporateNonSegmentMember

hsic:LossOnDisposalOfBusinessMember

hsic:Plan2024Member

2024-12-29

2025-09-27

0001000228

us-gaap:CorporateNonSegmentMember

hsic:Plan2024Member

2024-12-29

2025-09-27

0001000228

us-gaap:CorporateNonSegmentMember

hsic:SeveranceAndEmployeeRelatedCostsMember

hsic:Plan2022Member

2023-12-31

2024-09-28

0001000228

us-gaap:CorporateNonSegmentMember

hsic:Plan2022Member

hsic:ImpairmentAndAcceleratedDepreciationAndAmortizationMember

2023-12-31

2024-09-28

0001000228

us-gaap:CorporateNonSegmentMember

hsic:ExitAndOtherRelatedCostsMember

hsic:Plan2022Member

2023-12-31

2024-09-28

0001000228

us-gaap:CorporateNonSegmentMember

hsic:Plan2022Member

2023-12-31

2024-09-28

0001000228

hsic:SeveranceAndEmployeeRelatedCostsMember

hsic:Plan2024Member

2024-12-29

2025-09-27

0001000228

hsic:Plan2024Member

hsic:ImpairmentAndAcceleratedDepreciationAndAmortizationMember

2024-12-29

2025-09-27

0001000228

hsic:ExitAndOtherRelatedCostsMember

hsic:Plan2024Member

2024-12-29

2025-09-27

0001000228

hsic:LossOnDisposalOfBusinessMember

hsic:Plan2024Member

2024-12-29

2025-09-27

0001000228

hsic:SeveranceAndEmployeeRelatedCostsMember

hsic:Plan2022Member

2023-12-31

2024-09-28

0001000228

hsic:Plan2022Member

hsic:ImpairmentAndAcceleratedDepreciationAndAmortizationMember

2023-12-31

2024-09-28

0001000228

hsic:ExitAndOtherRelatedCostsMember

hsic:Plan2022Member

2023-12-31

2024-09-28

0001000228

srt:ChiefExecutiveOfficerMember

hsic:TimeBasedRestrictedStockRestrictedUnitsMember

2024-12-29

2025-09-27

0001000228

srt:ChiefExecutiveOfficerMember

hsic:PerformanceBasedRestrictedStockRestrictedUnitsMember

2024-12-29

2025-09-27

0001000228

hsic:TimeBasedRestrictedStockRestrictedUnitsMember

hsic:ExecutiveManagementCommitteeMember

2024-12-29

2025-09-27

0001000228

hsic:PerformanceBasedRestrictedStockRestrictedUnitsMember

hsic:ExecutiveManagementCommitteeMember

2024-12-29

2025-09-27

0001000228

hsic:TimeBasedRestrictedStockRestrictedUnitsMember

2023-12-31

2024-09-28

0001000228

hsic:PerformanceBasedRestrictedStockRestrictedUnitsMember

2023-12-31

2024-09-28

0001000228

us-gaap:OperatingSegmentsMember

hsic:GlobalDistributionAndValueAddedServicesMember

hsic:GlobalDentalMerchandiseMember

2024-06-30

2024-09-28

0001000228

us-gaap:OperatingSegmentsMember

hsic:GlobalDistributionAndValueAddedServicesMember

hsic:GlobalDentalEquipmentMember

2024-06-30

2024-09-28

0001000228

us-gaap:OperatingSegmentsMember

hsic:GlobalDistributionAndValueAddedServicesMember

hsic:GlobalValueAddedServicesMember

2024-06-30

2024-09-28

0001000228

us-gaap:OperatingSegmentsMember

hsic:GlobalDistributionAndValueAddedServicesMember

hsic:GlobalDentalMember

2024-06-30

2024-09-28

0001000228

us-gaap:OperatingSegmentsMember

hsic:GlobalDistributionAndValueAddedServicesMember

hsic:GlobalMedicalMember

2024-06-30

2024-09-28

0001000228

hsic:GlobalDistributionAndValueAddedServicesMember

2024-06-30

2024-09-28

0001000228

hsic:GlobalSpecialtyProductsMember

2024-06-30

2024-09-28

0001000228

hsic:GlobalTechnologyMember

2024-06-30

2024-09-28

0001000228

us-gaap:CorporateNonSegmentMember

2024-06-30

2024-09-28

0001000228

us-gaap:InvestorMember

2025-05-16

0001000228

2025-05-19

0001000228

2025-05-01

2025-05-31

0001000228

hsic:CyberIncidentMember

2024-12-29

2025-03-29

0001000228

hsic:Acquisitions2025Member

2024-12-29

2025-09-27

0001000228

srt:MinimumMember

hsic:Acquisitions2025Member

2025-09-27

0001000228

srt:MaximumMember

hsic:Acquisitions2025Member

2025-09-27

0001000228

hsic:Acquisitions2025Member

2025-09-27

0001000228

hsic:CustomerRelationshipsAndListsMember

hsic:Acquisitions2025Member

2024-12-29

2025-09-27

0001000228

us-gaap:TrademarksAndTradeNamesMember

hsic:Acquisitions2025Member

2024-12-29

2025-09-27

0001000228

us-gaap:NoncompeteAgreementsMember

hsic:Acquisitions2025Member

2024-12-29

2025-09-27

0001000228

us-gaap:FairValueInputsLevel1Member

us-gaap:FairValueMeasurementsRecurringMember

us-gaap:TotalReturnSwapMember

2025-09-27

0001000228

us-gaap:FairValueInputsLevel2Member

us-gaap:FairValueMeasurementsRecurringMember

us-gaap:TotalReturnSwapMember

2025-09-27

0001000228

us-gaap:FairValueInputsLevel3Member

us-gaap:FairValueMeasurementsRecurringMember

us-gaap:TotalReturnSwapMember

2025-09-27

0001000228

us-gaap:FairValueMeasurementsRecurringMember

us-gaap:TotalReturnSwapMember

2025-09-27

0001000228

hsic:TermCreditAgreementMember

2024-12-29

2025-06-05

0001000228

hsic:TermCreditAgreementMember

2025-06-06

2025-06-28

0001000228

hsic:InternetBrandsIncMember

hsic:HenryScheinOneMember

2018-04-03

0001000228

hsic:InternetBrandsIncMember

hsic:HenryScheinOneMember

2025-09-27

0001000228

us-gaap:CoVenturerMember

hsic:InternetBrandsIncMember

2024-12-29

2025-09-27

0001000228

srt:AffiliatedEntityMember

hsic:InternetBrandsIncMember

hsic:HenryScheinOneLLCMember

2025-09-27

0001000228

srt:AffiliatedEntityMember

hsic:InternetBrandsIncMember

hsic:HenryScheinOneLLCMember

2024-12-28

0001000228

us-gaap:RoyaltyAgreementsMember

us-gaap:CoVenturerMember

hsic:InternetBrandsIncMember

2024-12-29

2025-09-27

0001000228

us-gaap:RoyaltyAgreementsMember

us-gaap:CoVenturerMember

hsic:InternetBrandsIncMember

2025-06-29

2025-09-27

0001000228

us-gaap:RoyaltyAgreementsMember

us-gaap:CoVenturerMember

hsic:InternetBrandsIncMember

2024-06-30

2024-09-28

0001000228

us-gaap:InvestorMember

srt:MaximumMember

2025-01-29

0001000228

us-gaap:OperatingSegmentsMember

hsic:SeveranceAndEmployeeRelatedCostsMember

hsic:Plan2024Member

hsic:GlobalTechnologyMember

2025-06-29

2025-09-27

0001000228

us-gaap:OperatingSegmentsMember

hsic:Plan2024Member

hsic:GlobalTechnologyMember

hsic:ImpairmentAndAcceleratedDepreciationAndAmortizationMember

2025-06-29

2025-09-27

0001000228

us-gaap:OperatingSegmentsMember

hsic:ExitAndOtherRelatedCostsMember

hsic:Plan2024Member

hsic:GlobalTechnologyMember

2025-06-29

2025-09-27

0001000228

us-gaap:OperatingSegmentsMember

hsic:Plan2024Member

hsic:GlobalTechnologyMember

2025-06-29

2025-09-27

0001000228

us-gaap:OperatingSegmentsMember

hsic:SeveranceAndEmployeeRelatedCostsMember

hsic:Plan2022Member

hsic:GlobalTechnologyMember

2024-06-30

2024-09-28

0001000228

us-gaap:OperatingSegmentsMember

hsic:Plan2022Member

hsic:GlobalTechnologyMember

hsic:ImpairmentAndAcceleratedDepreciationAndAmortizationMember

2024-06-30

2024-09-28

0001000228

us-gaap:OperatingSegmentsMember

hsic:ExitAndOtherRelatedCostsMember

hsic:Plan2022Member

hsic:GlobalTechnologyMember

2024-06-30

2024-09-28

0001000228

us-gaap:OperatingSegmentsMember

hsic:Plan2022Member

hsic:GlobalTechnologyMember

2024-06-30

2024-09-28

0001000228

us-gaap:CommonStockMember

2024-06-29

0001000228

us-gaap:CommonStockMember

2024-09-28

0001000228

us-gaap:CommonStockMember

2024-06-30

2024-09-28

0001000228

us-gaap:AdditionalPaidInCapitalMember

2024-06-29

0001000228

us-gaap:AdditionalPaidInCapitalMember

2024-06-30

2024-09-28

0001000228

us-gaap:AdditionalPaidInCapitalMember

2024-09-28

0001000228

us-gaap:RetainedEarningsMember

2024-06-29

0001000228

us-gaap:AccumulatedOtherComprehensiveIncomeMember

2024-06-29

0001000228

us-gaap:NoncontrollingInterestMember

2024-06-29

0001000228

2024-06-29

0001000228

us-gaap:RetainedEarningsMember

2024-06-30

2024-09-28

0001000228

us-gaap:NoncontrollingInterestMember

2024-06-30

2024-09-28

0001000228

us-gaap:AccumulatedOtherComprehensiveIncomeMember

2024-06-30

2024-09-28

0001000228

us-gaap:RetainedEarningsMember

2024-09-28

0001000228

us-gaap:AccumulatedOtherComprehensiveIncomeMember

2024-09-28

0001000228

us-gaap:NoncontrollingInterestMember

2024-09-28

0001000228

us-gaap:CommonStockMember

2023-12-30

0001000228

us-gaap:CommonStockMember

2023-12-31

2024-09-28

0001000228

us-gaap:AdditionalPaidInCapitalMember

2023-12-30

0001000228

us-gaap:AdditionalPaidInCapitalMember

2023-12-31

2024-09-28

0001000228

us-gaap:RetainedEarningsMember

2023-12-30

0001000228

us-gaap:AccumulatedOtherComprehensiveIncomeMember

2023-12-30

0001000228

us-gaap:NoncontrollingInterestMember

2023-12-30

0001000228

us-gaap:RetainedEarningsMember

2023-12-31

2024-09-28

0001000228

us-gaap:NoncontrollingInterestMember

2023-12-31

2024-09-28

0001000228

us-gaap:AccumulatedOtherComprehensiveIncomeMember

2023-12-31

2024-09-28

0001000228

hsic:AcquisitionsOfControllingInterestsOfAffiliatesMember

2025-06-29

2025-09-27

0001000228

hsic:AcquisitionsOfControllingInterestsOfAffiliatesMember

2024-12-29

2025-09-27

0001000228

hsic:AcquisitionsOfControllingInterestsOfAffiliatesMember

2024-06-30

2024-09-28

0001000228

hsic:AcquisitionsOfControllingInterestsOfAffiliatesMember

2023-12-31

2024-09-28

0001000228

hsic:Plan2024Member

2024-06-30

2024-09-28

0001000228

hsic:Plan2024Member

2023-12-31

2024-09-28

0001000228

us-gaap:OperatingSegmentsMember

hsic:GlobalDistributionAndValueAddedServicesMember

hsic:Plan2024Member

hsic:SeveranceAndEmployeeRelatedCostsMember

2024-06-30

2024-09-28

0001000228

us-gaap:OperatingSegmentsMember

hsic:GlobalDistributionAndValueAddedServicesMember

hsic:Plan2024Member

hsic:ImpairmentAndAcceleratedDepreciationAndAmortizationMember

2024-06-30

2024-09-28

0001000228

us-gaap:OperatingSegmentsMember

hsic:GlobalDistributionAndValueAddedServicesMember

hsic:Plan2024Member

hsic:ExitAndOtherRelatedCostsMember

2024-06-30

2024-09-28

0001000228

us-gaap:OperatingSegmentsMember

hsic:GlobalDistributionAndValueAddedServicesMember

hsic:Plan2024Member

2024-06-30

2024-09-28

0001000228

us-gaap:OperatingSegmentsMember

hsic:GlobalSpecialtyProductsMember

hsic:Plan2024Member

hsic:SeveranceAndEmployeeRelatedCostsMember

2024-06-30

2024-09-28

0001000228

us-gaap:OperatingSegmentsMember

hsic:GlobalSpecialtyProductsMember

hsic:Plan2024Member

hsic:ImpairmentAndAcceleratedDepreciationAndAmortizationMember

2024-06-30

2024-09-28

0001000228

us-gaap:OperatingSegmentsMember

hsic:GlobalSpecialtyProductsMember

hsic:Plan2024Member

hsic:ExitAndOtherRelatedCostsMember

2024-06-30

2024-09-28

0001000228

us-gaap:OperatingSegmentsMember

hsic:GlobalSpecialtyProductsMember

hsic:Plan2024Member

2024-06-30

2024-09-28

0001000228

us-gaap:OperatingSegmentsMember

hsic:GlobalTechnologyMember

hsic:Plan2024Member

hsic:SeveranceAndEmployeeRelatedCostsMember

2024-06-30

2024-09-28

0001000228

us-gaap:OperatingSegmentsMember

hsic:GlobalTechnologyMember

hsic:Plan2024Member

hsic:ImpairmentAndAcceleratedDepreciationAndAmortizationMember

2024-06-30

2024-09-28

0001000228

us-gaap:OperatingSegmentsMember

hsic:GlobalTechnologyMember

hsic:Plan2024Member

hsic:ExitAndOtherRelatedCostsMember

2024-06-30

2024-09-28

0001000228

us-gaap:OperatingSegmentsMember

hsic:GlobalTechnologyMember

hsic:Plan2024Member

2024-06-30

2024-09-28

0001000228

us-gaap:CorporateNonSegmentMember

hsic:Plan2024Member

hsic:SeveranceAndEmployeeRelatedCostsMember

2024-06-30

2024-09-28

0001000228

us-gaap:CorporateNonSegmentMember

hsic:Plan2024Member

hsic:ImpairmentAndAcceleratedDepreciationAndAmortizationMember

2024-06-30

2024-09-28

0001000228

us-gaap:CorporateNonSegmentMember

hsic:Plan2024Member

hsic:ExitAndOtherRelatedCostsMember

2024-06-30

2024-09-28

0001000228

us-gaap:CorporateNonSegmentMember

hsic:Plan2024Member

2024-06-30

2024-09-28

0001000228

hsic:Plan2024Member

hsic:SeveranceAndEmployeeRelatedCostsMember

2024-06-30

2024-09-28

0001000228

hsic:Plan2024Member

hsic:ImpairmentAndAcceleratedDepreciationAndAmortizationMember

2024-06-30

2024-09-28

0001000228

hsic:Plan2024Member

hsic:ExitAndOtherRelatedCostsMember

2024-06-30

2024-09-28

0001000228

us-gaap:CorporateNonSegmentMember

hsic:Plan2024Member

hsic:SeveranceAndEmployeeRelatedCostsMember

2023-12-31

2024-09-28

0001000228

us-gaap:CorporateNonSegmentMember

hsic:Plan2024Member

hsic:ImpairmentAndAcceleratedDepreciationAndAmortizationMember

2023-12-31

2024-09-28

0001000228

us-gaap:CorporateNonSegmentMember

hsic:Plan2024Member

hsic:ExitAndOtherRelatedCostsMember

2023-12-31

2024-09-28

0001000228

us-gaap:CorporateNonSegmentMember

hsic:Plan2024Member

2023-12-31

2024-09-28

0001000228

hsic:Plan2024Member

hsic:SeveranceAndEmployeeRelatedCostsMember

2023-12-31

2024-09-28

0001000228

hsic:Plan2024Member

hsic:ImpairmentAndAcceleratedDepreciationAndAmortizationMember

2023-12-31

2024-09-28

0001000228

hsic:Plan2024Member

hsic:ExitAndOtherRelatedCostsMember

2023-12-31

2024-09-28

0001000228

us-gaap:OperatingSegmentsMember

hsic:GlobalDistributionAndValueAddedServicesMember

hsic:Plan2024Member

hsic:SeveranceAndEmployeeRelatedCostsMember

2023-12-31

2024-09-28

0001000228

us-gaap:OperatingSegmentsMember

hsic:GlobalDistributionAndValueAddedServicesMember

hsic:Plan2024Member

hsic:ImpairmentAndAcceleratedDepreciationAndAmortizationMember

2023-12-31

2024-09-28

0001000228

us-gaap:OperatingSegmentsMember

hsic:GlobalDistributionAndValueAddedServicesMember

hsic:Plan2024Member

hsic:ExitAndOtherRelatedCostsMember

2023-12-31

2024-09-28

0001000228

us-gaap:OperatingSegmentsMember

hsic:GlobalDistributionAndValueAddedServicesMember

hsic:Plan2024Member

2023-12-31

2024-09-28

0001000228

us-gaap:OperatingSegmentsMember

hsic:GlobalSpecialtyProductsMember

hsic:Plan2024Member

hsic:SeveranceAndEmployeeRelatedCostsMember

2023-12-31

2024-09-28

0001000228

us-gaap:OperatingSegmentsMember

hsic:GlobalSpecialtyProductsMember

hsic:Plan2024Member

hsic:ImpairmentAndAcceleratedDepreciationAndAmortizationMember

2023-12-31

2024-09-28

0001000228

us-gaap:OperatingSegmentsMember

hsic:GlobalSpecialtyProductsMember

hsic:Plan2024Member

hsic:ExitAndOtherRelatedCostsMember

2023-12-31

2024-09-28

0001000228

us-gaap:OperatingSegmentsMember

hsic:GlobalSpecialtyProductsMember

hsic:Plan2024Member

2023-12-31

2024-09-28

0001000228

us-gaap:OperatingSegmentsMember

hsic:GlobalTechnologyMember

hsic:Plan2024Member

hsic:SeveranceAndEmployeeRelatedCostsMember

2023-12-31

2024-09-28

0001000228

us-gaap:OperatingSegmentsMember

hsic:GlobalTechnologyMember

hsic:Plan2024Member

hsic:ImpairmentAndAcceleratedDepreciationAndAmortizationMember

2023-12-31

2024-09-28

0001000228

us-gaap:OperatingSegmentsMember

hsic:GlobalTechnologyMember

hsic:Plan2024Member

hsic:ExitAndOtherRelatedCostsMember

2023-12-31

2024-09-28

0001000228

us-gaap:OperatingSegmentsMember

hsic:GlobalTechnologyMember

hsic:Plan2024Member

2023-12-31

2024-09-28

0001000228

2025-07-01

2025-07-31

0001000228

us-gaap:RoyaltyAgreementsMember

us-gaap:CoVenturerMember

hsic:InternetBrandsIncMember

2023-12-31

2024-09-28

0001000228

srt:MaximumMember

us-gaap:SubsequentEventMember

us-gaap:InvestorMember

2025-11-04

0001000228

hsic:WalterSiegelMember

2025-06-29

2025-09-27

0001000228

hsic:WalterSiegelMember

2025-09-27

iso4217:USD

xbrli:pure

xbrli:shares

iso4217:USD

xbrli:shares

hsic:number

hsic:segments

hsic:claims

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION 
Washington, D.C. 20549
FORM 
10-Q
(Mark One) 


QUARTERLY

REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT 
OF 1934 
For the 
quarterly

period ended 
September 27, 
2025
or 


TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE

ACT

OF 1934 
For the transition period from ____________ to ____________ 
Commission File Number: 

0-27078
HENRY SCHEIN, INC.
(Exact name of registrant as specified in its charter) 
Delaware
11-3136595
(State or other jurisdiction of
(I.R.S. Employer Identification No.)
incorporation or organization)
135 Duryea Road
Melville
, 
New York
(Address of principal executive offices) 
11747
(Zip Code) 
(
631
) 
843-5500
(Registrants telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act: 
Title of each class 
Trading Symbol(s) 
Name of each exchange on which registered 
Common Stock, par value $.01 per share
HSIC
The 
Nasdaq

Global Select Market 
Indicate by check mark whether the registrant (1) has filed all reports required

to be filed by Section 13 or 15(d) of the Securities 
Exchange Act of 1934 during the preceding 12 months (or for such

shorter period that the registrant was required to file such 
reports), and (2) has been subject to such filing requirements for the

past 90 days. 
Yes


No


Indicate by check mark whether the registrant has submitted electronically every

Interactive Data File required to be submitted 
pursuant to Rule 405 of Regulation S-T (232.405 of this chapter) during

the preceding 12 months (or for such shorter period 
that the registrant was required to submit such files). 
Yes


No


Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller 
reporting company, or an emerging growth company.

See the definitions of large accelerated filer,

accelerated filer, 
smaller reporting company,

and emerging growth company

in Rule 12b-2 of the Exchange Act. 
Large accelerated filer

Accelerated filer 

Non-accelerated filer



Smaller reporting company 

Emerging growth company 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period

for 
complying with any new or revised financial accounting standards provided

pursuant to Section 13(a) of the Exchange Act.


Indicate by check mark whether the registrant is a shell company (as defined

in Rule 12b-2 of the Exchange Act). 
Yes 


No


As of October 27, 2025,
there were 
117,724,807

shares of the registrants common stock outstanding.

HENRY SCHEIN, INC. 
INDEX
PART

I.

FINANCIAL INFORMATION
Page
ITEM 1.
Condensed Consolidated Financial Statements:
Condensed Consolidated Balance Sheets
as of September 27, 2025 and December 28, 2024
3
Condensed Consolidated Statements of Income
for the three and nine months ended
September 27, 2025 and September 28, 2024
4 
Condensed Consolidated Statements of Comprehensive Income 
for the 
three and nine months ended September 27, 2025 and September

28, 2024 
5 
Condensed Consolidated Statement of Changes in Stockholders' Equity
for the three months ended 
September 27, 2025 and September 28, 2024
6 
Condensed Consolidated Statement of Changes in Stockholders' Equity
for the nine months ended
September 27, 2025 and September 28, 2024
7 
Condensed Consolidated Statements of Cash Flows
for the nine months ended
September 27, 2025 and September 28, 2024

8 
Notes to Condensed Consolidated Financial Statements
9 
Note 1  Basis of Presentation
9 
Note 2  Significant Accounting Policies and Recently 
Issued Accounting Standards 
10 
Note 3  Cyber Incident
11 
Note 4  Net Sales from Contracts with Customers
12 
Note 5  Segment Data
13 
Note 6  Business Acquisitions
16 
Note 7  Fair Value

Measurements
19 
Note 8  Debt
22 
Note 9  Income Taxes
25 
Note 10  Plans of Restructuring
26 
Note 11  Legal Proceedings
28 
Note 12  Stock-Based Compensation
29 
Note 13  Redeemable Noncontrolling Interests
32 
Note 14  Comprehensive Income
32 
Note 15  Earnings Per Share
34 
Note 16  Supplemental Cash Flow Information
34 
Note 17  Related Party Transactions
35 
Note 18  KKR Investment and Accelerated Share Repurchase Program
36 
ITEM 2.
Management's Discussion and Analysis of
Financial Condition and Results of Operations
37 
ITEM 3.
Quantitative and Qualitative Disclosures About Market Risk
55 
ITEM 4.
Controls and Procedures
55 
PART

II.

OTHER INFORMATION
ITEM 1.
Legal Proceedings
57 
ITEM 1A.
Risk Factors
57 
ITEM 2.
Unregistered Sales of Equity Securities and Use of Proceeds
57 
ITEM 5.
Other Information
58 
ITEM 6.
Exhibits
59 
Signature
60 

Table of Contents
See accompanying notes. 
3 
PART

I. FINANCIAL INFORMATION 
ITEM 1. CONDENSED CONSOLIDATED

FINANCIAL STATEMENTS 
HENRY SCHEIN, INC. 
CONDENSED CONSOLIDATED BALANCE SHEETS 
(in millions,

except share data) 
September 27, 
December 28, 
2025 
2024 
(unaudited) 
ASSETS 
Current assets: 
Cash and cash equivalents

$ 
136
$ 
122
Accounts receivable, net of allowance for credit losses of $
84

and $
78

(1) 
1,743
1,482
Inventories, net 
1,912
1,810
Prepaid expenses and other

604
569
Total current assets

4,395
3,983
Property and equipment, net

603
531
Operating lease right-of-use assets 
308
293
Goodwill

4,147
3,887
Other intangibles, net

1,046
1,023
Investments and other 
598
501
Total assets

$ 
11,097
$ 
10,218
LIABILITIES, REDEEMABLE NONCONTROLLING INTERESTS AND 
STOCKHOLDERS' EQUITY 
Current liabilities: 
Accounts payable

$ 
1,035
$ 
962
Bank credit lines

913
650
Current maturities of long-term debt

30
56
Operating lease liabilities 
81
75
Accrued expenses: 
Payroll and related

291
303
Taxes

181
139
Other

618
618
Total current liabilities

3,149
2,803
Long-term debt (1) 
2,153
1,830
Deferred income taxes

144
102
Operating lease liabilities 
264
259
Other liabilities

487
387
Total liabilities

6,197
5,381
Redeemable noncontrolling interests

877
806
Commitments and contingencies

(nil)
(nil)
Stockholders' equity: 
Preferred stock, $
0.01

par value, 
1,000,000

shares authorized, 
none

outstanding 
-
-
Common stock, $
0.01

par value, 
480,000,000

shares authorized, 
118,567,917

issued and outstanding on September 27, 2025 and 
124,155,884

issued and outstanding on December 28, 2024 
1
1
Additional paid-in capital 
207
-
Retained earnings

3,375
3,771
Accumulated other comprehensive loss

(
222
)
(
379
)
Total Henry Schein, Inc. stockholders' equity 
3,361
3,393
Noncontrolling interests 
662
638
Total stockholders' equity

4,023
4,031
Total liabilities, redeemable noncontrolling

interests and stockholders' equity 
$ 
11,097
$ 
10,218
(1)
Amounts presented include balances held by our consolidated variable interest entity (VIE).

At September 27, 2025 and 
December 28, 2024, includes trade accounts receivable of $
492

million and $
241

million, respectively, and long-term debt of $
400
million and $
150

million, respectively.

See 
Note 1  Basis of Presentation

for further information. 

Table of Contents
See accompanying notes. 
4 
HENRY SCHEIN, INC. 
CONDENSED CONSOLIDATED STATEMENTS

OF INCOME 
(in millions,

except share and per share data) 
(unaudited) 
Three Months Ended 
Nine Months Ended 
September 27, 
September 28, 
September 27, 
September 28, 
2025 
2024 
2025 
2024 
Net sales

$ 
3,339
$ 
3,174
$ 
9,747
$ 
9,482
Cost of sales

2,313
2,181
6,705
6,459
Gross profit

1,026
993
3,042
3,023
Operating expenses:

Selling, general and administrative

760
724
2,276
2,296
Depreciation and amortization 
68
64
194
188
Restructuring costs

34
48
82
73
Operating income

164
157
490
466
Other income (expense):

Interest income

9
7
24
18
Interest expense

(
38
)
(
34
)
(
111
)
(
96
)
Other, net

(
1
)
(
2
)
(
3
)
(
1
)
Income before taxes, equity in earnings of affiliates and 
noncontrolling interests 
134
128
400
387
Income taxes

(
28
)
(
32
)
(
94
)
(
97
)
Equity in earnings of affiliates, net of tax

3
3
10
12
Net income

109
99
316
302
Less: Net income attributable to noncontrolling interests

(
8
)
-
(
19
)
(
6
)
Net income attributable to Henry Schein, Inc.

$ 
101
$ 
99
$ 
297
$ 
296
Earnings per share attributable to Henry Schein, Inc.:

Basic

$ 
0.84
$ 
0.79
$ 
2.44
$ 
2.32
Diluted

$ 
0.84
$ 
0.78
$ 
2.42
$ 
2.30
Weighted-average common

shares outstanding:

Basic

120,199,552
126,124,715
121,965,991
127,550,045
Diluted

121,036,247
127,054,934
122,840,062
128,498,494

Table of Contents
See accompanying notes. 
5 
HENRY SCHEIN, INC. 
CONDENSED CONSOLIDATED STATEMENTS

OF COMPREHENSIVE INCOME 
(in millions)

(unaudited) 
Three Months Ended 
Nine Months Ended 
September 27, 
September 28, 
September 27, 
September 28, 
2025 
2024 
2025 
2024 
Net income 
$ 
109
$ 
99
$ 
316
$ 
302
Other comprehensive income, net of tax: 
Foreign currency translation gain (loss) 
(
1
)
58
208
(
58
)
Unrealized gain (loss) from hedging activities

4
(
18
)
(
22
)
(
3
)
Other comprehensive income (loss), net of tax 
3
40
186
(
61
)
Comprehensive income

112
139
502
241
Comprehensive income attributable to noncontrolling interests:

Net income 
(
8
)
-
(
19
)
(
6
)
Foreign currency translation loss (gain) 
2
(
12
)
(
29
)
3
Comprehensive income attributable to noncontrolling 
interests

(
6
)
(
12
)
(
48
)
(
3
)
Comprehensive income attributable to Henry Schein, Inc.

$ 
106
$ 
127
$ 
454
$ 
238

Table of Contents
See accompanying notes. 
6 
HENRY SCHEIN, INC. 
CONDENSED CONSOLIDATED STATEMENTS

OF CHANGES IN

STOCKHOLDERS EQUITY 
(in millions, except share data) 
(unaudited) 
Accumulated 
Common Stock 
Additional 
Other 
Total 
$0.01 Par Value 
Paid-in 
Retained 
Comprehensive 
Noncontrolling 
Stockholders' 
Shares 
Amount 
Capital 
Earnings 
Income (Loss) 

Interests 
Equity 
Balance, June 28, 2025 
121,895,045
$ 
1
$ 
186
$ 
3,485
$ 
(
227
)
$ 
643
$ 
4,088
Net income (excluding $
1

attributable to Redeemable 
noncontrolling interests) 
- 
- 
- 
101
- 
7
108
Foreign currency translation gain (loss) (excluding loss of $
1
attributable to Redeemable noncontrolling interests) 
- 
- 
- 
- 
1
(
1
)
-
Unrealized gain from hedging activities, 
net of tax of $
1
- 
- 
- 
- 
4
- 
4
Contributions from noncontrolling shareholders 
- 
- 
- 
- 
- 
12
12
Change in fair value of redeemable securities 
- 
- 
(
12
)
- 
- 
- 
(
12
)
Noncontrolling interests and adjustments related to 
business acquisitions and contingent consideration 
- 
- 
14
- 
- 
- 
14
Repurchase and retirement of common stock 
(
3,335,985
)
- 
7
(
211
)
- 
- 
(
204
)
Stock issued upon exercise of stock options 
2,446
- 
- 
- 
- 
- 
- 
Stock-based compensation expense 
9,789
- 
12
- 
- 
1
13
Shares withheld for payroll taxes 
(
3,442
)
- 
- 
- 
- 
- 
- 
Settlement of stock-based compensation awards 
64
- 
- 
- 
- 
- 
- 
Balance, September 27, 2025 
118,567,917
$ 
1
$ 
207
$ 
3,375
$ 
(
222
)
$ 
662
$ 
4,023
Accumulated 
Common Stock 
Additional 
Other 
Total 
$0.01 Par Value 
Paid-in 
Retained 
Comprehensive 
Noncontrolling 
Stockholders' 
Shares 
Amount 
Capital 
Earnings 
Income (Loss) 

Interests 
Equity 
Balance, June 29, 2024 
127,080,545
$ 
1
$ 
-
$ 
3,803
$ 
(
292
)
$ 
636
$ 
4,148
Net income (loss) (excluding $
1

attributable to Redeemable 
noncontrolling interests) 
- 
- 
- 
99
- 
(
1
)
98
Foreign currency translation gain (excluding gain of $
11
attributable to Redeemable noncontrolling interests) 
- 
- 
- 
- 
46
1
47
Unrealized loss from hedging activities, 
net of tax benefit of $
7
- 
- 
- 
- 
(
18
)
- 
(
18
)
Purchase of noncontrolling interests 
- 
- 
(
1
)
- 
- 
(
1
)
(
2
)
Change in fair value of redeemable securities 
- 
- 
(
6
)
- 
- 
- 
(
6
)
Noncontrolling interests and adjustments related to 
business acquisitions 
- 
- 
(
4
)
- 
- 
1
(
3
)
Repurchase and retirement of common stock 
(
1,954,076
)
- 
(
18
)
(
119
)
- 
- 
(
137
)
Stock issued upon exercise of stock options 
22,448
- 
1
- 
- 
- 
1
Stock-based compensation expense 
7,655
- 
10
- 
- 
- 
10
Shares withheld for payroll taxes 
(
2,403
)
- 
- 
- 
- 
- 
- 
Settlement of stock-based compensation awards 
25
- 
1
- 
- 
- 
1
Transfer of charges in excess of

capital 
- 
- 
17
(
17
)
- 
- 
- 
Balance, September 28, 2024 
125,154,194
$ 
1
$ 
-
$ 
3,766
$ 
(
264
)
$ 
636
$ 
4,139

Table of Contents
See accompanying notes. 
7 
HENRY SCHEIN, INC. 
CONDENSED CONSOLIDATED STATEMENTS

OF CHANGES IN

STOCKHOLDERS' EQUITY 
(in millions, except share data) 
(unaudited) 
Accumulated 
Common Stock 
Additional 
Other 
Total 
$0.01 Par Value 
Paid-in 
Retained 
Comprehensive 
Noncontrolling 
Stockholders' 
Shares 
Amount 
Capital 
Earnings 
Income (Loss) 

Interests 
Equity 
Balance, December 28, 2024 
124,155,884
$ 
1
$ 
-
$ 
3,771
$ 
(
379
)
$ 
638
$ 
4,031
Net income (excluding $
0

attributable to Redeemable 
noncontrolling interests)

- 
- 
- 
297
- 
19
316
Foreign currency translation gain (excluding gain of $
28
- 
- 
- 
- 
- 
- 
attributable to Redeemable noncontrolling interests) 
- 
- 
- 
- 
179
1
180
Unrealized loss from hedging activities, 
- 
- 
- 
- 
- 
- 
net of tax benefit of $
8
- 
- 
- 
- 
(
22
)
- 
(
22
)
Pension adjustment gain, net of tax of $
1
- 
- 
- 
- 
- 
- 
- 
Net contributions from noncontrolling shareholders 
- 
- 
- 
- 
- 
5
5
Purchase of noncontrolling interests 
- 
- 
(
1
)
- 
- 
(
1
)
(
2
)
Change in fair value of redeemable securities

- 
- 
(
50
)
- 
- 
- 
(
50
)
Noncontrolling interests and adjustments related to 
- 
- 
- 
- 
- 
- 
business acquisitions and contingent consideration 
- 
- 
(
46
)
- 
- 
(
1
)
(
47
)
Issuance of common stock 
3,285,151
- 
250
- 
- 
- 
250
Repurchase and retirement of common stock

(
9,249,302
)
- 
(
75
)
(
579
)
- 
- 
(
654
)
Stock issued upon exercise of stock options

16,538
- 
1
- 
- 
- 
1
Stock-based compensation expense 
556,270
- 
28
- 
- 
1
29
Shares withheld for payroll taxes

(
196,742
)
- 
(
14
)
- 
- 
- 
(
14
)
Settlement of stock-based compensation awards 
118
- 
- 
- 
- 
- 
- 
Transfer of charges in excess of

capital 
- 
- 
- 
114
(
114
)
- 
- 
- 
- 
Balance, September 27, 2025 
118,567,917
$ 
1
$ 
207
$ 
3,375
$ 
(
222
)
$ 
662
$ 
4,023
Accumulated 
Common Stock 
Additional 
Other 
Total 
$.01 Par Value 
Paid-in 
Retained 
Comprehensive 
Noncontrolling 
Stockholders' 
Shares 
Amount 
Capital 
Earnings 
Loss 

Interests 
Equity 
Balance, December 30, 2023 
129,247,765
$ 
1
$ 
-
$ 
3,860
$ 
(
206
)
$ 
634
$ 
4,289
Net income (excluding $
0

attributable to Redeemable 
noncontrolling interests)

- 
- 
- 
296
- 
6
302
Foreign currency translation gain/(loss) (excluding loss of $
4
attributable to Redeemable noncontrolling interests) 
- 
- 
- 
- 
(
55
)
1
(
54
)
Unrealized loss from hedging activities, 
net of tax benefit of $
1
- 
- 
- 
- 
(
3
)
- 
(
3
)
Distributions to noncontrolling shareholders 
- 
- 
- 
- 
- 
(
5
)
(
5
)
Purchase of noncontrolling interests 
- 
- 
(
7
)
- 
- 
(
1
)
(
8
)
Change in fair value of redeemable securities

- 
- 
(
87
)
- 
- 
- 
(
87
)
Noncontrolling interests and adjustments related to 
business acquisitions 
- 
- 
(
8
)
- 
- 
1
(
7
)
Repurchase and retirement of common stock

(
4,368,510
)
- 
(
42
)
(
271
)
- 
- 
(
313
)
Stock issued upon exercise of stock options

47,688
- 
3
- 
- 
- 
3
Stock-based compensation expense 
337,753
- 
30
- 
- 
- 
30
Shares withheld for payroll taxes

(
110,566
)
- 
(
9
)
- 
- 
- 
(
9
)
Settlement of stock-based compensation awards 
64
- 
1
- 
- 
- 
1
Transfer of charges in excess of

capital 
- 
- 
119
(
119
)
- 
- 
- 
Balance, September 28, 2024 
125,154,194
$ 
1
$ 
-
$ 
3,766
$ 
(
264
)
$ 
636
$ 
4,139

Table of Contents
See accompanying notes. 
8 
HENRY SCHEIN, INC. 
CONDENSED CONSOLIDATED STATEMENTS

OF CASH FLOWS 
(in millions) 
(unaudited) 
Nine Months Ended 
September 27, 
September 28, 
2025 
2024 
Cash flows from operating activities: 
Net income

$ 
316
$ 
302
Adjustments to reconcile net income to net cash provided by operating activities: 
Depreciation and amortization

229
221
Impairment charge on intangible assets 
1
-
Non-cash restructuring charges 
7
11
Stock-based compensation expense 
29
30
Provision for losses on trade and other accounts receivable

9
12
Benefit from deferred income taxes 
-
(
41
)
Equity in earnings of affiliates 
(
10
)
(
12
)
Distributions from equity affiliates

9
10
Changes in unrecognized tax benefits

6
3
Other

(
44
)
(
25
)
Changes in operating assets and liabilities, net of acquisitions: 
Accounts receivable

(
198
)
188
Inventories

(
25
)
38
Other current assets

(
3
)
38
Accounts payable and accrued expenses

5
(
131
)
Net cash provided by operating activities 
331
644
Cash flows from investing activities: 
Purchases of property and equipment 
(
96
)
(
112
)
Payments related to equity investments and business acquisitions, 
net of cash acquired

(
112
)
(
223
)
Proceeds from loan to affiliate 
2
3
Capitalized software costs 
(
38
)
(
30
)
Other

(
9
)
(
10
)
Net cash used in investing activities

(
253
)
(
372
)
Cash flows from financing activities: 
Net change in bank credit lines 
257
374
Proceeds from issuance of long-term debt

314
120
Principal payments for long-term debt

(
28
)
(
193
)
Debt issuance costs 
(
2
)
-
Proceeds from issuance of stock upon exercise of stock options

1
3
Payments for repurchases and retirement of common stock

(
650
)
(
310
)
Issuance of common stock 
250
-
Payments for taxes related to shares withheld for employee taxes 
(
14
)
(
9
)
Distributions to noncontrolling shareholders 
(
12
)
(
36
)
Payments for contingent consideration 
(
19
)
-
Acquisitions of noncontrolling interests in subsidiaries

(
79
)
(
255
)
Net cash provided by (used in) financing activities 
18
(
306
)
Effect of exchange rate changes on cash and cash equivalents 
(
82
)
(
11
)
Net change in cash and cash equivalents 
14
(
45
)
Cash and cash equivalents, beginning of period

122
171
Cash and cash equivalents, end of period

$ 
136
$ 
126

Table of Contents
HENRY SCHEIN, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(in millions, except share and per share data)
(unaudited
)
9 
Note 1  Basis of Presentation
Our condensed consolidated financial statements include the accounts of Henry

Schein, Inc., and all of our 
controlled subsidiaries and VIE (we, us and our).

All intercompany accounts and transactions are eliminated 
in consolidation.

Investments in unconsolidated affiliates for which we have the ability to influence

the operating 
or financial decisions are accounted for under the equity method.

Certain prior period amounts have been 
reclassified to conform to the current period presentation.

These reclassifications, individually and in the 
aggregate, did not have a material impact on our condensed consolidated

financial condition, results of operations 
or cash flows.
Our accompanying unaudited condensed consolidated financial statements

have been prepared in accordance with 
accounting principles generally accepted in the United States

(U.S. GAAP) for interim financial information and 
with the instructions to Form 10-Q and Article 10 of Regulation S-X.

Accordingly, they do not include all of the 
information and footnote disclosures required by U.S. GAAP for complete

financial statements.
The unaudited condensed consolidated financial statements should

be read in conjunction with the audited 
consolidated financial statements and notes to the consolidated financial

statements contained in our Annual Report 
on Form 10-K for the year ended December 28, 2024 and with the information

contained in our other publicly-
available filings with the Securities and Exchange Commission.

The condensed consolidated financial statements 
reflect all adjustments considered necessary for a fair presentation of

the consolidated results of operations and 
financial position for the interim periods presented.

All such adjustments are of a normal recurring nature.

The preparation of consolidated financial statements in conformity with

accounting principles generally accepted in 
the United States requires us to make estimates and assumptions that

affect the reported amounts of assets and 
liabilities and disclosure of contingent assets and liabilities at the date of

the financial statements and the reported 
amounts of revenues and expenses during the reporting period.

Actual results could differ from those estimates.

The results of operations for the three and nine months ended September

27, 2025 are not necessarily indicative of 
the results to be expected for any other interim period or for the year

ending December 27, 2025.
Our condensed consolidated financial statements reflect estimates and

assumptions made by us that affect, among 
other things, our goodwill, long-lived asset and definite-lived intangible

asset valuation; inventory valuation; equity 
investment valuation; assessment of the annual effective tax rate; valuation of

deferred income taxes and income 
tax contingencies; the allowance for credit losses; hedging activity; supplier

rebates; measurement of compensation 
cost for certain share-based performance awards and cash bonus plans; and

pension plan assumptions.
The primary beneficiary of a VIE is required to consolidate the assets and

liabilities of the VIE.

We are deemed to 
be the primary beneficiary of the VIE when we have the power to direct activities

that most significantly affect its 
economic performance and have the obligation to absorb the majority of

its losses or the right to receive benefits 
that could potentially be significant to the VIE.

In determining whether we are the primary beneficiary, we 
consider factors such as ownership interest, debt investments, management

representation, authority to control 
decisions, and contractual and substantive participating rights of each party.

For this VIE, related to our U.S. trade 
accounts receivable securitization as discussed in
Note 8  Debt
, 

the trade accounts receivable transferred to the 
VIE are pledged as collateral to the related debt.

The VIEs creditors have recourse to us for losses on these trade 
accounts receivable.

At September 27, 2025 and December 28, 2024, certain trade

accounts receivable that can 
only be used to settle obligations of this VIE were $
492

million and $
241

million, respectively, and the liabilities of 
this VIE where the creditors have recourse to us were $
400

million and $
150

million, respectively.

Table of Contents
HENRY SCHEIN, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(in millions, except share and per share data)
(unaudited
)
10 
Note 2  Significant Accounting Policies and Recently Issued Accounting

Standards
Significant Accounting Policies

There have been no material changes in our significant accounting policies during

the three and nine months ended 
September 27, 2025, as compared to the significant accounting policies

described in Item 8 of our Annual Report 
on Form 10-K for the year ended December 28, 2024. 
Recently Issued Accounting Standards 
In September 2025, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update 
(ASU) 2025-06, 
Intangibles - Goodwill and Other - Internal-Use Software (Subtopic 350-40): Targeted 
Improvements to the Accounting for Internal-Use Software
, which removes all references to software development 
project stages.

The ASU requires entities to begin capitalizing software costs when

management authorizes and 
commits to funding the software project, and it is probable

that the project will be completed and the software will 
be used for its intended purpose.

This ASU is effective for annual reporting periods beginning after December

15, 
2027, and interim reporting periods within those annual reporting

periods, with early adoption permitted.

Upon 
adoption, the guidance can be applied prospectively, retrospectively, or with a modified transition approach.

We 
are currently evaluating the impact that ASU 2025-06 will have

on our consolidated financial statements. 
In July 2025, the FASB issued ASU 2025-05, 
Financial Instruments - Credit Losses (Subtopic 326): Measurement 
of Credit Losses for Accounts Receivable and Contract Assets,
 which introduces a practical expedient permitting 
an entity to assume that conditions at the balance sheet date remain unchanged

throughout the remaining life of the 
asset when estimating expected credit losses on current accounts

receivable and current contract asset under Topic 
606 on revenue from contracts with customers. This ASU is effective for annual

reporting periods beginning after 
December 15, 2025, with early adoption permitted.

We do not expect ASU 2025-05 to have a material impact on 
our consolidated financial statements. 
In November 2024, the FASB issued ASU 2024-03, 
Income Statement - Reporting Comprehensive Income - 
Expense Disaggregation Disclosure (Subtopic 220-40)
: 
Disaggregation of Income Statement Expenses
, which 
requires additional disclosure about the specific expense categories in

the notes to financial statements at interim 
and annual reporting periods.

The amendments in this ASU do not change or remove current

expense disclosure 
requirements, but affect where this information appears in the notes to financial statements.

This ASU is effective 
for annual reporting periods beginning after December 15, 2026, and

interim reporting periods beginning after 
December 15, 2027, with early adoption permitted.

Upon adoption, the guidance can be applied prospectively

or 
retrospectively.

We are currently evaluating the impact that ASU 2024-03 will have on our consolidated financial 
statements. 
In December 2023, the FASB issued ASU 2023-09, 
Income Taxes (Topic

740): Improvements to Income Tax 
Disclosures
, which requires public business entities to disclose additional

information in specified categories with 
respect to the reconciliation of the effective tax rate to the statutory rate for federal, state and

foreign income taxes.

It also requires greater detail about individual reconciling items in

the rate reconciliation to the extent the impact of 
those items exceeds a specified threshold.

In addition to new disclosures associated with the rate reconciliation,

the 
ASU requires information pertaining to taxes paid (net of refunds received)

to be disaggregated for federal, state 
and foreign taxes and further disaggregated for specific jurisdictions

to the extent the related amounts exceed a 
quantitative threshold.

The ASU also describes items that need to be disaggregated

based on their nature, which is 
determined by reference to the items fundamental or essential characteristics, such as the transaction or event

that 
triggered the establishment of the reconciling item and the activity with which

the reconciling item is associated.

The ASU eliminates the historic requirement that entities disclose information

concerning unrecognized tax 
benefits having a reasonable possibility of significantly increasing

or decreasing in the 12 months following the 
reporting date.

This ASU is effective for annual periods beginning after December 15, 2024.

The adoption of this 

Table of Contents
HENRY SCHEIN, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(in millions, except share and per share data)
(unaudited
)
11 

ASU will expand our income tax disclosures and will not have a

material impact on our consolidated balance sheet 
or consolidated statement of income.
Note 3  Cyber Incident
In October 2023 Henry Schein experienced a cyber incident that primarily

affected the operations of our North 
American and European dental and medical distribution businesses.

Henry Schein One, our practice management 
software, revenue cycle management and patient relationship management

solutions business, was not affected, and 
our manufacturing businesses were mostly unaffected.

On November 22, 2023, we experienced a disruption of our 
ecommerce platform and related applications, which was remediated.
With respect to the October 2023 cyber incident, we have a $
60

million insurance policy, following a $
5

million 
retention.

During the three and nine months ended September 27, 2025,

we did 
no
t incur any expenses directly 
related to the cyber incident.

During the three and nine months ended September 28, 2024 we

incurred $
1

million 
and $
9

million, respectively, of expenses related to the cyber incident, mostly consisting of professional fees.

During the three and nine months ended September 28, 2024, we received

insurance proceeds of $
10

million and 
$
20

million, respectively, representing a partial insurance recovery of losses related to the cyber incident.

During 
the three months ended March 29, 2025 we received insurance proceeds

of $
20

million under this policy, 
representing the remaining insurance recovery of losses related to the cyber

incident.

The expenses and insurance 
recoveries related to the cyber incident are included in the selling, general

and administrative line in our condensed 
consolidated statements of income.

Table of Contents
HENRY SCHEIN, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(in millions, except share and per share data)
(unaudited
)
12 
Note 4  Net Sales from Contracts with Customers
Net sales are recognized in accordance with policies disclosed in Item

8 of our Annual Report on Form 10-K for 
the year ended December 28, 2024. 
Disaggregation of Net Sales 
As noted further in
Note 5  Segment Data
,

during the fourth quarter of our fiscal year ended December 28, 
2024, we revised our reportable segments to align with how the Chairman and

Chief Executive Officer manages 
the business, assesses performance and allocates resources.

All prior comparative segment information has 
been recast to reflect our new segment structure. 
The following table disaggregates our net sales by reportable segment:

Three Months Ended

Nine Months Ended 
September 27, 
September 28, 
September 27, 
September 28, 
2025 
2024 
2025 
2024 
Net Sales: 
Global Distribution and Value

-Added Services 
Global Dental merchandise 
$ 
1,210
$ 
1,155
$ 
3,613
$ 
3,579
Global Dental equipment 
440
417
1,263
1,245
Global Value

-added services 
64
63
174
175
Global Dental 
1,714
1,635
5,050
4,999
Global Medical

1,126
1,076
3,197
3,059
Total Global Distribution

and Value

-Added Services 
2,840
2,711
8,247
8,058
Global Specialty Products 
369
348
1,122
1,078
Global Technology 
173
157
502
470
Eliminations 
(
43
)
(
42
)
(
124
)
(
124
)
Total 
$ 
3,339
$ 
3,174
$ 
9,747
$ 
9,482
Contract Liabilities
The following table presents our contract liabilities:

As of 
September 27, 
December 28, 
September 28, 
December 30, 
Description 
2025 
2024 
2024 
2023 
Current contract liabilities 
$ 
79
$ 
81
$ 
76
$ 
89
Non-current contract liabilities 
9
8
8
9
Total contract

liabilities 
$ 
88
$ 
89
$ 
84
$ 
98
During the nine months ended September 27, 2025, we recognized $
66

million in net sales that had been previously 
deferred at December 28, 2024.

During the nine months ended September 28, 2024, we recognized

$
72

million in 
net sales that had been previously deferred at December 30, 2023.

Current contract liabilities are included in 
accrued expenses: other and the non-current contract liabilities are

included in other liabilities within our condensed 
consolidated balance sheets.

Table of Contents
HENRY SCHEIN, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(in millions, except share and per share data)
(unaudited
)
13 
Note 5

 
Segment Data
During the fourth quarter of our fiscal year ended December 28, 2024,

we revised our reportable segments to align 
with how the Chairman and Chief Executive Officer manages the business, assesses

performance and allocates 
resources.

Our revised 
reportable segments

now consist of: (i) Global Distribution and Value-Added Services; (ii) 
Global Specialty Products; and (iii) Global Technology.

These segments offer different products and services to 
the same customer base.

All prior comparative segment information has been recast

to reflect our new segment 
structure.

We aggregate operating segments into these reportable segments based on economic similarities, the nature of their 
products, customer base and methods of distribution.

Global Distribution and Value-Added Services includes distribution to the global dental and medical markets of 
national brand and corporate brand merchandise, as well as equipment and related

technical services.

This segment 
also includes value-added services such as financial services, continuing

education services, consulting and other 
services.

This segment also markets and sells under our own corporate brand

a portfolio of cost-effective, high-
quality consumable merchandise.

Global Specialty Products includes manufacturing, marketing

and sales of dental 
implant and biomaterial products; and endodontic, orthodontic and orthopedic

products and other health care-
related products and services.

Global Technology includes development and distribution of practice management 
software, e-services and other products, which are distributed to health

care providers. 
Our organizational structure also includes Corporate, which consists primarily of

income and expenses associated 
with support functions and projects. 
Our chief operating decision maker (CODM) is our Chairman

and Chief Executive Officer.

Our CODM uses 
adjusted operating income as the profitability metric for purposes of making

decisions about allocation of resources 
to each segment and assessing performance of each segment.

Adjusted operating income provides a measure of our 
underlying segment results that is in line with our approach to risk and performance

management.

We define 
adjusted operating income as operating income adjusted to exclude

(a) direct cybersecurity costs and related 
insurance recovery proceeds, (b) amortization of acquisition intangibles,

(c) organizational restructuring expenses, 
(d) impairment of intangible assets, (e) changes in fair value of contingent consideration,

(f) litigation settlements, 
and (g) costs associated with shareholder advisory matters and select value

creation consulting costs.

These 
adjustments are either: (i) non-cash or non-recurring in nature; (ii) not allocable

or controlled by the segment; or 
(iii) not tied to the operational performance of the segment.

Assets by segment are not a measure used to assess the 
performance of the Company by CODM and thus are not reported in

our disclosures.

Table of Contents
HENRY SCHEIN, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(in millions, except share and per share data)
(unaudited
)
14 
Segment adjusted operating income is presented in the following

table to reconcile to operating income as 
presented on the condensed consolidated statement of operations.

The reconciliation from operating income to 
income before taxes and equity in earnings of affiliates is presented on our condensed consolidated

statements of 
income.

Three Months Ended 
Nine Months Ended 
September 27, 
September 28, 
September 27, 
September 28, 
2025 
2024 
2025 
2024 
Gross Sales: 
Global Distribution and Value

-Added Services
(1)
$ 
2,840
$ 
2,711
$ 
8,247
$ 
8,058
Global Specialty Products
(2)
369
348
1,122
1,078
Global Technology
(3)
173
157
502
470
Total Gross Sales 
3,382
3,216
9,871
9,606
Less: Eliminations: 
Global Distribution and Value

-Added Services

(
5
)
(
5
)
(
13
)
(
26
)
Global Specialty Products 
(
38
)
(
37
)
(
111
)
(
98
)
Global Technology 
-
-
-
-
Total Eliminations 
(
43
)
(
42
)
(
124
)
(
124
)
Net Sales 
Global Distribution and Value

-Added Services

2,835
2,706
8,234
8,032
Global Specialty Products

331
311
1,011
980
Global Technology 
173
157
502
470
Total Net Sales 
3,339
3,174
9,747
9,482
Segment Cost of Sales
(4)
Global Distribution and Value

-Added Services

2,138
2,025
6,176
5,964
Global Specialty Products 
165
152
501
478
Global Technology 
58
50
163
152
Total Segment Cost of Sales 
2,361
2,227
6,840
6,594
Segment Operating Expenses
(5)
Global Distribution and Value

-Added Services

524
502
1,567
1,563
Global Specialty Products 
133
151
442
472
Global Technology 
69
68
206
211
Total Segment Operating Expenses 
726
721
2,215
2,246
Segment Operating Income 
Global Distribution and Value

-Added Services 
178
184
504
531
Global Specialty Products 
71
45
179
128
Global Technology 
46
39
133
107
Total Segment Operating Income 
295
268
816
766
Corporate, net 
(
33
)
(
25
)
(
99
)
(
55
)
Adjustments
(6)
(
98
)
(
86
)
(
227
)
(
245
)
Total Operating Income 
$ 
164
$ 
157
$ 
490
$ 
466
Three Months Ended 
Nine Months Ended 
September 27, 
September 28, 
September 27, 
September 28, 
2025 
2024 
2025 
2024 
Depreciation and Amortization 
Global Distribution and Value

-Added Services 
$ 
7
$ 
7
$ 
20
$ 
19
Global Specialty Products 
11
7
28
21
Global Technology 
9
8
26
26
Total Segment Depreciation and Amortization 
27
22
74
66
Corporate 
7
5
22
15
Acquisition intangible amortization within 
adjustments
(6)
46
47
133
140
Total Depreciation and Amortization 
$ 
80
$ 
74
$ 
229
$ 
221

Table of Contents
HENRY SCHEIN, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(in millions, except share and per share data)
(unaudited
)
15 

(1)
Global Distribution and Value

-Added Services: Includes distribution of infection-control products, handpieces, preventatives, 
impression materials, composites, anesthetics, teeth, gypsum, acrylics, articulators, abrasives, personal protective equipment 
(PPE) products,

branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, dental chairs, delivery units 
and lights, digital dental laboratories, X-ray supplies and equipment, high-tech and digital restoration equipment, equipment repair 
services, financial services on a non-recourse basis, continuing education services for practitioners, consulting and other services.

This segment also markets and sells under our own corporate brand a portfolio of cost-effective, high-quality consumable 
merchandise. 
(2)
Global Specialty Products: Includes manufacturing, marketing and sales of dental implant and biomaterial products; and 
endodontic, orthodontic and orthopedic products and other health care-related products and services. 
(3)
Global Technology: Includes development and distribution of practice management software, e-services and other products, which 
are distributed to health care providers. 
(4)
Cost of goods sold in our Global Distribution and Value-Added Services segment and our Global Specialty Products segment 
includes product cost and inbound and outbound freight charges.

Cost of goods sold in our Global Technology segment consists 
primarily of software development and third-party provider costs, including technology use and hosting fees.

(5)
Significant segment operating expenses for our reportable segments and Corporate include primarily compensation costs, and to a 
lesser extent, rent, depreciation and maintenance costs related to operating our facilities.

(6)
Adjustments represent items excluded from segment operating income to enable comparison of financial results between periods.

The following table presents a breakdown of such adjustments:

Three Months Ended 
Nine Months Ended 
September 27, 
September 28, 
September 27, 
September 28, 
2025 
2024 
2025 
2024 
Adjustments: 
Restructuring costs 
$ 
(
34
)
$ 
(
48
)
$ 
(
82
)
$ 
(
73
)
Acquisition intangible amortization 
(
46
)
(
47
)
(
133
)
(
140
)
Cyber incident-insurance proceeds, net of third-party advisory 
expenses 
-
9
20
11
Change in contingent consideration 
(
6
)
-
(
4
)
(
38
)
Litigation settlements 
(
2
)
-
(
3
)
(
5
)
Impairment of intangible assets 
-
-
(
1
)
-
Costs associated with shareholder advisory matters and select 
value creation consulting costs 
(
10
)
-
(
24
)
-
Total adjustments 
$ 
(
98
)
$ 
(
86
)
$ 
(
227
)
$ 
(
245
)

Table of Contents
HENRY SCHEIN, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(in millions, except share and per share data)
(unaudited
)
16 
Note 6

 
Business Acquisitions
Our acquisition strategy is focused on investments in companies that

add new customers and sales teams, increase 
our geographic footprint (whether entering a new country, such as emerging markets, or building scale where we 
have already invested in businesses), and finally, those that enable us to access new products and technologies.
2025 Acquisitions 
During the nine months ended September 27, 2025, we acquired companies

within the Global Distribution and 
Value

-Added Services and Global Specialty Products segments.

We acquired ownership interest in these 
companies ranging from 
60
% to 
100
%. 
The following table aggregates the preliminary estimated fair value, as of

the date of the acquisition, of 
consideration paid and net assets acquired for acquisitions during the nine months

ended September 27, 2025:

Preliminary 
Allocation as of 
September 27, 2025 
Acquisition consideration: 
Cash 
$ 
112
Deferred consideration 
1
Estimated fair value of contingent consideration payable 
11
Fair value of previously held equity method investments 
81
Noncontrolling interests 
85
Total consideration 
$ 
290
Identifiable assets acquired and liabilities assumed: 
Current assets 
$ 
50
Intangible assets 
116
Other noncurrent assets 
35
Current liabilities 
(
15
)
Long-term debt 
(
1
)
Deferred income taxes 
(
21
)
Other noncurrent liabilities 
(
4
)
Total identifiable

net assets 
160
Goodwill 
130
Total net assets acquired 
$ 
290
The accounting for acquisitions in the nine months ended September 27, 2025 has

not been completed in several 
areas, including, but not limited to, pending assessment of certain

assets, primarily including identifiable 
intangibles and certain equity method investments, and certain liabilities,

primarily including deferred income 
taxes. 
Goodwill is a result of the synergies and cross-selling opportunities that these acquisitions

are expected to provide 
for us, as well as the expected growth potential.

The majority of the acquired goodwill is not deductible

for tax 
purposes. 
During the three and nine months ended September 27, 2025, in connection

with acquisitions of controlling 
interests of affiliates, we recognized gains of approximately $
28

million and $
32

million, respectively, related to the 
remeasurement to fair value of our previously held equity investments.

Such gains were calculated using a 
discounted cash flow model based on Level 3 inputs, as defined in
Note 7  Fair Value Measurements
, 

which was 
recorded in selling, general and administrative in the condensed consolidated

statements of income.

Table of Contents
HENRY SCHEIN, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(in millions, except share and per share data)
(unaudited
)
17 
The following table summarizes the intangible assets acquired during the nine

months ended September 27, 2025:

2025 
Weighted Average

Useful 
Lives (in years) 
Customer relationships and lists 
97
10
Trademarks / Tradenames 
18
6
Non-compete agreements 
1
5
Total 
$ 
116
The impact of these acquisitions, individually and in the aggregate, was

not considered material to our condensed 
consolidated financial statements. 
Pro forma financial information since the acquisition date has not been presented

because the impact of these 
acquisitions was immaterial to our condensed consolidated

financial statements.
2024 Acquisitions
Acquisition of TriMed 
On April 1, 2024, we acquired a 
60
% voting equity interest in TriMed Inc. (TriMed), a global developer of 
solutions for the orthopedic treatment of lower and upper extremities, headquartered

in California, for consideration 
of $
315

million.

This acquisition is reported in our Global Specialty Products segment.

During the year ended 
December 28, 2024, we completed the accounting for this acquisition.
The following table aggregates the final fair value, as of the date of the acquisition,

of consideration paid and net 
assets acquired in the TriMed acquisition:

Final Allocation 
Acquisition consideration: 
Cash 
$ 
141
Deferred consideration 
21
Redeemable noncontrolling interests 
153
Total consideration 
$ 
315
Identifiable assets acquired and liabilities assumed: 
Current assets 
$ 
35
Intangible assets 
221
Other noncurrent assets 
10
Current liabilities 
(
7
)
Deferred income taxes 
(
62
)
Other noncurrent liabilities 
(
6
)
Total identifiable

net assets 
191
Goodwill 
124
Total net assets acquired 
$ 
315
Goodwill is a result of synergies that are expected to originate from the acquisition as well as

the expected growth 
potential of TriMed.

The acquired goodwill is not deductible for tax purposes. 
The intangible assets acquired consisted of product development of $
204

million, trademarks and tradenames of $
9
million, and in-process research and development of $
8

million.

Weighted average useful lives for these acquired 
intangible assets were 
9

years, 
7

years and indefinite-lived, respectively.

Except for in-process research and 
development (IPR&D), intangible assets acquired as a result of the

TriMed acquisition are being amortized over 

Table of Contents
HENRY SCHEIN, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(in millions, except share and per share data)
(unaudited
)
18 

their estimated useful lives using the straight-line method of amortization.

IPR&D is accounted for as an 
indefinite-lived intangible asset and is not amortized until completion or

abandonment of the associated research 
and development efforts.

IPR&D is tested for impairment annually or periodically if

an indicator of impairment 
exists during the period until completion. 
Pro forma financial information and TriMeds revenue and earnings since the acquisition date have not been 
presented because the impact of the TriMed acquisition was immaterial to our condensed consolidated

financial 
statements.
Other 2024 Acquisitions 
During the year ended December 28, 2024, we acquired companies within

the Global Distribution and Value-
Added Services and Global Specialty Products segments.

Our acquired ownership interest in these companies 
range from 
51
% to 
100
%.

Total consideration for these acquisitions was $
113

million (including cash paid of $
62
million, fair value of previously held equity investment of $
30

million, noncontrolling interest of $
18

million, 
estimated fair value of contingent consideration payable of $
2

million, and deferred consideration of $
1

million).

Net assets acquired primarily consisted of $
60

million of goodwill and $
64

million of intangible assets.

The 
intangible assets acquired consisted of customer relationships and lists of

$
33

million, trademarks and tradenames 
of $
24

million, product development of $
5

million and non-compete agreements of $
2

million.

Weighted average 
useful lives for these acquired intangible assets were 
11

years, 
7

years, 
9

years and 
5

years, respectively. 
During the first half of fiscal 2025 we completed the accounting for all

acquisitions that occurred in the year ended 
December 28, 2024.

We did not record material adjustments in our condensed consolidated financial statements 
relating to changes in estimated values of assets acquired, liabilities

assumed or contingent consideration assets and 
liabilities in respect to these acquisitions. 
Goodwill is a result of the synergies and cross-selling opportunities that these acquisitions

are expected to provide 
for us, as well as the expected growth potential.

The majority of the acquired goodwill is not deductible

for tax 
purposes. 
During the three and nine months ended September 28, 2024, in connection

with an acquisition of a controlling 
interest of an affiliate, we recognized a gain of approximately $
19

million related to the remeasurement to fair value 
of our previously held equity investment, using a discounted cash flow

model based on Level 3 inputs, as defined in
Note 7  Fair Value

Measurements
, 

which was recorded in selling, general and administrative

in the condensed 
consolidated statements of income.

Pro forma financial information for our 2024 acquisitions has not been

presented because the impact of the 
acquisitions was immaterial to our condensed consolidated

financial statements.
Acquisition Costs 
During the three and nine months ended September 27, 2025, we

incurred $
1

million and $
4

million in acquisition 
costs, respectively.

During the three and nine months ended September 28, 2024,

we incurred $
2

million and $
5
million in acquisition costs, respectively.

These costs are included in selling, general and administrative

in our 
condensed consolidated statements of income.

Table of Contents
HENRY SCHEIN, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(in millions, except share and per share data)
(unaudited
)
19 
Note 7  Fair Value Measurements

Fair value is defined as the price that would be received to sell an asset or

paid to transfer a liability in an orderly 
transaction between market participants at the measurement date.

The fair value hierarchy distinguishes between 
(1) market participant assumptions developed based on market data obtained

from independent sources (observable 
inputs) and (2) an entitys own assumptions about market participant assumptions developed based on the best 
information available in the circumstances (unobservable inputs). 
The fair value hierarchy consists of three broad levels, which gives the

highest priority to unadjusted quoted prices 
in active markets for identical assets or liabilities (Level 1) and the lowest priority

to unobservable inputs (Level 3).

The three levels of the fair value hierarchy are described as follows: 


Level 1 Unadjusted quoted prices in active markets for identical assets

or liabilities that are accessible at the 
measurement date. 


Level 2 Inputs other than quoted prices included within Level 1 that are

observable for the asset or liability, 
either directly or indirectly.

Level 2 inputs include: quoted prices for similar assets or liabilities

in active markets; 
quoted prices for identical or similar assets or liabilities in markets

that are not active; inputs other than quoted 
prices that are observable for the asset or liability; and inputs that are

derived principally from or corroborated by 
observable market data by correlation or other means. 


Level 3 Inputs that are unobservable for the asset or liability.

The following section describes the fair values of our financial instruments

and the methodologies that we used to 
measure their fair values.

Investments and notes receivable 
There are no quoted market prices available for investments in unconsolidated

affiliates and notes receivable.

Certain of our notes receivable contain variable interest rates.

We believe the carrying amounts of the notes 
receivable are a reasonable estimate of fair value based on the interest rates

in the applicable markets.

Our notes 
receivable fair value is based on Level 3 inputs within the fair value

hierarchy.

Debt 
The fair value of our debt (including bank credit lines, current maturities

of long-term debt and long-term debt) is 
based on Level 3 inputs within the fair value hierarchy, and as of September 27, 2025 and December 28, 2024 was 
estimated at $
3,096

million and $
2,536

million, respectively.

Factors that we considered when estimating the fair 
value of our debt include market conditions, such as interest rates and credit

spreads. 
Derivative contracts 
Derivative contracts are valued using quoted market prices and

significant other observable inputs.

Our derivative 
instruments primarily include foreign currency forward contracts, interest

rate swaps and total return swaps. 
The fair values for the majority of our foreign currency derivative contracts

are obtained by comparing our contract 
rate to a published forward price of the underlying market rates, which

are based on market rates for comparable 
transactions that are classified within Level 2 of the fair value hierarchy. 
The fair value of the interest rate swap, which is classified within Level 2

of the fair value hierarchy, is determined 
by comparing our contract rate to a forward market rate as of the

valuation date. 
The fair value of total return swaps is determined by valuing the underlying

exchange traded funds of the swap 
using market-on-close pricing by industry providers as of the valuation

date that are classified within Level 2 of the 

Table of Contents
HENRY SCHEIN, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(in millions, except share and per share data)
(unaudited
)
20 

fair value hierarchy. 
Redeemable noncontrolling interests 
The values for redeemable noncontrolling interests are based on recent

transactions and/or implied multiples of 
earnings that are classified within Level 3 of the fair value hierarchy.

See 
Note 13  Redeemable Noncontrolling 
Interests

for additional information. 
Intangible Assets
Assets measured on a non-recurring basis at fair value include intangibles.

Inputs for measuring intangibles are 
classified as Level 3 within the fair value hierarchy. 
Defined Benefit Plans
Assets of our defined benefit plans are measured on a recurring basis

and are classified as Level 1 within the fair 
value hierarchy. 
Contingent Consideration 
We estimate the fair value of contingent consideration payments as part of the acquisition price and record the 
estimated fair value of contingent consideration as a liability on our

condensed consolidated balance sheet.

For 
transactions accounted for as business combinations, subsequent changes

in the estimated fair value of contingent 
consideration payments are included in selling, general and administrative

expenses in our condensed consolidated 
statements of income

(see 
Note 6  Business Acquisitions
)
.

For transactions involving changes in our ownership in 
subsidiaries without a change in our control, subsequent changes

in the estimated fair value of contingent 
consideration payments are recognized in additional paid-in capital in our

condensed consolidated balance sheet. 
We measure contingent consideration at the fair value on a recurring basis using significant unobservable inputs 
classified as Level 3 of the fair value hierarchy.

We use various valuation techniques, including the Monte Carlo 
simulation and probability-weighted scenarios, to determine the fair value

of the contingent consideration liabilities 
on the acquisition date and at each reporting period.

Our fair value measurement inputs include expected operating 
performance, discount and risk-free rates, and credit spread. 
The components of the change in the fair value of contingent consideration

for the three and nine months ended 
September 27, 2025 and September 28, 2024 are presented in the following

table:

Three Months Ended 
Nine Months Ended 
September 27, 
September 28, 
September 27, 
September 28, 
2025 
2024 
2025 
2024 
Balance, beginning of period

$ 
106
$ 
46
$ 
30
$ 
6
Increase in contingent consideration due to business 
acquisitions and acquisitions of noncontrolling interests in 
subsidiaries 
1
-
95
2
Decrease in contingent consideration due to payments 
-
-
(
19
)
-
Change in fair value of contingent consideration in 
connection with business acquisitions 
7
-
5
38
Change in fair value of contingent consideration in 
connection with

changes in ownership in consolidated 
subsidiaries 
(
18
)
-
(
15
)
-
Balance, end of period

$ 
96
$ 
46
$ 
96
$ 
46

Table of Contents
HENRY SCHEIN, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(in millions, except share and per share data)
(unaudited
)
21 
The following table presents our assets and liabilities that are measured and

recognized at fair value on a recurring 
basis classified under the appropriate level of the fair value hierarchy as of

September 27, 2025 and December 28, 
2024:

September 27, 2025 
Level 1 
Level 2 
Level 3 
Total 
Assets: 
Derivative contracts designated as hedges 
$ 
-
$ 
2
$ 
-
$ 
2
Derivative contracts undesignated 
-
1
-
1
Total return

swap 
-
2
-
2
Total assets

$ 
-
$ 
5
$ 
-
$ 
5
Liabilities: 
Derivative contracts designated as hedges 
$ 
-
$ 
23
$ 
-
$ 
23
Derivative contracts undesignated 
-
-
-
-
Contingent consideration 
-
-
96
96
Total liabilities

$ 
-
$ 
23
$ 
96
$ 
119
Redeemable noncontrolling interests

$ 
-
$ 
-
$ 
877
$ 
877
December 28, 2024 
Level 1 
Level 2 
Level 3 
Total 
Assets: 
Derivative contracts designated as hedges 
$ 
-
$ 
10
$ 
-
$ 
10
Derivative contracts undesignated 
-
7
-
7
Total assets

$ 
-
$ 
17
$ 
-
$ 
17
Liabilities: 
Derivative contracts designated as hedges 
$ 
-
$ 
5
$ 
-
$ 
5
Derivative contracts undesignated 
-
4
-
4
Total return

swap 
-
3
-
3
Contingent consideration 
-
-
30
30
Total liabilities

$ 
-
$ 
12
$ 
30
$ 
42
Redeemable noncontrolling interests

$ 
-
$ 
-
$ 
806
$ 
806

Table of Contents
HENRY SCHEIN, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(in millions, except share and per share data)
(unaudited
)
22 
Note 8  Debt
Bank Credit Lines
Bank credit lines consisted of the following:

September 27, 
December 28, 
2025 
2024 
Revolving credit agreement 
$ 
250
$ 
-
Other short-term bank credit lines 
663
650
Total 
$ 
913
$ 
650
Revolving Credit Agreement
On 
August 20, 2021
, we entered into a $
1.0

billion revolving credit agreement (the Revolving Credit Agreement) 
which was amended and restated on 
July 11, 2023

to extend the maturity date to 
July 11, 2028

and update the 
interest rate provisions to reflect the current market approach for a

multicurrency facility.

On June 6, 2025, we 
amended and restated the Revolving Credit Agreement to, among other

things, modify certain financial definitions 
and covenants.

The interest rate on this revolving credit facility is based on Term Secured Overnight Financing 
Rate (
Term SOFR
) plus a spread based on our leverage ratio at the end

of each financial reporting quarter.

As of 
September 27, 2025 the interest rate on this revolving credit

facility was 
4.14
% plus 
1.07
% for a combined rate of 
5.21
%.

As of December 28, 2024 the interest rate on this revolving

credit facility was 
4.45
% plus 
1.18
%, for a 
combined rate of 
5.63
%.

The Revolving Credit Agreement requires, among other things, that we

maintain certain maximum leverage ratios.

Additionally, the Revolving Credit Agreement contains customary representations, warranties and affirmative 
covenants as well as customary negative covenants, subject to negotiated

exceptions, on liens, indebtedness, 
significant corporate changes (including mergers), dispositions and certain restrictive

agreements.

As of September 
27, 2025 and December 28, 2024, we had $
250

million and $
0

million in borrowings, respectively, under this 
revolving credit facility.

During the nine months ended September 27, 2025, the

average outstanding balance under 
the Revolving Credit Agreement was approximately $
181

million.

As of September 27, 2025 and December 28, 
2024, there were $
10

million and $
11

million of letters of credit, respectively, provided to third parties under the 
Revolving Credit Agreement.
Other Short-Term Bank Credit

Lines
As of September 27, 2025 and December 28, 2024, we had various other

short-term bank credit lines available, in 
various currencies, with a maximum borrowing capacity of $
783

million and $
790

million, respectively.

As of 
September 27, 2025 and December 28, 2024, $
663

million and $
650

million, respectively, were outstanding.

During the nine months ended September 27, 2025, the average outstanding

balances under our various other short-
term bank credit lines was approximately $
675

million.

As of September 27, 2025 and December 28, 2024, 
borrowings under other short-term bank credit lines had weighted average

interest rates of 
5.11
% and 
5.35
%, 
respectively.

Table of Contents
HENRY SCHEIN, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(in millions, except share and per share data)
(unaudited
)
23 
Long-term debt 
Long-term debt consisted of the following:

September 27, 
December 28, 
2025 
2024 
Private placement facilities

$ 
975
$ 
975
Term loan 
749
712
U.S. trade accounts receivable securitization 
400
150
Various

collateralized and uncollateralized loans payable with interest, 
in varying installments through 2031 at interest rates 
from 
0.00
% to 
9.42
% at September 27, 2025 and 
from 
0.00
% to 
9.42
% at December 28, 2024 
52
43
Finance lease obligations 
7
6
Total

2,183
1,886
Less current maturities 
(
30
)
(
56
)
Total long-term debt

$ 
2,153
$ 
1,830
Private Placement Facilities
Our private placement facilities provided by 
four

insurance companies have a total facility amount of $
1.5

billion, 
and are available on an uncommitted basis at fixed rate economic terms

to be agreed upon at the time of issuance, 
from time to time through 
October 20, 2026
.

The facilities allow us to issue senior promissory notes to the

lenders 
at a fixed rate based on an agreed upon spread over applicable treasury

notes at the time of issuance.

The term of 
each possible issuance will be selected by us and can range from 
five

to 
15 years

(with an average life no longer 
than 
12 years
).

The proceeds of any issuances under the facilities will be used

for general corporate purposes, 
including working capital and capital expenditures, to refinance existing

indebtedness, and/or to fund potential 
acquisitions.

The agreements provide, among other things, that we maintain

certain maximum leverage ratios, and 
contain restrictions relating to subsidiary indebtedness, liens, affiliate transactions,

disposal of assets and certain 
changes in ownership.

These facilities contain make-whole provisions in the event that we

pay off the facilities 
prior to the applicable due dates.
The components of our private placement facility borrowings as of

September 27, 2025, which have a weighted 
average interest rate of 
3.70
%, are presented in the following table:

Amount of 
Date of

Borrowing 
Borrowing

Borrowing 
Outstanding 
Rate 
Due Date 
June 16, 2017
$ 
100
3.42
% 
June 16, 2027
September 15, 2017
100
3.52
September 15, 2029
January 2, 2018
100
3.32
January 2, 2028
September 2, 2020
100
2.35
September 2, 2030
June 2, 2021
100
2.48
June 2, 2031
June 2, 2021
100
2.58
June 2, 2033
May 4, 2023
75
4.79
May 4, 2028
May 4, 2023
75
4.84
May 4, 2030
May 4, 2023
75
4.96
May 4, 2033
May 4, 2023
150
4.94
May 4, 2033
Total 
$ 
975

Table of Contents
HENRY SCHEIN, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(in millions, except share and per share data)
(unaudited
)
24 
The components of our private placement facility borrowings as of December

28, 2024, which have a weighted 
average interest rate of 
3.70
%, are presented in the following table:

Amount of 
Date of

Borrowing 
Borrowing

Borrowing 
Outstanding 
Rate 
Due Date 
June 16, 2017
$ 
100
3.42
% 
June 16, 2027
September 15, 2017
100
3.52
September 15, 2029
January 2, 2018
100
3.32
January 2, 2028
September 2, 2020
100
2.35
September 2, 2030
June 2, 2021
100
2.48
June 2, 2031
June 2, 2021
100
2.58
June 2, 2033
May 4, 2023
75
4.79
May 4, 2028
May 4, 2023
75
4.84
May 4, 2030
May 4, 2023
75
4.96
May 4, 2033
May 4, 2023
150
4.94
May 4, 2033
Total 
$ 
975
Term Loan
On July 11, 2023, we entered into a 
three-year

$
750

million term loan credit agreement (the Term Credit 
Agreement), which was originally scheduled to mature on 
July 11, 2026
.

On June 6, 2025, this agreement was 
amended and restated to, among other things, (i) extend the maturity date

to 
June 6, 2030
, and (ii) modify certain 
financial definitions and covenants.

The interest rate on this term loan is based on the 
Term SOFR

plus a spread 
based on our leverage ratio at the end of each financial reporting quarter.

Beginning in June 2026 and continuing 
through June 2027, we are required to make quarterly payments of $
5

million.

In September 2027, the quarterly 
payment amount increases to $
9

million, continuing through June 2030 with the remaining balance due June

6, 
2030.

As of September 27, 2025, the borrowings outstanding under this

term loan were $
749

million.

At 
September 27, 2025, the interest rate under the Term Credit Agreement was 
4.18
% plus 
1.25
%, for a combined rate 
of 
5.43
%.

As of December 28, 2024, the borrowings outstanding under this

term loan were $
712

million.

At 
December 28, 2024, the interest rate under the Term Credit Agreement was 
4.45
% plus 
1.60
%, for a combined rate 
of 
6.05
%.

However, at December 28, 2024, we had a hedge in place creating an effective fixed rate of 
6.04
%.

After renewing the Term Credit Agreement in June of 2025, our hedged portion of the Term Credit Agreement was 
approximately 
91
% of the notional total.

As of September 27, 2025, the effective fixed rate was 
5.69
% and the 
floating rate was 
5.43
%, resulting in a weighted average rate of 
5.67
%.

The Term Credit Agreement requires, 
among other things, that we maintain certain maximum leverage ratios.

Additionally, the Term

Credit Agreement 
contains customary representations, warranties and affirmative covenants as well

as customary negative covenants, 
subject to negotiated exceptions, on liens, indebtedness, significant corporate

changes (including mergers), 
dispositions and certain restrictive agreements.
U.S. Trade Accounts Receivable Securitization 
We have a facility agreement based on our U.S. trade accounts receivable that is structured as an asset-backed 
securitization program with pricing committed for up to 
three years
.

On December 6, 2024, we extended the 
expiration date of this facility agreement to 
December 6, 2027

(the previous maturity date was 
December 15, 2025
).

This facility agreement has a purchase limit of $
450

million with 
two

banks as agents. 
As of September 27, 2025 and December 28, 2024, the borrowings

outstanding under this securitization facility 
were $
400

million and $
150

million, respectively.

At September 27, 2025, the interest rate on borrowings under 
this facility was based on the 
asset-backed commercial paper rate

of 
4.36
% plus 
0.75
%, for a combined rate of 
5.11
%.

At December 28, 2024, the interest rate on borrowings under

this facility was based on the asset-backed 
commercial paper rate of 
4.73
% plus 
0.75
%, for a combined rate of 
5.48
%. 

Table of Contents
HENRY SCHEIN, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(in millions, except share and per share data)
(unaudited
)
25 

If our accounts receivable collection pattern changes due to customers

either paying late or not making payments, 
our ability to borrow under this facility may be reduced.

We are required to pay a commitment fee of 
30

to 
35

basis 
points depending upon program utilization.
Note 9  Income Taxes

For the three months ended September 27, 2025, our effective tax rate was 
21.3
%, compared to 
24.7
% for the prior 
year period.

The difference between our effective and federal statutory tax rates primarily relates to state and 
foreign income taxes and interest expense.

For the three months ended September 27, 2025, the difference was 
further impacted by the tax treatment associated with the acquisition of a

controlling interest of a previously held 
non-controlling equity investment.

For the nine months ended September 27, 2025, our effective tax rate was 
23.5
%, compared to 
25.1
% for the prior 
year period.

The difference between our effective tax rate and the federal statutory tax rate is primarily

due to state 
and foreign income taxes and interest expense.

For the nine months ended September 27, 2025, the difference was 
further impacted by the tax treatment associated with the acquisition of a

controlling interest of a previously held 
non-controlling equity investment. 
On July 4, 2025, President Trump signed the reconciliation tax bill, commonly known as the One

Big Beautiful 
Bill Act (OBBBA),

into law.

Corporate provisions in the OBBBA include immediate expensing of domestic 
research and experimental expenditures, limitations on certain deductions

and modifications to international tax 
provisions.

As a result of the OBBBA, we anticipate a reduction in current

income tax liabilities and deferred tax 
assets. 
The Organization of Economic Co-Operation and Development

(OECD) issued technical and administrative 
guidance on Pillar Two rules in December 2021, which provides for a global minimum tax rate on the earnings of 
large multinational businesses on a country-by-country basis.

Effective January 1, 2024, the minimum global tax 
rate is 15% for various jurisdictions pursuant to the Pillar Two rules.

Future tax reform resulting from these 
developments may result in changes to long-standing tax principles, which

may adversely impact our effective tax 
rate going forward or result in higher cash tax liabilities.

As of September 27, 2025,

the impact of the Pillar Two 
rules to our financial statements was immaterial. 
The total amount of unrecognized tax benefits, which are included in

other liabilities within our condensed 
consolidated balance sheets, as of September 27, 2025 and December 28,

2024 was $
114

million and $
108

million, 
respectively, of which $
107

million and $
100

million, respectively, would affect the effective tax rate if recognized.

It is possible that the amount of unrecognized tax benefits will

change in the next 12 months, which may result in a 
material impact on our condensed consolidated statements of income. 
All tax returns audited by the IRS are officially closed through 2020.

The tax years subject to examination by the 
IRS include years 2021 and forward.

In addition, limited positions reported in the 2017 tax year are subject

to IRS 
examination. 
The amount of tax interest expense included as a component of the provision

for taxes was $
2

million and $
0
million for the three months ended September 27, 2025 and September

28, 2024, respectively.

The amount of tax 
interest expense included as a component of the provision for taxes was

$
3

million and $
1

million for the nine 
months ended September 27, 2025 and September 28, 2024, respectively.

The total amount of accrued interest is 
included in other liabilities within our condensed consolidated balance sheets,

and was $
21

million as of September 
27, 2025 and $
18

million as of December 28, 2024.

The amount of penalties accrued for during the periods 
presented was not material to our condensed consolidated financial statements.

Table of Contents
HENRY SCHEIN, INC.
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(in millions, except share and per share data)
(unaudited
)
26 
Note 10  Plans of Restructuring
On August 6, 2024, we committed to a new restructuring plan (the 2024

Plan) to integrate recent acquisitions, 
right-size operations and further increase efficiencies.

We currently expect completion of this plan to be at the end 
of 2027.

During the three months ended September 27, 2025 and September

28, 2024, we recorded restructuring 
charges associated with the 2024 Plan of $
34

million and $
36

million, respectively.

During the nine months ended 
September 27, 2025 and September 28, 2024, we recorded restructuring

charges associated with the 2024 Plan of 
$
82

million and $
36

million, respectively.

The restructuring costs for these periods primarily related

to severance 
and employee-related costs, accelerated amortization of right-of-use assets and

fixed assets, and other exit costs.

We expect to record restructuring charges associated with the 2024 Plan through the end of 2027; however,

an 
estimate of the amount of these charges for 2025 through 2027 has not yet been determined. 
On August 1, 2022, we committed to a restructuring plan (the 2022

Plan) focused on funding the priorities of the 
BOLD+1 strategic plan, streamlining operations and other initiatives to

increase efficiency.

The 2022 Plan was 
completed as of July 31, 2024.

During the three and nine months ended September 28, 2024, in connection

with 
our 2022 Plan, we recorded restructuring costs of $
12

million and $
37

million, respectively, which primarily related 
to severance and employee-related costs, accelerated amortization of

right-of-use assets and fixed assets, and other 
exit costs.

Restructuring costs recorded for the three and nine months ended September

27, 2025 and September 28, 2024 in 
connection with the 2024

Plan and 2022 Plan, respectively, consisted of the following:

Three Months Ended September 27, 2025 
Global Distribution 
and Value-Added 
Services 
Global 
Specialty 
Products 
Global 
Technology 
Corporate 
Total 
2024 Plan 
Severance and employee-related costs 
$ 
13
$ 
4
$ 
1
$ 
9
$ 
27
Impairment and accelerated depreciation and amortization 
of right-of-use lease assets and other long-lived assets 
-
4
(
1
)
-
3
Exit and other related costs 
1
3
-
-
4
Restructuring costs-2024 Plan 
$ 
14
$ 
11
$ 
-
$ 
9
$ 
34
Three Months Ended September 28, 2024 
Global Distribution 
and Value-Added 
Services 
Global 
Specialty 
Products 
Global 
Technology 
Corporate 
Total 
2024 Plan 
Severance and employee-related costs 
$ 
23
$ 
2
$ 
5
$ 
1
$ 
31
Impairment and accelerated depreciation and amortization 
of right-of-use lease assets and other long-lived assets 
2
-
2
-
4
Exit and other related costs 
1
-
-
-
1
Restructuring costs-2024 Plan 
$ 
26
$ 
2
$ 
7
$ 
1
$ 
36
Three Months Ended September 28, 2024 
Global Distribution 
and Value-Added 
Services 
Global 
Specialty 
Products 
Global 
Technology 
Corporate 
Total 
2022 Plan 
Severance and employee-related costs 
$ 
6
$ 
2
$ 
-
$ 
-
$ 
8
Impairment and accelerated depreciation and amortization 
of right-of-use lease assets and other long-lived assets 
1
-
-
-
1
Exit and other related costs 
1
2
-
-
3
Restructuring costs-2022 Plan 
$ 
8
$ 
4
$ 
-
$ 
-
$ 
12

Table of Contents
HENRY SCHEIN, INC. 
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 
(in millions, except share and per share data) 
(unaudited
) 
27 

Nine Months Ended September 27, 2025 
Global Distribution 
and Value-Added 
Services 
Global 
Specialty 
Products 
Global 
Technology 
Corporate 
Total 
2024 Plan 
Severance and employee-related costs 
$ 
34
$ 
14
$ 
2
$ 
17
$ 
67
Impairment and accelerated depreciation and amortization 
of right-of-use lease assets and other long-lived assets 
1
6
(
1
)
-
6
Exit and other related costs 
4
3
1
-
8
Loss on disposal of a business 
1
-
-
-
1
Restructuring costs-2024 Plan 
$ 
40
$ 
23
$ 
2
$ 
17
$ 
82
Nine Months Ended September 28, 2024 
Global Distribution 
and Value-Added 
Services 
Global 
Specialty 
Products 
Global 
Technology 
Corporate 
Total 
2024 Plan 
Severance and employee-related costs 
$ 
23
$ 
2
$ 
5
$ 
1
$ 
31
Impairment and accelerated depreciation and amortization 
of right-of-use lease assets and other long-lived assets 
2
-
2
-
4
Exit and other related costs 
1
-
-
-
1
Restructuring costs-2024 Plan 
$ 
26
$ 
2
$ 
7
$ 
1
$ 
36
Nine Months Ended September 28, 2024 
Global Distribution 
and Value-Added 
Services 
Global 
Specialty 
Products 
Global 
Technology 
Corporate 
Total 
2022 Plan 
Severance and employee-related costs 
$ 
18
$ 
5
$ 
1
$ 
-
$ 
24
Impairment and accelerated depreciation and amortization 
of right-of-use lease assets and other long-lived assets 
10
-
-
(
3
)
7
Exit and other related costs 
2
2
-
2
6
Restructuring costs-2022 Plan 
$ 
30
$ 
7
$ 
1
$ 
(
1
)
$ 
37
The following table summarizes,

by plan year the activity related to the liabilities associated with

our restructuring 
initiatives under the 2022 Plan and the 2024 Plan for the nine months

ended September 27, 2025.

The remaining 
accrued balance of restructuring costs as of September 27, 2025, which

primarily relates to severance and 
employee-related costs, is included in accrued expenses: other within

our condensed consolidated balance sheets.

Liabilities related to exited leased facilities are recorded within our current

and non-current operating lease 
liabilities within our condensed consolidated balance sheets.

2022 Plan 
2024 Plan 
Total 
Balance, December 28, 2024

$ 
12
$ 
28
$ 
40
Restructuring costs
-
82
82
Non-cash impairment, accelerated depreciation and 
amortization 
-
(
6
)
(
6
)
Non-cash impairment on disposal of a business 
-
(
1
)
(
1
)
Cash payments and other adjustments

(
10
)
(
52
)
(
62
)
Balance, September 27, 2025

$ 
2
$ 
51
$ 
53

Table of Contents
HENRY SCHEIN, INC. 
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 
(in millions, except share and per share data) 
(unaudited
) 
28 
Note 11  Legal Proceedings
Henry Schein, Inc. has been named as a defendant in multiple opioid

related lawsuits (currently less than twenty 
(
20
); one or more of Henry Schein, Inc.s subsidiaries is also named as a defendant in a number of those 
cases).

Generally, the lawsuits allege that the manufacturers of prescription opioid drugs engaged in a false 
advertising campaign to expand the market for such drugs and their own

market share and that the entities in the 
supply chain (including Henry Schein, Inc. and its subsidiaries) reaped

financial rewards by refusing or otherwise 
failing to monitor appropriately and restrict the improper distribution of those

drugs.

The actions that remain have 
been consolidated within the MultiDistrict Litigation (MDL) proceeding

In Re National Prescription Opiate 
Litigation (MDL No. 2804; Case No. 17-md-2804) and are currently

stayed.

Of Henry Scheins 2024 net sales of 
approximately $
12.7

billion, sales of opioids represented less than 
four
-tenths of 1 percent.

Opioids represent a 
negligible part of our business.

We intend to defend ourselves vigorously against these actions. 
From time to time, we may become a party to other legal proceedings,

including, without limitation, product 
liability claims, employment matters, commercial disputes, governmental

inquiries and investigations (which may 
in some cases involve our entering into settlement arrangements or consent

decrees), and other matters arising out 
of the ordinary course of our business.

While the results of any legal proceeding cannot be predicted with certainty, 
in our opinion none of these other pending matters are currently

anticipated to have a material adverse effect on our 
consolidated financial position, liquidity or results of operations. 
As of September 27, 2025, we had accrued our best estimate of potential

losses relating to claims that were 
probable to result in liability and for which we were able to reasonably

estimate a loss.

This accrued amount, as 
well as related expenses, was not material to our financial position,

results of operations or cash flows.

Our method 
for determining estimated losses considers currently available facts,

presently enacted laws and regulations and 
other factors, including probable recoveries from third parties.

Table of Contents
HENRY SCHEIN, INC. 
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 
(in millions, except share and per share data) 
(unaudited
) 
29 
Note 12  Stock-Based Compensation

Stock-based awards are provided to certain employees under our 2024 Stock Incentive

Plan (formerly known as our 
2020 Stock Incentive Plan) and to non-employee directors under our 2023 Non-Employee

Director Stock Incentive 
Plan (together, the Plans).

The Plans are administered by the Compensation Committee of the Board

of Directors 
(the Compensation Committee).

Historically, equity-based awards to our employees have been granted solely in 
the form of time-based and performance-based restricted stock units (RSUs) with

the exception of our 2021 plan 
year in which non-qualified stock options were issued in place of performance-based

RSUs and in 2022, when we 
granted time-based and performance-based RSUs, as well as non-qualified

stock options. 
Starting with our 2023 plan year, we returned to granting our employees equity-based awards solely

in the form of 
time-based RSUs (which vest solely based on the recipients continued service over time) and performance-based 
RSUs (which vest based on achieving specified performance

measurements and the recipients continued service 
over time).

Our non-employee directors receive equity-based awards solely in

the form of time-based RSUs. 
In our 2025 plan year, stock awards issued to our Chief Executive Officer were allocated 
35
% to time-based RSU 
awards with 
four-year

cliff vesting and 
65
% to performance-based RSU awards with 
three-year

cliff vesting.

In our 
2025 plan year, stock awards issued to members of our Executive Management Committee were allocated 
50
% to 
time-based RSU awards with 
four-year

cliff vesting and 
50
% to performance-based RSU awards with 
three-year
cliff vesting.

In our 2025 plan year, stock awards issued to our eligible vice-presidents were allocated 
80
% to time-based RSU 
awards and 
20
% to performance-based RSU awards with 
three-year

cliff vesting.

Our vice-president level time-
based awards will vest 
50
% on the third anniversary of the grant date with the remaining 
50
% vesting on the fourth 
anniversary of the grant date. 
In our 2025 plan year, we began granting only time-based RSU awards to our eligible director level employees.

Our director level time-based RSU awards will vest 
50
% on the third anniversary of the grant date with the 
remaining 
50
% vesting on the fourth anniversary of the grant date.

RSUs are stock-based awards granted to recipients with specified vesting provisions.

In the case of RSUs, common 
stock is delivered on or following satisfaction of vesting conditions.

We issue RSUs to employees that primarily 
vest (i) solely based on the recipients continued service over time, primarily with 
four
-year cliff vesting for RSU 
awards granted prior to 2025 and with vesting upon third and fourth anniversary

of the grant date for RSU awards 
granted in 2025 and/or (ii) based on achieving specified performance

measurements and the recipients continued 
service over time, primarily with 
three
-year cliff vesting.

RSUs granted to our non-employee directors primarily 
include 
12
-month cliff vesting.

For the performance-based RSUs and the time-based RSUs with cliff vesting 
(issued in 2022-2024 plan years), we recognize the cost as compensation

expense on a straight-line basis.

For the 
time-based RSUs with graded vesting (issued in the 2025 plan year), we recognize

the cost as compensation 
expense on an accelerated basis.

For all RSUs, we estimate the fair value based on our closing stock

price on the grant date.

With respect to 
performance-based RSUs, the number of shares that ultimately vest and

are received by the recipient is based upon 
our performance as measured against specified targets over a specified period, as

determined by the Compensation 
Committee.

Although there is no guarantee that performance targets will be achieved, we

estimate the fair value of 
performance-based RSUs based on our closing stock price at time of grant. 
Each of the Plans provide for certain adjustments to the performance

measurement in connection with awards under 
the Plans.

With respect to the performance-based RSUs granted under our 2024 Stock Incentive Plan, such 
performance measurement adjustments relate to significant events, including,

without limitation, acquisitions, 
divestitures, new business ventures, changes in fair value of contingent

consideration (solely with respect to 
performance-based RSUs granted in the 2024 and 2025 plan years),

certain capital transactions (including share 

Table of Contents
HENRY SCHEIN, INC. 
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 
(in millions, except share and per share data) 
(unaudited
) 
30 

repurchases), differences in budgeted average outstanding shares (other

than those resulting from capital 
transactions referred to above), restructuring costs, amortization

expense recorded for acquisition-related intangible 
assets, certain litigation settlements or payments, changes in accounting

principles or in applicable laws or 
regulations, changes in income tax rates in certain markets, foreign exchange

fluctuations, the financial impact 
either positive or negative, of the difference in projected earnings generated by COVID-19

test kits (solely with 
respect to performance-based RSUs granted in the 2023 plan year), intangibles

impairment charges and costs 
related to shareholder advisory matters (solely with respect to performance-based

RSUs granted in the 2025 plan 
year). 
Over the performance period, the number of performance-based RSUs that will

ultimately vest and be issued and 
the related compensation expense is adjusted upward or downward based upon

our estimation of achieving such 
performance targets.

The ultimate number of shares delivered to recipients and

the related compensation cost 
recognized as an expense is based on our actual performance against the

pre-determined performance metrics (in 
each case as adjusted). 
Stock options are awards that allow the recipient to purchase shares of our

common stock after vesting at a fixed 
price set at the time of grant.

Stock options were granted at an exercise price equal to our

closing stock price on the 
date of grant.

Stock options issued in 2021 and 2022 vest 
one-third

per year based on the recipients continued 
service, subject to the terms and conditions of the 2020 Stock Incentive Plan,

are fully vested 
three years

from the 
grant date and have a contractual term of 
ten years

from the grant date, subject to earlier termination of term and 
term acceleration upon certain events.

Compensation expense for stock options is recognized on

an accelerated 
basis.

We estimate grant date fair value of stock options using the Black-Scholes valuation model.

During the nine 
months ended September 27, 2025, we did 
no
t grant any stock options.

Our condensed consolidated statements of income reflect pre-tax share-based compensation

expense of $
13

million 
and $
29

million for the three and nine months ended September 27, 2025,

respectively.

For the three and nine 
months ended September 28, 2024, we recorded pre-tax share-based compensation

expense of $
10

million and $
30
million. 
Total unrecognized compensation cost related to unvested awards as of September 27, 2025 was $
80

million, which 
is expected to be recognized over a weighted-average period of approximately 
2.5

years. 
Our condensed consolidated statements of cash flows present our

stock-based compensation expense as a 
reconciling adjustment between net income and net cash provided by operating

activities for all periods presented.

There were no cash benefits associated with tax deductions in excess of

recognized compensation for the nine 
months ended September 27, 2025 and September 28, 2024.

Table of Contents
HENRY SCHEIN, INC. 
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 
(in millions, except share and per share data) 
(unaudited
) 
31 
The following table summarizes the stock option activity for the nine months

ended September 27, 2025:

Stock Options 
Weighted Average 
Weighted Average 
Aggregate 
Exercise 
Remaining Contractual

Intrinsic 
Shares 
Price 
Life (in years) 

Value 
Outstanding at beginning of period

963,491
$ 
72.16

Granted

- 

-

Exercised

(
17,724
)
62.71

Forfeited

(
13,793
)
81.10

Outstanding at end of period

931,974
$ 
72.21

5.8

$ 
2
Options exercisable at end of period

931,708
$ 
72.21

Weighted Average 
Weighted Average 
Aggregate 
Number of 
Exercise 
Remaining Contractual 
Intrinsic 
Options 
Price 
Life (in years) 
Value 
Expected to vest 
266
$ 
83.28
7.2
$ 
-
The following tables summarize the activity of our unvested RSUs for

the nine months ended September 27, 2025:

Time-Based 
Restricted Stock Units 
Performance-Based 

Restricted Stock Units 
Weighted Average

Weighted Average

Grant Date Fair 
Grant Date Fair 
Shares/Units 
Value Per Share 
Shares/Units 
Value Per Share 
Outstanding at beginning of period

1,685,550
$ 
72.90
389,111
$ 
75.98
Granted

581,486
75.15
249,526
75.29
Performance adjustment 
n/a 
n/a 
4,147
76.26
Vested

(
542,050
)
66.11
(
14,220
)
84.05
Forfeited

(
89,459
)
77.31
(
199,546
)
77.74
Outstanding at end of period

1,635,527
$ 
75.70
429,018
$ 
75.83
The fair value of time and performance RSUs that vested was $
36

million and $
1

million, respectively, for the nine 
months ended September 27, 2025; and $
21

million and $
1

million, respectively, for the nine months ended 
September 28, 2024.

Table of Contents
HENRY SCHEIN, INC. 
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 
(in millions, except share and per share data) 
(unaudited
) 
32 
Note 13  Redeemable Noncontrolling Interests 
Some minority stockholders in certain of our subsidiaries have the right,

at certain times, to require us to acquire 
their ownership interest in those entities at fair value.

Accounting Standards Codification Topic 480-10 is 
applicable for noncontrolling interests where we are or may be required

to purchase all or a portion of the 
outstanding interest in a consolidated subsidiary from the noncontrolling

interest holder under the terms of a put 
option contained in contractual agreements.

The components of the change in the redeemable noncontrolling 
interests for the nine months ended September 27, 2025 and September

28, 2024 are presented in the following 
table:

September 27, 
September 28, 
2025 
2024 
Balance, beginning of period

$ 
806
$ 
864
Decrease in redeemable noncontrolling interests due to acquisitions of

noncontrolling interests in subsidiaries 
(
78
)
(
257
)
Increase in redeemable noncontrolling interests due to business acquisitions 
86
172
Distributions declared, net of capital contributions 
(
15
)
(
30
)
Effect of foreign currency translation gain (loss) attributable to 

redeemable noncontrolling interests

28
(
4
)
Change in fair value of redeemable securities

50
87
Balance, end of period

$ 
877
$ 
832

Note 14  Comprehensive Income 
Comprehensive income includes certain gains and losses that, under U.S.

GAAP,

are excluded from net income and 
are recorded directly to stockholders equity.

The following table summarizes our Accumulated other comprehensive loss, net of

applicable taxes as of:

September 27, 
December 28, 
2025 
2024 
Attributable to redeemable noncontrolling interests: 
Foreign currency translation adjustment

$ 
(
28
)
$ 
(
56
)
Attributable to noncontrolling interests: 
Foreign currency translation adjustment

$ 
-
$ 
(
1
)
Attributable to Henry Schein, Inc.: 
Foreign currency translation adjustment 
$ 
(
192
)
$ 
(
371
)
Unrealized loss from hedging activities

(
22
)
-
Pension adjustment loss

(
8
)
(
8
)
Accumulated other comprehensive loss

$ 
(
222
)
$ 
(
379
)
Total Accumulated

other comprehensive loss

$ 
(
250
)
$ 
(
436
)

Table of Contents
HENRY SCHEIN, INC. 
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 
(in millions, except share and per share data) 
(unaudited
) 
33 
The following table summarizes the components of comprehensive income, net

of applicable taxes as of:

Three Months Ended 
Nine Months Ended 
September 27, 
September 28, 
September 27, 
September 28, 
2025 
2024 
2025 
2024 
Net income 
$ 
109
$ 
99
$ 
316
$ 
302
Foreign currency translation gain (loss) 
(
1
)
58
208
(
58
)
Tax effect

-
-
-
-
Foreign currency translation gain (loss) 
(
1
)
58
208
(
58
)
Unrealized gain (loss) from hedging activities 
5
(
25
)
(
30
)
(
4
)
Tax effect

(
1
)
7
8
1
Unrealized gain (loss) from hedging activities 
4
(
18
)
(
22
)
(
3
)
Pension adjustment gain 
-
-
1
-
Tax effect

-
-
(
1
)
-
Pension adjustment gain 
-
-
-
-
Comprehensive income

$ 
112
$ 
139
$ 
502
$ 
241
Our financial statements are denominated in U.S. Dollars.

Fluctuations in the value of foreign currencies as 
compared to the U.S. Dollar may have a significant impact on our

comprehensive income.

The foreign currency 
translation gain (loss) during the nine months ended September 27, 2025 and

nine months ended September 28, 
2024 was primarily due to changes in foreign currency exchange

rates of the Brazilian Real, British Pound, Euro, 
Swiss Franc, Israel Shekel, Canadian Dollar,

and New Zealand Dollar. 
The hedging gain (loss) during the three and nine months ended September

27, 2025, and September 28, 2024 was 
attributable to a net investment hedge.
The following table summarizes our total comprehensive income, net of

applicable taxes as follows:

Three Months Ended 
Nine Months Ended 
September 27, 
September 28, 
September 27, 
September 28, 
2025 
2024 
2025 
2024 
Comprehensive income attributable to 
Henry Schein, Inc.

$ 
106
$ 
127
$ 
454
$ 
238
Comprehensive income attributable to 
noncontrolling interests

6
-
20
7
Comprehensive income (loss) attributable to 
Redeemable noncontrolling interests

-
12
28
(
4
)
Comprehensive income

$ 
112
$ 
139
$ 
502
$ 
241

Table of Contents
HENRY SCHEIN, INC. 
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 
(in millions, except share and per share data) 
(unaudited
) 
34 
Note 15

 
Earnings Per Share 
Basic earnings per share is computed by dividing net income attributable

to Henry Schein, Inc. by the weighted-
average number of common shares outstanding for the period.

Our diluted earnings per share is computed similarly 
to basic earnings per share, except that it reflects the effect of common shares issuable

for unvested RSUs and upon 
exercise of stock options using the treasury stock method in periods

in which they have a dilutive effect. 
A reconciliation of shares used in calculating earnings per basic and

diluted share follows:

Three Months Ended 
Nine Months Ended 
September 27, 
September 28, 
September 27, 
September 28, 
2025 
2024 
2025 
2024 
Basic

120,199,552
126,124,715
121,965,991
127,550,045
Effect of dilutive securities: 
Stock options and restricted stock units

836,695
930,219
874,071
948,449
Diluted

121,036,247
127,054,934
122,840,062
128,498,494
The number of antidilutive securities that were excluded from the calculation

of diluted weighted average common 
shares outstanding are as follows:

Three Months Ended 
Nine Months Ended 
September 27, 
September 28, 
September 27, 
September 28, 
2025 
2024 
2025 
2024 
Stock options 
393,413
412,574
397,613
416,065
Restricted stock units 
4,630
17,627
4,523
16,339
Total anti-dilutive

securities excluded from earnings per 
share computation 
398,043
430,201
402,136
432,404
Note 16  Supplemental Cash Flow Information

Cash paid for interest and income taxes was:

Nine Months Ended 
September 27, 
September 28, 
2025 
2024 
Interest 
$ 
109
$ 
92
Income taxes 
114
127
For the nine months ended September 27, 2025 and September 28, 2024, we had

$
(
30
)

million and $
(
4
)

million of 
non-cash net unrealized losses related to hedging activities, respectively.

Table of Contents
HENRY SCHEIN, INC. 
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 
(in millions, except share and per share data) 
(unaudited
) 
35 
Note 17  Related Party Transactions
During 2018, we entered into a joint venture with Internet Brands to create Henry

Schein One, LLC.

Internet 
Brands initially held a 
26
% noncontrolling interest, which has since increased to a 
33.6
% noncontrolling interest in 
Henry Schein One, LLC, and a freestanding and separately exercisable right

to put its noncontrolling interest to 
Henry Schein, Inc. for fair value following the fifth anniversary of the effective date of the

formation of the joint 
venture.

On January 29, 2025, Henry Schein, Inc. signed a Memorandum of Understanding

with Internet Brands to 
extend the time-based trigger for the exercise of our call option to July 1, 2032

and to pause the exercise by Internet 
Brands of its put option for a period of 
four years
, to January 29, 2029. 
In connection with the formation of Henry Schein One, LLC, we entered

into a 
ten-year

royalty agreement with 
Internet Brands whereby we will pay Internet Brands approximately $
31

million annually for the use of their 
intellectual property.

During the three and nine months ended September 27, 2025,

we recorded $
8

million and $
23
million, respectively, within selling, general and administrative in our condensed consolidated statements of 
income, in connection with costs related to this royalty agreement.

During the three and nine months ended 
September 28, 2024 we recorded $
8

million and $
23

million, respectively, within selling, general and 
administrative in our condensed consolidated statements of income,

in connection with costs related to this royalty 
agreement.

As of September 27, 2025 and December 28, 2024, Henry Schein One,

LLC had a net payable balance 
to Internet Brands of $
1

million and $
1

million, respectively, comprised of amounts related to results of operations 
and the royalty agreement.

The components of this payable are recorded within accrued expenses: other

within our 
condensed consolidated balance sheets. 
We have interests in entities that we account for under the equity accounting method.

In our normal course of 
business, during the three and nine months ended September 27, 2025, we recorded

net sales of $
14

million and 
$
42

million respectively, to such entities.

During the three and nine months ended September 28, 2024, we 
recorded net sales of $
14

million and $
38

million respectively, to such entities.

During the three and nine months 
ended September 27, 2025, we purchased $
3

million and $
7

million respectively, from such entities.

During the 
three and nine months ended September 28, 2024, we purchased $
3

million and $
8

million respectively, from such 
entities.

At September 27, 2025 and December 28, 2024, we had an aggregate

$
32

million and $
31

million, 
respectively, due from our equity affiliates, and $
7

million and $
6

million, respectively, due to our equity affiliates. 
Certain of our facilities related to our acquisitions are leased from employees

and minority shareholders.

These 
leases are classified as operating leases and have a remaining lease term ranging

from less than 
a

year to 
approximately 
12 years
.

As of September 27, 2025, current and non-current liabilities associated

with related party 
operating leases were $
5

million and $
23

million, respectively.

At September 27, 2025, related party leases 
represented 
6.5
% and 
8.7
% of the total current and non-current operating lease liabilities, respectively.

At 
December 28, 2024, current and non-current liabilities associated with

related party operating leases were $
6
million and $
20

million, respectively.

At December 28, 2024, related party leases represented 
7.6
% and 
7.8
% of 
the total current and non-current operating lease liabilities, respectively.

Table of Contents
HENRY SCHEIN, INC. 
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 
(in millions, except share and per share data) 
(unaudited
) 
36 
Note 18  KKR Investment and Accelerated Share Repurchase Program

On January 29, 2025, Henry Schein, Inc. announced a strategic investment

by funds affiliated with KKR, a leading 
global investment firm, and entered into a Strategic Partnership Agreement

with KKR (the Agreement).

On May 
16, 2025, we issued 
3,285,151

shares of common stock to funds affiliated with KKR for an investment of $
250
million, at approximately $
76.10

per share.

Combined with KKRs previous holdings, funds affiliated with KKR 
currently own approximately 
14.5
% of the Companys common stock.

KKR also has the ability to purchase 
additional shares via open market purchases up to a total equity stake of 
14.9
% of the outstanding shares of 
common stock of the Company.

In addition, under the Agreement, 
two

independent directors have joined our 
Board of Directors. 
On May 19, 2025, we executed an accelerated share repurchase program

to repurchase a total of $
250

million of 
our outstanding common stock based on volume-weighted average prices.

In May 2025 we received 
3,122,832
shares at an estimated fair value of $
224

million.

In July 2025, we received an additional 
368,651

shares at an 
estimated fair value of $
26

million, representing the final amount of shares to be received under

this accelerated 
share repurchase program. 
On November 4, 2025, the Company and KKR entered into an amendment

to the Agreement that increased the 
beneficial ownership limit from 
14.9
% to 
19.9
% of the outstanding shares of the Companys common stock that 
KKR is permitted to acquire during the standstill period.

The standstill provisions, including the increased 
ownership limit, continue in effect for a period of six months following the later

of the expiration of the term of the 
Agreement and the date on which no KKR director appointed pursuant

to the Agreement is serving on the Board of 
Directors.

Table of Contents
37 
ITEM 2.

MANAGEMENTS DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND 
RESULTS OF OPERATIONS 

Cautionary Note Regarding Forward-Looking Statements
In accordance with the Safe Harbor provisions of the Private Securities

Litigation Reform Act of 1995, we 
provide the following cautionary remarks regarding important factors

that, among others, could cause future results 
to differ materially from the forward-looking statements, expectations and assumptions

expressed or implied herein.

All forward-looking statements made by us are subject to risks and uncertainties

and are not guarantees of future 
performance.

These forward-looking statements involve known and unknown

risks, uncertainties and other factors 
that may cause our actual results, performance and achievements

or industry results to be materially different from 
any future results, performance or achievements expressed or implied

by such forward-looking statements.

These 
statements are generally identified by the use of such terms as may, could, expect, intend, believe, 
plan, estimate, forecast, project, anticipate, to be, to

make or other comparable terms.

Factors that 
could cause or contribute to such differences include, but are not limited to,

those discussed in the documents we 
file with the Securities and Exchange Commission (SEC), including our Annual

Report on Form 10-K.

Risk factors and uncertainties that could cause actual results to differ materially from

current and historical results 
include, but are not limited to: our dependence on third parties for

the manufacture and supply of our products and 
where we manufacture products, our dependence on third parties

for raw materials or purchased components; risks 
relating to the achievement of our strategic growth objectives, including

anticipated results of restructuring and 
value-optimization initiatives; risks related to the Strategic Partnership Agreement

with KKR Hawaii Aggregator 
L.P.

entered into in January 2025; transitions in senior company leadership;

our ability to develop or acquire and 
maintain and protect new products (particularly technology and specialty

products) and services and utilize new 
technologies that achieve market acceptance with acceptable margins; transitional

challenges associated with 
acquisitions and joint ventures, including the failure to achieve anticipated

synergies/benefits, as well as significant 
demands on our operations, information systems, legal, regulatory, compliance, financial and human resources 
functions in connection with acquisitions, dispositions and joint ventures; certain

provisions in our governing 
documents that may discourage third-party acquisitions of us; adverse changes

in supplier rebates or other 
purchasing incentives; risks related to the sale of corporate brand products;

risks related to activist investors; 
security risks associated with our information systems and technology

products and services, such as cyberattacks 
or other privacy or data security breaches (including the October 2023 incident);

effects of a highly competitive 
(including, without limitation, competition from third-party online commerce

sites) and consolidating market; 
political, economic and regulatory influences on the health care

industry; risks from expansion of customer 
purchasing power and multi-tiered costing structures; increases in shipping costs

for our products or other service 
issues with our third-party shippers, and increases in fuel and energy costs; changes

in laws and policies governing 
manufacturing, development and investment in territories and countries

where we do business; general global and 
domestic macro-economic and political conditions, including inflation,

deflation, recession, unemployment (and 
corresponding increase in under-insured populations), consumer confidence,

sovereign debt levels, fluctuations in 
energy pricing and the value of the U.S. dollar as compared to foreign currencies

and changes to other economic 
indicators; failure to comply with existing and future regulatory

requirements, including relating to health care; 
risks associated with the EU Medical Device Regulation; failure to comply with

laws and regulations relating to 
health care fraud or other laws and regulations; failure to comply with

laws and regulations relating to the 
collection, storage and processing of sensitive personal information or standards

in electronic health records or 
transmissions; changes in tax legislation, changes in tax rates and availability

of certain tax deductions; risks related 
to product liability, intellectual property and other claims; risks associated with customs policies or legislative 
import restrictions; risks associated with disease outbreaks, epidemics,

pandemics (such as the COVID-19 
pandemic), or similar wide-spread public health concerns and other

natural or man-made disasters; risks associated 
with our global operations; the threat or outbreak of war (including, without

limitation, geopolitical wars), terrorism 
or public unrest (including, without limitation, the war in Ukraine, the Israel-Gaza

war and other unrest and threats 
in the Middle East and the possibility of a wider European or global conflict);

changes to laws and policies 
governing foreign trade, tariffs and sanctions or greater restrictions on imports and

exports, including changes to 
international trade agreements and the current imposition of (and the

potential for additional) tariffs by the U.S. on 
numerous countries and retaliatory tariffs; supply chain disruption; litigation

risks; new or unanticipated litigation 
developments and the status of litigation matters; our dependence on

our senior management (including, without 
limitation, succession planning for our Chief Executive Officer), employee hiring

and retention, increases in labor 

Table of Contents
38 
costs or health care costs, and our relationships with customers, suppliers

and manufacturers; and disruptions in 
financial markets.

The order in which these factors appear should not be

construed to indicate their relative 
importance or priority.
We caution that these factors may not be exhaustive and that many of these factors are beyond our ability to control 
or predict.

Accordingly, any forward-looking statements contained herein should not be relied upon as a prediction 
of actual results.

We undertake no duty and have no obligation to update forward-looking statements except as 
required by law.
Where You

Can Find Important Information
We may disclose important information through one or more of the following channels: SEC filings, public 
conference calls and webcasts, press releases, the investor relations

page of our website (www.henryschein.com) 
and the social media channels identified on the About Media Center page

of our website.
Recent Developments 
While the U.S. economy has experienced inflationary pressures and fluctuation

of the U.S. dollar, their impacts 
have not been material to our results of operations.

Though inflation impacts both our revenues and costs, the

depth 
and breadth of our product portfolio often allows us to offer lower-cost national brand solutions

or corporate brand 
alternatives to our more price-sensitive customers who are unwilling to

absorb price increases, thus positioning us 
to protect our gross profit. 
Segment Reporting
During the fourth quarter of our fiscal year ended December 28, 2024,

we revised our reportable segments to align 
with how the Chairman and Chief Executive Officer manages the business, assesses

performance and allocates 
resources.

Our revised reportable segments now consist of: (i) Global Distribution

and Value

-Added Services; (ii) 
Global Specialty Products; and (iii) Global Technology. 
Global Distribution and Value-Added Services includes distribution to the global dental and medical markets of 
national brand and corporate brand merchandise, as well as equipment and related

technical services.

This segment 
also includes value-added services such as financial services, continuing

education services, consulting and other 
services.

This segment also markets and sells under our own corporate brand

a portfolio of cost-effective, high-
quality consumable merchandise.

Global Specialty Products includes manufacturing, marketing

and sales of dental 
implant and biomaterial products; and endodontic, orthodontic and orthopedic

products and other health care-
related products and services.

Global Technology includes development and distribution of practice management 
software, e-services and other products, which are distributed to health

care providers. 
Cyber Incident 
As previously reported, in October 2023 Henry Schein experienced

a cyber incident that primarily affected the 
operations of our North American and European dental and medical

distribution businesses.

During the three and nine months ended September 28, 2024, we had a

sales decrease in our dental and medical 
distribution businesses, which we believe was primarily a result of lower sales

to episodic customers following the 
cyber incident. 
With respect to the October 2023 cyber incident, we have a $60 million insurance policy, following a $5 million 
retention.

During the three and nine months ended September 27, 2025,

we did not incur any expenses directly 
related to the cyber incident.

During the three and nine months ended September 28, 2024 we

incurred $3 million 
and $8 million, respectively, of expenses related to the cyber incident, mostly consisting of professional

fees.

During the three and nine months ended September 28, 2024, we received

insurance proceeds of $10 million and 
$20 million, respectively, representing a partial insurance recovery of losses related to the cyber incident.

During 
the three months ended March 29, 2025 we received insurance proceeds

of $20 million, representing the remaining 

Table of Contents
39 
insurance recovery of losses related to the cyber incident.

The expenses and insurance recoveries related to the 
cyber incident are included in the selling, general and administrative

line in our condensed consolidated statements 
of income. 
Tariffs and Related Economic Conditions

The U.S. has adopted new and increased tariffs on imports from countries, subject

to evolving exemptions, with 
additional tariff increases proposed but currently on pause.

Some countries have imposed retaliatory tariffs and 
other restrictions on imports from the U.S.

The U.S. government is reported to be in negotiations with certain

other 
countries over tariff rates and other trade policies.

These developments, and anticipated future developments, have 
created a volatile environment for global trade, and new trade policies

with individual countries, if finalized, are 
expected to be announced incrementally over a period of time.

The tariffs did not have a material impact on our results of operations in the first,

second, or third quarter of this 
fiscal year, although sales of U.S. dental equipment were temporarily impacted by market uncertainty

related to 
tariffs in the second half of the quarter ended June 28, 2025.

It is unclear whether, or the extent to which, the 
current tariffs on trade with numerous countries will remain in place, or change, the

exceptions that may apply, and 
their timing.

One Big Beautiful Bill Act 
In the United States, the OBBBA, signed into law on July 4, 2025, includes

a number of provisions that are 
expected to result in reductions in the number of Medicaid enrollees, which

will reduce utilization of services and 
covered products generally.

There are also several provisions that will reduce federal funding to state

Medicaid 
programs.

The OBBBA, in combination with tariffs, will almost certainly have an

adverse impact on utilization, 
Medicaid payment and cost of production (if foreign components are used).

The OBBBA also includes changes to corporate tax rates, limitations

on certain deductions and modifications to 
international tax provisions.

Table of Contents
40 
Executive-Level Overview 
Henry Schein, Inc. is a solutions company for health care professionals powered

by a network of people and 
technology.

We 
believe we are the worlds largest provider of health care products and services primarily to office-
based dental and medical practitioners, as well as alternate sites of care.

We 
serve more than one million customers 
worldwide including dental practitioners, laboratories, physician practices and

ambulatory surgery centers, as well 
as government, institutional health care clinics, home health providers, and

other alternate care clinics.

We 
believe 
that we have a strong brand identity due to our more than 93 years of experience

distributing health care products.
We 
are headquartered in Melville, New York, employ more than 25,000 people (of which approximately 13,000 are 
based outside of the United States) and have operations or affiliates in 33 countries and

territories.

Our broad 
global footprint has evolved over time through our organic growth as well as through

contribution from strategic 
acquisitions.
We 
have established strategically located distribution centers around

the world to enable us to better serve our 
customers and increase our operating efficiency.

This infrastructure, together with broad product and service 
offerings at competitive prices, and a strong commitment to customer service, enables

us to be a single source of 
supply for our customers needs.
As a distributor, we market and sell branded products as well as our own corporate brand portfolio of

cost-effective, 
high-quality consumable merchandise products.

We 
also manufacture, source and sell a range of company-owned 
manufactured products, primarily implants, biomaterial products, endodontics,

handpiece and small equipment, 
hand instrument and repair, restoratives, orthodontics, wound care, orthopedics and dental lab products.

We 
have 
achieved scale in these global businesses primarily through acquisitions, as

manufacturers of these products 
typically do not utilize a distribution channel to serve customers.
During the fourth quarter of our fiscal year ended December 28, 2024, we

revised our reportable segments to align 
with how the Chairman and Chief Executive Officer manages the business, assesses performance

and allocates 
resources.

Our revised reportable segments now consist of: (i) Global Distribution

and Value

-Added Services; (ii) 
Global Specialty Products; and (iii) Global Technology.
Global Distribution and Value-Added Services includes distribution to the global dental and medical markets of 
national brand and corporate brand merchandise, as well as equipment and related

technical services.

This segment 
also includes value-added services such as financial services, continuing education

services, consulting and other 
services.

This segment also markets and sells under our own corporate brand,

a portfolio of cost-effective, high-
quality consumable merchandise.

Global Specialty Products includes manufacturing, marketing

and sales of dental 
implant and biomaterial products; and endodontic, orthodontic and orthopedic

products and other health care-
related products and services.

Global Technology includes development and distribution of practice management 
software, e-services and other products, which are distributed to health

care providers.
A key element to grow closer to our customers is our One Schein initiative, which

is a unified go-to-market 
approach that enables practitioners to work synergistically with our supply chain,

equipment sales and service and 
other value-added services, allowing our customers to leverage the

combined value that we offer through a single 
program.

Specifically, One Schein provides customers with streamlined access to our comprehensive offering of 
national brand products, corporate brand products and proprietary specialty products

and solutions (including 
implant, orthodontic and endodontic products).

In addition, customers have access to a wide range of services, 
including software and other value-added services.
Industry Overview
In recent years, the health care industry has increasingly focused on cost containment.

This trend has benefited 
distributors capable of providing a broad array of products and services at low

prices.

It also has accelerated the 
growth of DSOs, GPOs, HMOs, group practices, other managed care

accounts and collective buying groups, which, 
in addition to their emphasis on obtaining products at competitive prices,

tend to favor distributors capable of 
providing specialized management information support.

We 
believe that the trend towards cost containment has 

Table of Contents
41 
the potential to favorably affect demand for technology solutions, including software, which

can enhance the 
efficiency and facilitation of practice management.
Our operating results in recent years have been significantly affected by strategies

and transactions that we 
undertook to expand our business, domestically and internationally, in part to address significant changes in the 
health care industry, including consolidation of health care distribution companies, health care reform, trends 
toward managed care, cuts in Medicare and collective purchasing arrangements.
Industry Consolidation
The health care products distribution industry, as it relates to office-based health care practitioners, is fragmented 
and diverse.

The industry ranges from sole practitioners working out of

relatively small offices to group practices 
or service organizations ranging in size from a few practitioners to a large number of practitioners who have 
combined or otherwise associated their practices.
Due in part to the inability of office-based health care practitioners to store and manage

large quantities of supplies 
in their offices, the distribution of health care supplies and small equipment to office-based health

care practitioners 
has been characterized by frequent, small quantity orders, and a need for rapid,

reliable and substantially complete 
order fulfillment.

The purchasing decisions within an office-based health care practice are typically

made by the 
practitioner or an administrative assistant.

Supplies and small equipment are generally purchased from more

than 
one distributor, with one generally serving as the primary supplier.
The trend of consolidation extends to our customer base.

Health care practitioners are increasingly seeking to 
partner, affiliate or combine with larger entities such as hospitals, health systems, group practices or physician 
hospital organizations.

In many cases, purchasing decisions for consolidated groups are

made at a centralized or 
professional staff level; however, orders are delivered to the practitioners offices.
Our approach to acquisitions and joint ventures has been to expand our role

as a provider of products and services 
to the health care industry.

This trend has resulted in our expansion into service areas that complement

our existing 
operations and provide opportunities for us to develop synergies with, and thus strengthen, the acquired

businesses.
As industry consolidation continues, we believe that we are positioned

to capitalize on this trend, as we believe we 
have the ability to support increased sales through our existing infrastructure, although

there can be no assurances 
that we will be able to successfully accomplish this.

We 
are focused on building relationships with decision makers 
who do not reside in the office-based practitioner setting.
As the health care industry continues to change, we continually evaluate possible

candidates for joint venture or 
acquisition and intend to continue to seek opportunities to expand our

role as a provider of products and services to 
the health care industry.

There can be no assurance that we will be able to successfully pursue

any such 
opportunity or consummate any such transaction, if pursued.

If additional transactions are entered into or 
consummated, we would incur merger and/or acquisition-related costs, and there

can be no assurance that the 
integration efforts associated with any such transaction would be successful.
Aging Population and Other Market Influences
The health care products distribution industry continues to experience growth

due to the aging population, 
increased health care awareness, the proliferation of medical technology

and testing, new pharmacological 
treatments, and expanded third-party insurance coverage, partially offset by the effects of unemployment

on 
insurance coverage.

In addition, the physician market continues to benefit from the

shift of procedures and 
diagnostic testing from acute care settings to alternate-care sites, particularly

physicians offices.
According to the U.S. Census Bureaus International Database, between 2025 and 2035, the 45 and older 
population is expected to grow by approximately 10%.

Between 2025 and 2045, this age group is expected to grow 
by approximately 17%.

This compares with expected total U.S. population growth

rates of approximately 4% 
between 2025 and 2035 and approximately 6% between 2025 and 2045.

Table of Contents
42 
According to the U.S. Census Bureaus International Database, in 2025 there are approximately seven million 
Americans aged 85 years or older, the segment of the population most in need of long-term care

and elder-care 
services.

By the year 2050, that number is projected to increase to approximately

17 million.

The population aged 
65 to 84 years is projected to increase by approximately 15% during

the same period.
As a result of these market dynamics, annual expenditures for health care services

continue to increase in the 
United States.

We 
believe that demand for our products and services will grow while

continuing to be impacted by 
current and future operating, economic and industry conditions.

The Centers for Medicare and Medicaid Services, 
or CMS, published National Health Expenditure Data indicating that

total national health care spending reached 
approximately $4.9 trillion in 2023, or 17.6% of the nations gross domestic product, the benchmark measure

for 
annual production of goods and services in the United States.

Health care spending is projected to reach 
approximately $8.6 trillion by 2033, or 20.3% of the nations projected gross domestic product.
We 
believe similar demographic changes are also occurring in other

markets we serve outside the U.S.
Government
Certain of our businesses involve the distribution, manufacturing, importation,

exportation, marketing, sale and 
promotion of pharmaceuticals and/or medical devices, and in this regard, we

are subject to extensive local, state, 
federal and foreign governmental laws and regulations, including as applicable

to our wholesale distribution of 
pharmaceuticals and medical devices, manufacturing activities, and as part of

our specialty home medical supplies 
businesses that distribute and sell medical equipment and supplies directly

to patients.

Federal, state and certain 
foreign governments have also increased enforcement activity in the health care

sector, particularly in areas of fraud 
and abuse, anti-bribery and anti-corruption, controlled substances handling,

medical device regulations and data 
privacy and security standards.
Certain of our businesses involve pharmaceuticals and/or medical devices,

including orthopaedic, in vitro 
diagnostic devices, software regulated as a medical device, and sales of

medical equipment and supplies directly to 
patients, that are paid for by third parties and/or patients and must operate in

compliance with a variety of 
burdensome and complex coding, billing and record-keeping requirements in

order to substantiate claims for 
payment under federal, state and commercial health care reimbursement programs.
Government and private insurance programs fund a large portion of the total cost of medical

care, and there have 
been efforts to limit such private and government insurance programs, including efforts, thus far

unsuccessful, to 
seek repeal of the entire United States Patient Protection and Affordable Care Act,

as amended by the Health Care 
and Education Reconciliation Act, each enacted in March 2010.
Certain of our businesses are subject to various additional federal, state,

local and foreign laws and regulations, 
including with respect to the sale, transportation, importation, storage, handling

and disposal of hazardous or 
potentially hazardous substances; forever chemicals such as per-and

polyfluoroalkyl substances; amalgam bans; 
pricing disclosures; supply chain transparency around labor practices; and safe working

conditions.

In addition, 
activities to control medical costs, including laws and regulations lowering

reimbursement rates for 
pharmaceuticals, medical devices, medical supplies and/or medical treatments

or services, are ongoing.

Laws and 
regulations are subject to change and their evolving implementation may impact

our operations and our financial 
performance.
Certain of our businesses also maintain contracts with governmental agencies

and are subject to certain regulatory 
requirements specific to government contractors.

Table of Contents
43 
Our businesses are generally subject to numerous laws and regulations that could

impact our financial performance, 
and failure to comply with such laws or regulations could have a material adverse

effect on our business.

A few 
noteworthy items that have come into effect recently are noted below:

Regulation (EU) 2023/1182 of June 14, 2023, entered into force on January 1, 2025, under the conditions 
set out in Article 14.

This regulation lays down specific rules relating to medicinal

products for human use 
intended to be placed on the market in Northern Ireland in accordance with

Article 6 of 
Directive 2001/83/EC. 

Directive No. 2025/794 of April 14, 2025, known as the Stop-the-Clock

Directive, amended Directives 
(EU) 2022/2464 (CSRD) and (EU) 2024/1760 (CSDDD) by introducing

a uniform two-year postponement 
of the sustainability reporting and due diligence requirements for financial

years beginning on or after 
January 1, 2025 and on or after January 1, 2026.

Regulation (EU) 2025/327 of February 11, 2025 on the European Health Data Space and amending 
Directive 2011/24/EU and Regulation (EU) 2024/2847 establishes the European Health Data Space 
(EHDS) by providing for common rules, standards and infrastructures and

a governance framework, with a 
view to facilitating access to electronic health data for the purpose of primary

use and secondary use of this 
data.

This could potentially affect Henry Schein or its customers.

In the United States, as noted above, the OBBBA includes a number

of provisions that are expected to 
result in reductions in the number of Medicaid enrollees, as well as reductions

in federal funding to state 
Medicaid programs, resulting in potentially adverse impacts on utilization

of services and coverage of 
products.

The OBBBA also includes changes to corporate tax rates, limitations on

certain deductions and 
modifications to international tax provisions.

A more detailed discussion of governmental laws and regulations is

included in Managements Discussion & 
Analysis of Financial Condition and Results of Operations, contained in our Annual

Report on Form 10-K for the 
fiscal year ended December 28, 2024, filed with the SEC on February

25, 2025.

Table of Contents
44 
Results of Operations 
The following tables summarize the significant components of our operating

results for the three and nine months 
ended September 27, 2025 and September 28, 2024 and cash flows for

the nine months ended September 27, 2025 
and September 28, 2024 (in millions): 
Three Months Ended 
Nine Months Ended 
September 27, 
September 28, 
September 27, 
September 28, 
2025 
2024 
2025 
2024 
Operating results: 
Net sales

$ 
3,339 
$ 
3,174 
$ 
9,747 
$ 
9,482 
Cost of sales

2,313 
2,181 
6,705 
6,459 
Gross profit

1,026 
993 
3,042 
3,023 
Operating expenses: 
Selling, general and administrative

760 
724 
2,276 
2,296 
Depreciation and amortization 
68 
64 
194 
188 
Restructuring costs 
34 
48 
82 
73 
Operating income 
$ 
164 
$ 
157 
$ 
490 
$ 
466 
Other expense, net

$ 
(30) 
$ 
(29) 
$ 
(90) 
$ 
(79) 
Income taxes 
(28) 
(32) 
(94) 
(97) 
Net income 
109 
99 
316 
302 
Net income attributable to Henry Schein, Inc. 
101 
99 
297 
296 
Nine Months Ended 
September 27, 
September 28, 
2025 
2024 
Cash flows:

Net cash provided by operating activities 
$ 
331 
$ 
644 
Net cash used in investing activities 
(253) 
(372) 
Net cash provided by (used in) financing activities 
18 
(306) 
Plans of Restructuring 
On August 6, 2024, we committed to a new restructuring plan (the 2024

Plan) to integrate recent acquisitions, 
right-size operations and further increase efficiencies.

We currently expect completion of this plan to be at the end 
of 2027.

During the three months ended September 27, 2025 and September

28, 2024, we recorded restructuring 
charges associated with the 2024 Plan of $34 million and $36 million, respectively.

During the nine months ended 
September 27, 2025 and September 28, 2024, we recorded restructuring

charges associated with the 2024 Plan of 
$82 million and $36 million, respectively.

The restructuring costs for these periods primarily related

to severance 
and employee-related costs, accelerated amortization of right-of-use assets and

fixed assets, and other exit costs.

We expect to record restructuring charges associated with the 2024 Plan through the end of 2027; however,

an 
estimate of the amount of these charges for 2025 through 2027 has not yet been determined. 
On August 1, 2022, we committed to a restructuring plan (the 2022

Plan) focused on funding the priorities of the 
BOLD+1 strategic plan, streamlining operations and other initiatives to

increase efficiency.

The 2022 Plan was 
completed as of July 31, 2024.

During the three and nine months ended September 28, 2024, in connection

with 
our 2022 Plan, we recorded restructuring costs of $12 million and $37 million,

respectively, which primarily related 
to severance and employee-related costs, accelerated amortization of

right-of-use assets and fixed assets, and other 
exit costs. 

Table of Contents
45 
Three Months Ended September 27, 2025 Compared to Three Months Ended September 28, 2024
Note: Percentages for Net Sales; Gross Profit; Operating Expenses; Other

Expense, Net; and Income Taxes are 
based on actual values and may not recalculate due to rounding.
During the fourth quarter of our fiscal year ended December 28, 2024,

we revised our reportable segments to align 
with how the Chairman and Chief Executive Officer manages the business, assesses

performance and allocates 
resources.

Our revised reportable segments now consist of: (i) Global Distribution

and Value

-Added Services; (ii) 
Global Specialty Products; and (iii) Global Technology.

All prior comparative segment information has been recast 
to reflect our new segment structure. 
Net Sales
Net sales by reportable segment and by major product or service type were

as follows:
September 27, 
% of 
September 28, 
% of 
Increase / (Decrease) 
2025 
Total 
2024 
Total 
$ 
% 
Global Distribution and Value

-Added Services 
Global Dental Merchandise
(1)
$ 
1,210 
36.2 
% 
$ 
1,155 
36.4 
% 
$ 
55 
4.6 
% 
Global Dental Equipment
(2)
440 
13.2 
417 
13.1 
23 
5.5 
Global Value

-Added Services
(3)
64 
1.9 
63 
2.0 
1 
3.3 
Global Dental 
1,714 
51.3 
1,635 
51.5 
79 
4.8 
Global Medical
(4)
1,126 
33.8 
1,076 
33.9 
50 
4.7 
Total Global Distribution and Value

-Added Services 
2,840 
85.1 
2,711 
85.4 
129 
4.8 
Global Specialty Products
(5)
369 
11.0 
348 
11.0 
21 
5.9 
Global Technology
(6)
173 
5.2 
157 
4.9 
16 
9.7 
Eliminations 
(43) 
(1.3) 
(42) 
(1.3) 
(1) 
n/a 
Total

$ 
3,339 
100.0 
$ 
3,174 
100.0 
$ 
165 
5.2 
(1)
Includes infection-control products, handpieces, preventatives, impression materials, composites, anesthetics, teeth, gypsum, 
acrylics, articulators, abrasives, PPE products and our own corporate brand of consumable merchandise. 
(2)
Includes dental chairs, delivery units and lights, digital dental laboratories, X-ray supplies and equipment, equipment repair 
services and high-tech and digital restoration equipment. 
(3)
Consists of financial services on a non-recourse basis, continuing education services for practitioners, consulting and other services. 
(4)
Includes branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, X-ray 
products, equipment, PPE products and vitamins. 
(5)
Includes manufacturing, marketing and sales of dental implant and biomaterial products; and endodontic, orthodontic and 
orthopedic products and other health care-related products and services. 
(6)
Consists of development and distribution of practice management software, e-services and other products, which are distributed to 
health care providers. 
The components of our sales growth were as follows:
Constant Currency Growth 
Total Constant

Currency Growth 
Foreign 
Exchange 
Impact 
Total Sales 
Growth 
Local Internal 
Growth 
Acquisition 
Growth 
Global Distribution and Value

-Added Services 
Global Dental Merchandise 
2.8 
% 
0.1 
% 
2.9 
% 
1.7 
% 
4.6 
% 
Global Dental Equipment 
3.0 
0.4 
3.4 
2.1 
5.5 
Global Value

-Added Services 
0.7 
2.2 
2.9 
0.4 
3.3 
Global Dental 
2.8 
0.2 
3.0 
1.8 
4.8 
Global Medical 
3.0 
1.6 
4.6 
0.1 
4.7 
Total Global Distribution and Value

-Added Services 
2.9 
0.8 
3.7 
1.1 
4.8 
Global Specialty Products 
2.8 
1.1 
3.9 
2.0 
5.9 
Global Technology 
9.0 
- 
9.0 
0.7 
9.7 
Total 
3.3 
0.7 
4.0 
1.2 
5.2 

Table of Contents
46 
Global Sales
Global net sales for the three months ended September 27, 2025 increased 5.2%.

Foreign exchange and 
acquisitions contributed 1.2% and 0.7% to sales growth,

respectively.

The components of our sales increase are 
presented in the table above.
Global Distribution and Value-Added Services Sales
Global Distribution and Value-Added Services net sales for the three months ended September 27, 2025 increased 
4.8%.

The components of our sales increase are presented in

the table above.

The 2.8% increase in internally generated local currency dental sales was

due to merchandise sales growth in the 
U.S and internationally, and traditional equipment sales growth internationally.

The U.S. merchandise growth 
reflects the positive impact of the targeted promotional programs initiated last quarter. 
The 3.0% increase in internally generated local currency medical sales was

attributable to growth in medical 
products and pharmaceuticals and our Home Solutions business, partially offset by

lower demand for respiratory 
diagnostic products and a decline in influenza vaccine sales. 
We estimate that sales of PPE products and COVID-19 test kits were approximately $146 million for the three 
months ended September 27, 2025, as compared to $155 million for

the three months ended September 28, 2024, 
representing an estimated decrease of $9 million primarily due to lower sales

of COVID-19 test kits.

The estimated 
increase in the segments internally generated local currency sales, excluding PPE products and COVID-19

test 
kits, was 3.4%.
Global Specialty Products
Global Specialty Products net sales for the three months ended September

27, 2025 increased 5.9%.

The 
components of our sales increase are presented in the table above.
The 2.8% increase in internally generated local currency sales was attributable

to growth in dental implants and 
biomaterials.
Global Technology
Global Technology net sales for the three months ended September 27, 2025 increased 9.7%.

The components of 
sales growth are presented in the table above. 
The internally generated local currency increase of 9.0% in Global Technology sales was primarily attributable to 
the adoption of our core practice management solutions, particularly

our cloud-based platforms, as well as an 
increase in revenue cycle management solutions. 

Table of Contents
47 
Gross Profit
Gross profit and gross margin percentages by segment and in total were as follows:
September 27, 
Gross 
September 28, 
Gross 
Increase 
2025 
Margin % 
2024 
Margin % 
$ 
% 
Global Distribution and Value

-Added Services 
$ 
702 
24.7 
% 
$ 
686 
25.3 
% 
$ 
16 
2.5 
% 
Global Specialty Products 
204 
55.3 
196 
56.3 
8 
4.0 
Global Technology 
115 
66.9 
107 
68.1 
8 
7.7 
Corporate 
5 
n/a 
4 
n/a 
1 
n/a 
Total

$ 
1,026 
30.7 
$ 
993 
31.3 
$ 
33 
3.3 
As a result of different practices of categorizing costs associated with distribution networks

throughout our 
industry, our gross margins may not necessarily be comparable to other distribution companies.

Gross margin 
percentages vary between our segments.

We realize substantially higher gross margin from sales of products that 
we develop and manufacture within our Global Specialty Products segment

compared to gross margin from sales of 
products that we distribute within our Global Distribution and Value-Added Services segment.

Within our Global 
Technology segment, higher gross margins result from us being both the developer and seller of software products 
and services.

Within our Global Distribution and Value

-Added Services segment, gross profit margins may vary between the 
periods as a result of the changes in the mix of products sold as well as

changes in our customer mix.

With respect 
to customer mix, sales to our large-group customers are typically completed at lower gross

margins due to the 
higher volumes sold as opposed to the gross margin on sales to office-based practitioners, which

normally purchase 
lower volumes.

The increase in Global Distribution and Value-Added Services gross profit for the three months ended September 
27, 2025 compared to the prior-year-period was attributable to the growth in internally

generated sales volume as 
described above. The decrease in gross margin rates was attributable to product

mix. 
The increase in Global Specialty Products gross profit reflects increased

internally generated sales volume as 
described above.

The decrease in gross margin rates was due to product mix.

The increase in Global Technology gross profit is the result of increased internally generated sales volume as 
described above.

The decrease in gross margin rates was due to an increase in customer service

expense. 
Operating Expenses
Operating expenses (consisting of selling, general and administrative

expenses; depreciation and amortization; and 
restructuring costs) by segment were as follows:
% of 
% of 
September 27, 
Respective 
September 28, 
Respective 
Increase / (Decrease) 
2025 
Gross Sales 
2024 
Gross Sales 
$ 
% 
Global Distribution and Value

-Added Services 
$ 
524 
18.5 
% 
$ 
502 
18.5 
% 
$ 
22 
4.6 
% 
Global Specialty Products 
133 
36.0 
151 
43.6 
(18) 
(12.6) 
Global Technology 
69 
40.3 
68 
43.3 
1 
2.2 
Corporate 
38 
n/a 
29 
n/a 
9 
n/a 
764 
22.9 
750 
23.6 
14 
1.8 
Adjustments
(1)
98 
n/a 
86 
n/a 
12 
n/a 
Total operating expenses 
$ 
862 
25.8 
$ 
836 
26.3 
$ 
26 
3.2 
(1)
Adjustments represent items excluded from segment operating income to enable comparison of financial results between periods.

These 
items may vary independently of business performance.

Please see 
Note 5  Segment Data
.

These adjustments (current quarter vs. prior 
quarter) consist of (i) acquisition intangible amortization ($46 million vs. $47 million), (ii) restructuring costs ($34 million vs. $48 
million),

(iii) change in contingent consideration ($6 million vs. $0 million),

(iv) cyber incident-insurance proceeds, net of third-party 
advisory expenses (no activity) vs. $(9) million net proceeds), (v) litigation settlements ($2 million vs. $0 million), and (vi) costs 
associated with shareholder advisory matters and select value creation consulting costs ($10 million vs. $0 million). 

Table of Contents
48 
The net increase in operating expenses was attributable to the following:
Operating Costs 
(excluding 
acquisitions) 
Acquisitions 
Adjustments 
Total 
Global Distribution and Value

-Added Services 
$ 
17 
$ 
5 
$ 
- 
$ 
22 
Global Specialty Products 
(19) 
1 
- 
(18) 
Global Technology 
1 
- 
- 
1 
Corporate 
9 
- 
- 
9 
8 
6 
- 
14 
Adjustments 
- 
- 
12 
12 
Total operating expenses 
$ 
8 
$ 
6 
$ 
12 
$ 
26 
The components of the net increase in total operating expenses are presented

in the table above.

The increase in 
operating costs (excluding acquisitions) during the three months

ended September 27, 2025 included an increase in 
Corporate investments in technology supporting the launch of our Global E-Commerce

Platform 
(www.henryschein.com)

and the impact of certain compensation related costs, partially offset by a gain

of $28 
million related to the remeasurement to fair value of a previously held

equity investment within our Global 
Specialty Products segment.
Other Expense, Net
Other expense, net was as follows:
September 27, 
September 28, 
Variance 
2025 
2024 
$ 
% 
Interest income

$ 
9 
$ 
7 
$ 
2 
47.0 
% 
Interest expense

(38) 
(34) 
(4) 
(12.0) 
Other, net

(1) 
(2) 
1 
(40.8) 
Other expense, net

$ 
(30) 
$ 
(29) 
$ 
(1) 
(2.4) 
Interest income increased primarily due to increased interest rates.

Interest expense increased primarily due to 
increased borrowings.
Income Taxes
Our effective tax rate was 21.3% for the three months ended September 27, 2025, compared

to 24.7% for the prior 
year period.

The difference between our effective and federal statutory tax rates primarily relates to state

and 
foreign income taxes and interest expense.

For the three months ended September 27, 2025, the difference was 
further impacted by the tax treatment associated with the acquisition of a controlling

interest of a previously held 
non-controlling equity investment.
On July 4, 2025, President Trump signed the reconciliation tax bill, commonly known as the One Big Beautiful 
Bill Act (OBBBA), into law.

Corporate provisions in the OBBBA include immediate expensing of domestic 
research and experimental expenditures, limitations on certain deductions,

and modifications to international tax 
provisions.

As a result of the OBBBA, we anticipate a reduction in current income

tax liabilities and deferred tax 
assets.
The OECD issued technical and administrative guidance on Pillar Two rules in December 2021, which provides for 
a global minimum tax rate on the earnings of large multinational businesses on a country-by-country

basis.

Effective January 1, 2024, the minimum global tax rate is 15% for various jurisdictions pursuant

to the Pillar Two 
rules.

Future tax reform resulting from these developments may result

in changes to long-standing tax principles, 
which may adversely impact our effective tax rate going forward or result in higher cash

tax liabilities.

As of 
September 27, 2025, the impact of the Pillar Two rules to our financial statements was immaterial.

Table of Contents
49 
Nine Months Ended September 27, 2025 Compared to Nine Months Ended September

28, 2024
Note: Percentages for Net Sales; Gross Profit; Operating Expenses; Other

Expense, Net; and Income Taxes are 
based on actual values and may not recalculate due to rounding.
During the fourth quarter of our fiscal year ended December 28, 2024,

we revised our reportable segments to align 
with how the Chairman and Chief Executive Officer manages the business, assesses

performance and allocates 
resources.

Our revised reportable segments now consist of: (i) Global Distribution

and Value

-Added Services; (ii) 
Global Specialty Products; and (iii) Global Technology.

All prior comparative segment information has been recast 
to reflect our new segment structure. 
Net Sales
Net sales by reportable segment and by major product or service type were

as follows:
September 27, 
% of 
September 28, 
% of 
Increase 
2025 
Total 
2024 
Total 
$ 
% 
Global Distribution and Value

-Added Services 
Global Dental Merchandise
(1)
$ 
3,613 
37.1 
% 
$ 
3,579 
37.7 
% 
$ 
34 
0.9 
% 
Global Dental Equipment
(2)
1,263 
13.0 
1,245 
13.1 
18 
1.4 
Global Value

-Added Services
(3)
174 
1.8 
175 
1.8 
(1) 
(0.3) 
Global Dental 
5,050 
51.9 
4,999 
52.6 
51 
1.0 
Global Medical
(4)
3,197 
32.8 
3,059 
32.3 
138 
4.5 
Total Global Distribution and Value

-Added Services 
8,247 
84.7 
8,058 
84.9 
189 
2.4 
Global Specialty Products
(5)
1,122 
11.5 
1,078 
11.4 
44 
4.0 
Global Technology
(6)
502 
5.1 
470 
5.0 
32 
6.7 
Eliminations 
(124) 
(1.3) 
(124) 
(1.3) 
- 
n/a 
Total

$ 
9,747 
100.0 
$ 
9,482 
100.0 
$ 
265 
2.8 
(1)
Includes infection-control products, handpieces, preventatives, impression materials, composites, anesthetics, teeth, gypsum, 
acrylics, articulators, abrasives, PPE products and our own corporate brand of consumable merchandise. 
(2)
Includes dental chairs, delivery units and lights, digital dental laboratories, X-ray supplies and equipment, equipment repair 
services and high-tech and digital restoration equipment. 
(3)
Consists of financial services on a non-recourse basis, continuing education services for practitioners, consulting and other services. 
(4)
Includes branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, X-ray 
products, equipment, PPE products and vitamins. 
(5)
Includes manufacturing, marketing and sales of dental implant and biomaterial products; and endodontic, orthodontic and 
orthopedic products and other health care-related products and services. 
(6)
Consists of development and distribution of practice management software, e-services and other products, which are distributed to 
health care providers. 
The components of our sales growth/(decline) were as follows:
Constant Currency 
Growth/(Decline) 
Total Constant

Currency 
Growth/(Decline) 
Foreign 
Exchange 
Impact 
Total Sales 
Growth/ 
(Decline) 
Local Internal 
Growth/(Decline) 
Acquisition 
Growth 
Global Distribution and Value

-Added Services 
Global Dental Merchandise 
0.6 
% 
0.4 
% 
1.0 
% 
(0.1) 
% 
0.9 
% 
Global Dental Equipment 
0.3 
0.6 
0.9 
0.5 
1.4 
Global Value

-Added Services 
(5.0) 
4.9 
(0.1) 
(0.2) 
(0.3) 
Global Dental 
0.4 
0.5 
0.9 
0.1 
1.0 
Global Medical 
3.0 
1.5 
4.5 
- 
4.5 
Total Global Distribution and Value

-Added Services 
1.4 
0.9 
2.3 
0.1 
2.4 
Global Specialty Products 
2.3 
1.5 
3.8 
0.2 
4.0 
Global Technology 
6.3 
- 
6.3 
0.4 
6.7 
Total 
1.8 
0.9 
2.7 
0.1 
2.8 

Table of Contents
50 
Global Sales
Global net sales for the nine months ended September 27, 2025

increased 2.8%, attributable to acquisition growth 
of 0.9%,

and an increase in foreign exchange of 0.1%.

The components of our sales increase are presented in the 
table above.
Global Distribution and Value-Added Services Sales
Global Distribution and Value-Added Services net sales for the nine months ended September 27, 2025 increased 
2.4%.

The components of our sales increase are presented in

the table above.

The 0.4% increase in internally generated local currency dental sales was

primarily due to sales growth in U.S and 
international dental merchandise as well as growth in international equipment.
The 3.0% increase in internally generated local currency medical sales was

attributable to growth of our Home 
Solutions business,

and medical products and pharmaceuticals.
The decrease in internally generated local currency value-added services

sales was attributable primarily to lower 
sales in our practice transitions business, which can fluctuate from quarter

to quarter.
We estimate that sales of PPE products and COVID-19 test kits were approximately $448 million for the nine 
months ended September 27, 2025, as compared to $475

million for the nine months ended September 28, 2024, 
representing an estimated decrease of $27 million primarily due to lower glove

prices and lower sales of COVID-19 
test kits.

The estimated increase in the segments internally generated local currency sales, excluding PPE products 
and COVID-19 test kits, was 1.8%.
Global Specialty Products
Global Specialty Products net sales for the nine months ended September

27, 2025 increased 4.0%.

The 
components of our sales increase are presented in the table above.
The 2.3% increase in internally generated local currency sales was attributable

to growth in our implant and 
biomaterial businesses, partially offset by a decline in orthodontic sales.
Global Technology
Global Technology net sales for the nine months ended September 27, 2025 increased 6.7%.

The components of 
sales growth are presented in the table above.
The internally generated local currency increase of 6.3% in Global Technology sales was primarily attributable to 
the adoption of our core practice management solutions, particularly our

cloud-based platforms, as well as an 
increase in revenue cycle management solutions.

Table of Contents
51 
Gross Profit
Gross profit and gross margin percentages by segment and in total were as follows:
September 27, 
Gross 
September 28, 
Gross 
Increase / (Decrease) 
2025 
Margin % 
2024 
Margin % 
$ 
% 
Global Distribution and Value

-Added Services 
$ 
2,071 
25.1 
% 
$ 
2,094 
26.0 
% 
$ 
(23) 
(1.1) 
% 
Global Specialty Products 
621 
55.4 
600 
55.6 
21 
3.6 
Global Technology 
339 
67.5 
318 
67.6 
21 
6.5 
Corporate 
11 
n/a 
11 
n/a 
- 
n/a 
Total

$ 
3,042 
31.2 
$ 
3,023 
31.9 
$ 
19 
0.6 
As a result of different practices of categorizing costs associated with distribution networks

throughout our 
industry, our gross margins may not necessarily be comparable to other distribution companies.

Gross margin 
percentages vary between our segments.

We realize substantially higher gross margin from sales of products that 
we develop and manufacture within our Global Specialty Products segment

compared to gross margin from sales of 
products that we distribute within our Global Distribution and Value-Added Services segment.

Within our Global 
Technology segment, higher gross margins result from us being both the developer and seller of software products 
and services.

Within our Global Distribution and Value

-Added Services segment, gross profit margins may vary between the 
periods as a result of the changes in the mix of products sold as well as

changes in our customer mix.

With respect 
to customer mix, sales to our large-group customers are typically completed at lower gross

margins due to the 
higher volumes sold as opposed to the gross margin on sales to office-based practitioners, which

normally purchase 
lower volumes.

The decrease in Global Distribution and Value-Added Services gross profit for the nine months ended September 
27, 2025 compared to the prior-year-period is due to decreased internally generated

sales volume as described 
above.

The decrease in gross margin rates was attributable to the impact of targeted promotional

programs and 
lower gross margins on glove sales.

The increase in Global Specialty Products gross profit reflects increased

internally generated sales volume and 
gross profit from acquisitions.

Gross margin rates were relatively flat. 
The increase in Global Technology gross profit is the result of higher internally generated sales.

Gross margin rates 
were relatively flat.
Operating Expenses
Operating expenses (consisting of selling, general and administrative

expenses; depreciation and amortization; and 
restructuring costs) by segment were as follows:
% of 
% of 
September 27, 
Respective 
September 28, 
Respective 
Increase / (Decrease) 
2025 
Gross Sales 
2024 
Gross Sales 
$ 
% 
Global Distribution and Value

-Added Services 
$ 
1,567 
19.0 
% 
$ 
1,563 
19.4 
% 
$ 
4 
0.3 
% 
Global Specialty Products 
442 
39.4 
472 
43.8 
(30) 
(6.4) 
Global Technology 
206 
41.1 
211 
45.0 
(5) 
(2.4) 
Corporate 
110 
n/a 
66 
n/a 
44 
n/a 
2,325 
23.9 
2,312 
24.4 
13 
0.6 
Adjustments
(1)
227 
n/a 
245 
n/a 
(18) 
n/a 
Total operating expenses 
$ 
2,552 
26.2 
$ 
2,557 
27.0 
$ 
(5) 
(0.2) 
(1)
Adjustments represent items excluded from segment operating income to enable comparison of financial results between periods.

These 
items may vary independently of business performance.

Please see 
Note 5  Segment Data
.

These adjustments (current year-to-date vs. 
prior year-to-date) consist of (i) acquisition intangible amortization ($133 million vs. $140 million), (ii) restructuring costs ($82 million 
vs. $73 million), (iii) change in contingent consideration ($4

million vs. $38 million), (iv) litigation settlements ($3 million vs. $5 
million), (v) cyber incident-insurance proceeds, net of

third-party advisory expenses ($(20) million net proceeds vs. $(11) million net 

Table of Contents
52 
proceeds), (vi) impairment of intangible assets ($1 million vs. $0 million), and (vii) costs associated with shareholder advisory matters 
and select value creation consulting costs ($24 million vs. $0 million). 
The net decrease in operating expenses was attributable to the following:
Operating Costs 
(excluding 
acquisitions) 
Acquisitions 
Adjustments 
Total 
Global Distribution and Value

-Added Services 
$ 
(15) 
$ 
19 
$ 
- 
$ 
4 
Global Specialty Products 
(29) 
(1) 
- 
(30) 
Global Technology 
(5) 
- 
- 
(5) 
Corporate 
44 
- 
- 
44 
(5) 
18 
- 
13 
Adjustments 
- 
- 
(18) 
(18) 
Total operating expenses 
$ 
(5) 
$ 
18 
$ 
(18) 
$ 
(5) 
The components of the net decrease in total operating expenses are presented

in the table above.

The decrease in 
operating costs (excluding acquisitions) during the nine months ended September

27, 2025 included cost savings 
from our restructuring activities, certain changes in estimates and other operating

cost efficiencies, partially offset 
by an increase in Corporate investments in technology supporting the

launch of our Global E-Commerce Platform 
(www.henryschein.com), the impact of certain compensation related costs, and the timing of certain non-income 
tax credits.

In addition, during the nine months ended September 27, 2025,

our operating costs were impacted by 
recognition of remeasurement gains related to the remeasurement to fair value

of previously held equity 
investments of $28 million within our Global Specialty Products segment

and $4 million within our Global 
Distribution and Value-Added Services segment.

During the nine months ended September 28, 2024, our operating 
costs were impacted by recognition of a remeasurement gain related to the

remeasurement to fair value of a 
previously held equity investments of $18 million within our Global Distribution

and Value

-Added Services 
segment.
Other Expense, Net
Other expense, net was as follows:
September 27, 
September 28, 
Variance 
2025 
2024 
$ 
% 
Interest income

$ 
24 
$ 
18 
$ 
6 
39.2 
% 
Interest expense

(111) 
(96) 
(15) 
(15.7) 
Other, net

(3) 
(1) 
(2) 
(844.9) 
Other expense, net

$ 
(90) 
$ 
(79) 
$ 
(11) 
(14.1) 
Interest income increased primarily due to increased interest rates.

Interest expense increased primarily due to 
increased borrowings.
Income Taxes
Our effective tax rate was 23.5% for the nine months ended September 27, 2025, compared

to 25.1% for the prior 
year period.

The difference between our effective and federal statutory tax rates primarily relates to state

and 
foreign income taxes and interest expense.

For the nine months ended September 27, 2025, the difference was 
further impacted by the tax treatment associated with the acquisition of a controlling

interest of a previously held 
non-controlling equity investment.
On July 4, 2025, President Trump signed the reconciliation tax bill, commonly known as the One Big Beautiful 
Bill Act (OBBBA), into law.

Corporate provisions in the OBBBA include, immediate expensing of domestic 
research and experimental expenditures, limitations on certain deductions,

and modifications to international tax 
provisions.

As a result of the OBBBA, we anticipate a reduction in current income

tax liabilities and deferred tax 
assets.

Table of Contents
53 
The OECD issued technical and administrative guidance on Pillar Two rules in December 2021, which provides for 
a global minimum tax rate on the earnings of large multinational businesses on a country-by-country

basis.

Effective January 1, 2024, the minimum global tax rate is 15% for various jurisdictions pursuant

to the Pillar Two 
rules.

Future tax reform resulting from these developments may result

in changes to long-standing tax principles, 
which may adversely impact our effective tax rate going forward or result in higher cash

tax liabilities.

As of 
September 27, 2025, the impact of the Pillar Two rules to our financial statements was immaterial.
Liquidity and Capital Resources 
Our principal capital requirements have included funding of acquisitions, purchases

of additional noncontrolling 
interests, repayments of debt principal, the funding of working capital needs,

purchases of fixed assets and 
repurchases of common stock.

Working capital requirements generally result from increased sales, special 
inventory forward buy-in opportunities and payment terms for receivables

and payables.

Historically, sales have 
tended to be stronger during the second half of the year and special inventory

forward buy-in opportunities have 
been most prevalent just before the end of the year, and have caused our working capital requirements

to be higher 
from the end of the third quarter to the end of the first quarter of

the following year. 
We finance our business primarily through cash generated from our operations, revolving credit facilities and debt 
placements.

Please see 
Note 8  Debt

for further information.

Our ability to generate sufficient cash flows from 
operations is dependent on the continued demand of our customers

for our products and services, and access to 
products and services from our suppliers. 
Our business requires a substantial investment in working capital, which

is susceptible to fluctuations during the 
year as a result of inventory purchase patterns and seasonal demands.

Inventory purchase activity is a function of 
sales activity, special inventory forward buy-in opportunities and our desired level of inventory. 
We finance our business to provide adequate funding for at least 12 months.

Funding requirements are based on 
forecasted profitability and working capital needs, which, on occasion, may

change.

Consequently, we may change 
our funding structure to reflect any new requirements. 
We believe that our cash and cash equivalents, our ability to access private debt markets and public equity markets, 
and our available funds under existing credit facilities provide us with

sufficient liquidity to meet our currently 
foreseeable short-term and long-term capital needs. 
Our acquisition strategy is focused on investments in companies that

add new customers and sales teams, increase 
our geographic footprint (whether entering a new country, such as emerging markets, or building scale where we 
have already invested in businesses), and finally, those that enable us to access new products and technologies. 
Net cash provided by operating activities was $331 million for the

nine months ended September 27, 2025, 
compared to net cash provided by operating activities of $644 million for

the prior year.

The net change of $313 
million was primarily attributable to changes in working capital accounts

(primarily accounts receivable,

inventory, 
and accounts payable and accrued expenses).

Our operating cash flows during the nine months ended September 
28, 2024 were affected by the residual impacts of the 2023 cyber incident and included a higher-than-normal

level 
of cash collections.

Our cash collections normalized during the nine months ended September

27, 2025. 
Net cash used in investing activities was $253 million for the nine months

ended September 27, 2025, compared to 
net cash used in investing activities of $372 million for the prior year.

The net change of $119 million was 
primarily attributable to reduced payments for equity investments and business

acquisitions. 
Net cash provided by financing activities was $18 million for the nine

months ended September 27, 2025, 
compared to net cash used in financing activities of $306 million for the prior

year.

The net change of $324 million 
was primarily due to increased net borrowings from debt to finance our

investments and proceeds received from the 
issuance of common stock, and a reduction in acquisitions of noncontrolling

interests in subsidiaries, partially offset 
by increased repurchases of common stock. 

Table of Contents
54 
The following table summarizes selected measures of liquidity and capital

resources: 
September 27, 
December 28, 
2025 
2024 
Cash and cash equivalents

$ 
136 
$ 
122 
Working

capital

(1)
1,246 
1,180 
Debt: 
Bank credit lines

$ 
913 
$ 
650 
Current maturities of long-term debt

30 
56 
Long-term debt

2,153 
1,830 
Total debt

$ 
3,096 
$ 
2,536 
Leases: 
Current operating lease liabilities 
$ 
81 
$ 
75 
Non-current operating lease liabilities 
264 
259 
(1)

Includes $492 million and $241 million of certain accounts receivable, which serve as security for U.S. trade accounts receivable 
securitization at September 27, 2025 and December 28, 2024, respectively. 
Our cash and cash equivalents consist of bank balances and investments

in money market funds representing 
overnight investments with a high degree of liquidity. 
Accounts receivable days sales outstanding and inventory turns 
Our accounts receivable days sales outstanding from operations decreased

to 45.3 days as of September 27, 2025 
from 48.6 days as of September 28, 2024, which was primarily attributable

to impact that the cyber incident had on 
the cash collections during the three months ended March 30, 2024.

During the nine months ended September 27, 
2025, we wrote off approximately $12 million of fully reserved accounts receivable

against our trade receivable 
reserve.

Our inventory turns from operations decreased to 4.8 as of September

27, 2025 from 5.0 as of September 
28, 2024.

Our working capital accounts may be impacted by current

and future economic conditions. 
Leases 
We 
have operating and finance leases for corporate offices, office space, distribution and other facilities,

vehicles 
and certain equipment.

Our leases have remaining terms of less than one year to approximately

16 years, some of 
which may include options to extend the leases for up to 10 years.

As of September 27, 2025, our right-of-use 
assets related to operating leases were $308 million and our current and non-current

operating lease liabilities were 
$81 million and $264 million, respectively. 
Stock Repurchases 
On January 27, 2025, our Board of Directors authorized the repurchase

of up to an additional $500 million in shares 
of our common stock. 
On May 19, 2025, we executed an accelerated share repurchase program

to repurchase a total of $250 million of 
our outstanding common stock based on volume-weighted average

prices.

In May 2025, we received 3,122,832 
shares at an estimated fair value of $224

million.

In July 2025, we received an additional 368,651 shares at an 
estimated fair value of $26 million, representing the final amount of shares

to be received under this accelerated 
share repurchase program. 
On September 8, 2025, our Board of Directors authorized the repurchase of

up to an additional $750 million in 
shares of our common stock. 
From March 3, 2003 through September 27, 2025, we repurchased $5.8 billion,

or 105,063,756 shares,

under our 
common stock repurchase programs, with $980 million available

as of September 27, 2025 for future common 
stock share repurchases. 

Table of Contents
55 
Redeemable Noncontrolling Interests 
Some minority stockholders in certain of our subsidiaries have the right,

at certain times, to require us to acquire 
their ownership interest in those entities at fair value.

Accounting Standards Codification Topic 480-10 is 
applicable for noncontrolling interests where we are or may be required

to purchase all or a portion of the 
outstanding interest in a consolidated subsidiary from the noncontrolling

interest holder under the terms of a put 
option contained in contractual agreements.

As of September 27, 2025 and December 28, 2024, our balance

for 
redeemable noncontrolling interests was $877 million and $806 million,

respectively.

Please see 
Note 13 
Redeemable Noncontrolling Interests

for further information. 
Critical Accounting Policies and Estimates
There have been no material changes in our critical accounting policies

and estimates from those disclosed in Item 
7 of our Annual Report on Form 10-K for the year ended December 28, 2024.
Accounting Standards Update
For a discussion of accounting standards updates that have been adopted

or will be adopted, see 
Note 2 - Significant
Accounting Policies and Recently Issued Accounting Standards

of the Notes to the Condensed Consolidated 
Financial Statements included under Item 1.
ITEM 3.

QUANTITATIVE

AND QUALITATIVE

DISCLOSURES ABOUT MARKET RISK 
There have been no material changes in our exposure to market risk

from that disclosed in Item 7A of our Annual 
Report on Form 10-K for the year ended December 28, 2024. 
ITEM 4.

CONTROLS AND PROCEDURES
Evaluation of Disclosure Controls and Procedures
Under the supervision and with the participation of management, including

our principal executive officer and 
principal financial officer, we evaluated the effectiveness of the design and operation of our disclosure controls and 
procedures as of the end of the period covered by this quarterly report

as such term is defined in Rules 13a-15(e) 
and 15d-15(e) promulgated under the Securities Exchange Act of 1934, as

amended (the Exchange Act).

Based 
on this evaluation, our management, including our principal executive

officer and principal financial officer, 
concluded that our disclosure controls and procedures were effective as of September 27,

2025, to ensure that all 
material information required to be disclosed by us in reports that we file

or submit under the Exchange Act is 
accumulated and communicated to them as appropriate to allow timely

decisions regarding required disclosure and 
that all such information is recorded, processed, summarized and reported

within the time periods specified in the 
SECs rules and forms, and the rules of the Nasdaq stock exchange.
Changes in Internal Control over Financial Reporting
The combination of acquisitions, continued acquisition integrations and systems

implementation activity 
undertaken during the quarter ended September 27, 2025,

and carried over from prior quarters, when considered in 
the aggregate, represents a material change in our internal control

over financial reporting.
During the quarter ended September 27, 2025, we completed the acquisition

of a controlling interest of a Global 
Specialty Products segment affiliate.

Also, post-acquisition integration related activities continued

for businesses 
acquired during prior quarters within our Global Specialties Products

segment and Global Distribution and Value-
Added Services segment.

These acquisitions, the majority of which utilize separate information

and financial 
accounting systems, have been included in our condensed consolidated

financial statements since their respective 
dates of acquisition.

Table of Contents
56 
Additionally, during the quarter ended September 27, 2025, we continued systems implementation activities for

the 
phased roll-out of a new e-commerce system for our Global Distribution

and Value

-Added Services segment in the 
U.S. and Canada.

Finally, we completed the systems implementation activities for upgrading the ERP business 
system for our Global Distribution and Value-Added Services segment in Australia and New Zealand.

All acquisitions, continued acquisition integrations,

and systems implementation activities involve necessary

and 
appropriate change-management controls that are considered in our quarterly

assessment of the design and 
operating effectiveness of our internal control over financial reporting.
Limitations of the Effectiveness of Internal Control 
A control system, no matter how well conceived and operated, can provide

only reasonable, not absolute, assurance 
that the objectives of the internal control system are met.

Because of the inherent limitations of any internal control 
system, no evaluation of controls can provide absolute assurance that

all control issues, if any, within a company 
have been detected.

Table of Contents
57 
PART

II.

OTHER INFORMATION

ITEM 1.

LEGAL PROCEEDINGS

For a discussion of Legal Proceedings, see 
Note 11Legal Proceedings

of the Notes to the Condensed Consolidated 
Financial Statements included under Item 1. 
ITEM 1A. RISK FACTORS 

There have been no material changes from the risk factors disclosed in

Part 1, Item 1A, of our Annual Report on 
Form 10-K for the year ended December 28, 2024. 
ITEM 2.

UNREGISTERED SALES OF EQUITY SECURITIES

AND USE OF PROCEEDS
Purchases of equity securities by the issuer 
Our share repurchase program, announced on March 3, 2003, originally

allowed us to repurchase up to two million 
shares pre-stock splits (eight million shares post-stock splits) of our common

stock, which represented 
approximately 2.3% of the shares outstanding at the commencement

of the program.

Subsequent additional 
increases since 2003 that have aggregated to an additional $6.7 billion,

authorized by our Board, to the repurchase 
program provide for a total of $6.8 billion (including $500 million authorized on

January 27, 2025 and an 
additional $750 million authorized on September 8, 2025) of shares of our common

stock to be repurchased under 
this program,

with $980 million currently available for future share repurchases. 
On May 19, 2025, we executed an accelerated share repurchase program to

repurchase a total of $250 million of 
our outstanding common stock based on volume-weighted average prices.

In May 2025 we received 3,122,832 
shares at an estimated fair value of $224 million, which were recorded in

treasury stock.

In July 2025, we received 
an additional 368,651 shares at an estimated fair value of $26 million,

representing the final amount of shares to be 
received under this accelerated share repurchase program.

As of September 27, 2025, we had repurchased approximately $5.8 billion

of common stock (105,063,756)

shares 
under these initiatives. 
The following table summarizes repurchases of our common stock

under our stock repurchase program during the 
fiscal quarter ended September 27, 2025: 
Total Number 
Maximum Number 
Total 
of Shares 
of Shares 
Number 
Average 
Purchased as Part 
that May Yet 
of Shares 
Price Paid 
of Our Publicly 
Be Purchased Under 
Fiscal Month 
Purchased (1) 
Per Share 
Announced Program 
Our Program (2) 
6/29/2025 through 8/2/2025 
811,024 
$ 
71.20 
811,024 
5,511,891 
8/3/2025 through 8/30/2025 
2,312,016 
67.74 
2,312,016 
3,134,393 
9/1/2025 through 9/27/2025 
212,945 
68.38 
212,945 
14,434,296 
3,335,985 
3,335,985 
(1) 
All repurchases were executed in the open market under our existing publicly announced authorized program. 
(2) 
The maximum number of shares that may yet be purchased under this program is determined at the end of each month based on the 
closing price of our common stock at that time.

This table excludes shares withheld from employees to satisfy minimum tax withholding 
requirements for equity-based transactions. 

Table of Contents
58 
ITEM 5.

OTHER INFORMATION 
KKR Investment
On November 4, 2025, the Company and KKR entered into an amendment

to the Strategic Partnership Agreement, 
dated January 29, 2025 (the Agreement), between the parties that increased the

beneficial ownership limit from 
14.9% to 19.9% of the outstanding shares of the Companys common stock that KKR is permitted to acquire

during 
the standstill period.

The standstill provisions, including the increased ownership

limit, continue in effect for a 
period of six months following the later of the expiration of the term of the Agreement

and the date on which no 
KKR director appointed pursuant to the Agreement is serving on the Board

of Directors.

Extension of 2024 Restructuring Plan 
On August 6, 2024, we committed to a new restructuring plan (the 2024

Plan) to integrate recent acquisitions, 
right-size operations and further increase efficiencies.

We currently expect completion of this plan to be at the end 
of 2027.

Since the 2024 Plan initiation we recorded restructuring charges of $155 million, and we

currently expect 
to record additional restructuring charges associated with the plan in 2025 and through

the end of 2027; however, 
an estimate of the amount of these charges for 2025 through 2027 has not yet been determined.

Rule 10b5-1 Trading Arrangements 

During the three months ended September 27, 2025 
Walter Siegel
, the Companys former 
Senior Vice President 
and Chief Legal Officer
, 
adopted

a 
Rule10b5
-1 trading arrangement (which is a trading plan for the future sale

of 
securities that is intended to satisfy the affirmative defense of Exchange Act 
Rule
10b5
-1(c), as well as the 
requirements of the Companys insider trading policy) while he was an executive officer of the Company. The plan 
is subject to an initial cooling off period during which there may be no transactions

between the adoption date 
and a date that is the later of 90 days or two business days following

the Companys filing of its next quarterly 
report on Form 10-Q or Annual Report on form 10-K.

On 
August 18, 2025
, Mr. Siegel adopted the trading plan to 
sell 
4,176

shares based on a limit order at a specified price, with a term through 
August 18, 2026
.

Table of Contents
59 
ITEM 6.

EXHIBITS
10.1
Amendment No. 1 to the Strategic Partnership Agreement, dated November

4, 
2025, by and between the Company and KKR Hawaii Aggregator L.P.+
31.1
Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.+
31.2
Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.+
32.1
Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.+
101.INS 
Inline XBRL Instance Document - the instance document does not appear

in the 
Interactive Data File because its XBRL tags are embedded within the Inline 
XBRL document+ 
101.SCH 
Inline XBRL Taxonomy Extension Schema Document+ 
101.CAL 
Inline XBRL Taxonomy Extension Calculation Linkbase Document+ 
101.DEF 
Inline XBRL Taxonomy Extension Definition Linkbase Document+ 
101.LAB 
Inline XBRL Taxonomy Extension Label Linkbase Document+ 
101.PRE 
Inline XBRL Taxonomy Extension Presentation Linkbase Document+ 
104 
The cover page of Henry Schein, Inc.s Quarterly Report on Form 10-Q for the 
quarter ended September 27, 2025, formatted in Inline XBRL (included

within 
Exhibit 101 attachments).+ 
_________ 
+ Filed or furnished herewith. 

Table of Contents
60 
SIGNATURE 
Pursuant to the requirements of the Securities Exchange Act of 1934, the

Registrant has duly caused this report to 
be signed on its behalf by the undersigned, thereunto duly authorized. 
Henry Schein, Inc. 
(Registrant) 
By: /s/ RONALD N. SOUTH 
Ronald N. South 
Senior Vice President and 
Chief Financial Officer 
(Authorized Signatory and Principal Financial 
and Accounting Officer) 
Dated: November 4, 2025